var title_f22_38_23136="DIP stack splint";
var content_f22_38_23136=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F67892&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F67892&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Stack splint for DIP joint",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 288px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAEgAbADASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD5vxjr3oPTFDYGMYp2ODzQITHHNAGOBQMkGlFACc4pw6fSl2gg+tOUflQAzPOaUnmnBcZ9DSgYBx2oAYeOTS49CMUpB6n8aApJ5oAQ8dqCcUY+b1pWGRxQADjpQOfTNIMn6UfdoGPBoUZ7/hSLjv3pxZcDA5oAaOuDT+nQCm7sc4BpwPtmgBVI79acoB64pucjNOHXkigBRRnnFLgdzRj2zQAhJGM4+tITzxxSE8YIOaUA7SSKQCbsZoJGAf0oC5oYEYoAfnI5/CkIBHPFNPHOaXPqM0AVp1IIxUDcfWtCVA49MdKpSoRQIaj4qYOCQKqnjmlBwaALe8EHI5rW8NaW2q6kkRH7scufasASHPNe0fDLQhb6cs0i/vJRvOf5VjWqckdNzehT55a7G9oWlxwKBHGFRRtHGOK3PIQgADpV+ws8xgkfhVyW1CpnbXnbs9PQ5q8sd6bVUEnvWBq/hy2uogk9uj/UYP512qxkMzDkUySAOMnpVbbDaTPF9S8BIWY2rtGf7rDIrltR8L6jZk7oDIo/iTmvoSa0DMVx+NZtxYBj9zPbFaRxE4+ZhPCwltofOMsLIxDAgj1rr/BGil3F5Ouf7ma77VvDVpecywRk+oGDTbK1WyjEWwhB0IFaTxPNGyM4YVwldlizhCyIR0zW7pN8VvzBLj7vFZ0QCAOuGjPcdjUd/MsM9vOhwwbafpXLfqdvkdlakYIB6GrcT/Ng9D6Vjadc+ZGcHvWhHJh1z3ppksuSoGYjjHXNU5oQwII69KkluApz3xTILgSZHei4rmLe2Y5GOemawLy0Xy2yvzDjFdpcgHB9KxLy167eSTmoZpFnlXinRFk+ZeJOxFcBcQFJGRxhwcV73qVvG6sjgEkYOK868R6EXJdBtcdPf2NdeHr292Rx4nD83vRODVdppammiaNyrAgj1qFiFHNd55pdA+b1IpdwI560309DxSZGeOlAEm/pgcU8MeD0qIA9unrTlHvQBIh+bg8GndG4Hy1EpxyKXfnHagCx0GO1AAIB5xUXmDGM++Kdvzzx0oAnKj14PpTCgPPYVAZTx6dDR9o2j2oAseXz8tNZCMCoYrorwDge9PF0DgHB96AHbCPbNNZBu9af5yEDJAxzSmZG5wPwoAi28kjrR0571KXUjINAVduS3PpQBF2pRgckcVMyD8D3pBDu4zxQAgIwD09qdxnJ6UFMHA5pSvPI5FACDHTHNHelVQc549qQZ9OKADr/AI0DkcnpQQQcg4pcHOSMfSgBOPbNNPB6U5hSNxz1pDEA3daBn8qMYOD3peSwAH/16BCgd+Ksrp9zcR70tpSvYhDg16F4B8JQsq3V+ivIeQrDIX/69emWthC2CI12LwOK5p4lJ2idUMM2rs+YrrTbuAFpLaZV9WQiqBBBwQQa+r7rTreZSpjU/hXJ674O066B861Qg8blXB/Ooji9dUW8I3szwOwQS39ujdGkAP519KeFtv2VFQcBcY/CvKtS+HdxaTrPpku8I27ypODj2Nd94PuprUJHcoySKehqa1SM2mjTD0pQTUj0bSvnRVC5bjA9avXkSkHAPXkEY+tY+n3GPu8DtWubgTLvc/NngDpWN0dDWtzPnhVchf8A9dVvKA4HQ1pzYKDBGcVE1sRh2zjpxSKT0Mu6i2gYUse5HaqcsIbgqw963ZIeM9/b1qGeAkg9MjpUNFpnMzQEEnG0etULi1LAn5cjoB3FdLLAcsHGc9RWXcQqAzrkY5HvUlWOekgltzujzg9RVHU3820bauGXkrXSvHl02k4bp7Gqd3pokJZOKadiGrEPh+8Bt15rcE7HBz0NcosLWUhABC/pWhBfhlAzhq1VmZttG3d3ACZzTNGmMoZj61lXd2v2dvm6jH41d0I+VaKHI3dTWcty4rQ25sbS34AVnXBAAHc1JPdKO4PoKqTOM7nYZP6VLKSK32VXcnGSe/vWXqdgvlneBz3rW+0qp2oefaoppoyB8pdvQdqEUzzHxBoKygkL83ZgK4e/024tmPmISo/iFe7z6a9yf4UB7Vhapoflg5GT6EV1U67hozkrYaM9VueSkdBShRyORSb+2OaQsRkc+9eieUPOAQOcUDuM5FRGQluD0pWcbeO3vQA8nbk1GZMnk01nLd81E5oAnZhgetNMnbPSoA3TsRQ7DrQBOZex4pjMM8VAW4pu6gCcvyeab5hFRFqTJoAmEp5yeaDMc/KcVATSUAWPPPGTTvtT561UozQBoC8Ycg59qlS/IUisrNLk0Aba3SsQSRmrAuF5O7Nc8rkd6lSXaMGgDdV92CCBTt43ep96yY7ok85Iq0k6uvv6UAWyeOSPpTt+0rkZqoGycA09X3E5agCdnBxnilyp6ngd6qs/y46AU3dz0J96QFpgGPrWx4W017/VYwF3KnPTv2rnRIc9cCvZ/hhpIhsY5pB+9kG41jXnyQ06nRh4c8rvodlpGnNHbRxLwccmughtDGgwvA6U7S4w+T6mt1bb5M4PHNedynoOTTsYRjwMEc9zVKSESyn+6vQ1vXESuGUdfSqxgEa7QOtO1jRMwJbQEnPWqc1iByF5610j2pznGage3x0xg9jzUj0ZhQ3Elu2GG4Vq2l6si4VgG9D1qKe2BOMA1Rltdp/HtSuJpnR2z7iSTzVtJeCDgg1ytvdTQEZO5R2PWtKHUo5MjO1j2NO5LRtHkYHfjrQ5VuSgzjp7Vm/awCDng1ZWXcoIp3BJkNxGI5CB35BFZN3FgMTgcZwK1n+Zs98VTni8wuRn3qWaxZhSKfMiY8Z7U6IDnf0B49q0Z7c5GwZ2gDdjvjpVd7ZY0K5yc4LVJV0Z13bLMMbVGR1rGm0whsw5A9TXRleNu3juaUxF/unr19aExNHLlTEMTwiVRzkVcgvYGA2o4FaUlvGCQEMh7ntWfdWRIJ4T0I4qrkuPYkEts5HOG7E9qhkMecr84+lUSkmcI5Y9OmaUNLER5i49eMUybNExkRTnZ+lTR3kWBnCn6Ukcivx8pHtTvJR0OApzQO4ovIimCeQeuaa5+09gRjvUEloOAoI/Cq7b4fWkPmR4RnBPrSFlI6nOeeKV+OexphH1xXtHghuIJxxxTN2eppcEHmk24DUAAJHfpTCSaU8LzTT2xQA3PNBNLTCPagAzSU4ikxQAlBpcetJigA7UlLRigBKKdijFADaKfs68Gl2EUAR0vNP8smgLg9aAGqxqxFKV65zUG3n2p4GRQBcjlJPPB9ak3nAOOfaqaKc/SplJ5I/GkBYLdMnr60hcgde1NXLLj9aGUk4NAD7ch7iJSPvMAfzr6L8GkLaxKAOcDFfOtkmLuEAEHeOfxr3nwhP/AKOhJ5AFcmK3R34PZno+lOVO1hgAkH2rp4HQR8uVPYk559647TZl8w46Ma3EuAUVeMHqK5k7HVJXZcEZO6SQYBGcetVWjycmpri5LjBOQO3pQGUkbSDlefrSbuJELRjOD3HPvUMlvl8DkHgVfbaVbHTqDUDn59wyGHOe/wBallIzp7fnpnHeqNxbt02/iOtbrgnZhQCR/DVaeLeCEYBh1zU2KTObe3Pfn3qpPDjoOK6GaAhxxg/oarTQLkqF6jIz3pFGEZpVXZuOB0z2q9pd+xUxzcMP1oeHqMVRng2vxnjmi3UNjfFwMZBpFcEbm6dx61z6zyxAgtkDtViG+Zl3BSRRcDZkk2DLcEfdUVX2ZGSOB0/xqnDctI+5lbPbParRinmQfvERO2OaaTZN7FaRVViAct1+lQFlGS7hR3qc6fGDl7hyT15qvLYJzsfdjueaORj50V3vBJhLcDP6VGYY25nYyHrgdKWW2VckSAYPoBUTJuyAxc/XNFrF8y6ENwNj5CKB2zUBknWMEKWHuOKviNkXcqBiPVhxVeRizYkwB/dH+NO47pmdcAN8zqsf+4cHNMivJoeRh4we/XFaYSNlOxkB6HpxVJogQyyP8oz9z+tF7k2TLFvqENwMjGfSrBhjlTJIY/XNY0tpHuUwhgMdc45qET3dvwV8xO3rQS4nihwONpORx7VFjGcjgHkirHQZz7/T/PFDbTtXH4H1r2TwSoQAO59KYwBHerbRFiBkDB5NRSLt4J6egoAgI45ppWpGJxk5pq4PBP8A9egYwrSlPXrU2Oe2KUJnHFAFbb1pNp7DmrBTBOe/p2oKkDAA+tAFfGRSVKVP4U0igBhGTTlTOfSnADPqamjCg8/lQAwQYPzHmniEZzxkdalXowUHjmnBvl4H6UANEa8E03ywQcY/Gpl3Ege9B9xkigRD5WRn0pBFkE8VMCAfY0EY59OtAEDRjg4/Cjy8DvU7LjGM80EDHJ/CgZCyY2980AYOCDmp2IK44z34pjfNzmgQ1Sc4xUoIOODkVGOBx1NPBGMDj3oGXdOiaa9j2nJzmvZPCwJtkK/WvMPCVt5k7ykcrwK9L8MyqkrDO0DtXDiZanoYVWjc7a0ldCM9PStmG4Jwx64rO0+W2uV27xuHoelXmi2jKnK1y+h1c1y4lxgc1Ilxg4zj0rPjYk47ilkyPm7UXA24J8rhumfWklbcrZ6frWNFdAEAmrwkLhcVLBFqBtrIZO3pTbiQeYxxjPbNQeYVAIOeeKjaT5juz0pXLt1Gt/rCA3UZFNkO4RgDLg4IqCSQ+YrY46U6RyHfkY60XKsL5O9wBjJ6DHUVSkgyOBkCrTSHdluOOo9acG2gE8MwwB6CncdjFurYCE4HOMis8K8UhKMACMkGuolgDlY0II67vWqR09SzEjdjik7gkjL8/wAtVljXI/iGOKsG4gkGQApz0FOuLPYrIg57ms2OJ4yRztB5NCb2J5DSaeDDAoc44Kiq/lq2DhR2780RSwBOThuhzUheJFJ3MRjoCKq4lGxCLRAfmjB9zS+QqchBjsRSrc2+RnGfepY5Vb7hUgemKCiMKudr+Yfwpk0MZA4cHHZRVsspHz5/CjYjA7Q/4gmgVjEuLYKTjd+IzVJ42j5wVz6DFdLJEpGMZ+gNVHslYYK4z055osJuxiAKw6bj6k80x8sw4AHTJq9c6eAcx7iT2FZ8qMh+beMe+al3QXueEZHboaXJK9uPegMTgAZ7/WlY9CABn07f5/pXtngjUbk5Xr6UssYxnOeKcyfdHHPOe/8A9akm/wBVyevYf5/zigCjJ8vA4oR8DHHFMlXDHv3qHv1oGXgQx65NSAlgBjIHIrPUkHqamibjk8+lAFtVHUkZppBwffvTARgAHPNOLY5PBFADGUDBPHtjrTGAHIpXLEcmmAUAPGcgDv0p4BHce9NjALYPT8qlAzwTigQo+Ybd3A9qVW64FA6AE0g46EgCgBwODwTzSjngcijhSo7U5QM+npQAHdgAjH9KTqowMkdqcOG5BzSj0Xr3zQBGWPWlYZUD8qDwRn600YJJxxQA1uMY61IYHSBJ8fIxIB+lNbbnjp6UbsH5elADCRtznk01snAz0HapGXOcAY9TUZHtzQB2nhEbbVSOprq7C5WK9+b5dwwa5Pwmc2aAV1q2S3ScNskHQ15tfWTPUoWUUbc9s+0XGnzNHMOeDw3sRWnoHiwTSG1vh5VyvBB6H6Vy8c2o6coWSIyR/wB5eax9bufNdblEMcyH0wSK51HsdG+57KlyhYMrcGrmQ6cHNebeH9bNzaqC+WArrNK1PzBtZsEdaSdnqDgT3xeE5HSr+jXy3Mf3vmXgio7hUnjPfIrmhM+j6qjsf9HkO1j6HtTemo0r6HcE8YFMmb09OtNglV1UjBBp8wB6UmhxkVncALknikdgV6nJ4pJF5FRSnOPWpsaXFMuTjPAqRJCWxnJPSqWGeTGDjr9asp8vXO7GBVIvQsh2jyQx3NSiVQoAJwvb1NQSMSQF5Yj8qjMR2lg2CtUK19y2q7lIIPmHn8KznCs5VM5HcCnvMU4Yls+lJGSZDlQOOAaLFKJX+xK2QR36017KJMER8DrxV9RyQCQxPPoBT/N3EBRhR/d7+9FkS0Y5hwCny+o4zVJo/kICjep5OQM1swld21gBgZJ/lUTWibw7EDccCkDiY4vHhIHzr7EZH51oWt6jqA/l+x5pZ7XfI4yOOOlZk1mw5iA3UaoVjcjy44RH91poYjoQCfbNYSXNxDlTHux3FSjVJfLwdwyehFK4nE1yM5Jyw9QQarSQCXcAyH1OMVSN7vB3lenqRTDeMAApUjtnpRzGbgfNqOQcE85q3HIDn0xgZPT/ACazzk461NAw3DIH517Z4ReI5I2Z4/z/AJ9qZcndkcntz60quOBjjOfbPuP8fWoJmBYgE7T+PFAirKAScdPWoqlYZ4yMD1NR7aBjacp5/GkxjIoFAFiM98dKfk4z61HGfTI5zmphzgkjJ60AREnGM/nSxpk54PtSgDo3AqUDBOeOMZFACMCrAcenFSDlc44/WkUDdgfr6UoJ4wBjOcUCFAOzGM80Akr0PuKZzux1p+DjgA/0oAXJYcn2pyrnuMjoBTIz82FOB3p6ADOcj2oGOU/KeoakOW+oGOBTzg8jjjrTGJA+XPNIBrAsPYd6aTzyPapJFOcgc+1AyGHT3pgRtwMDnsc0mM9O/WnnhuB+dIR0PQUgG/w59KcuCcjBGPpSMQPXB6008H5SMdaYjpPCM2EZMHAbt2rv9PdGxuAPuK8z8IXAi1RonON4ypzXqNqkTKpkUfUV52JVpHpYaXum5aDK/KxI+maS6slmjYNInIx92qkKQ5G2YgdhnFPne3jHzT7vq1YJs3tc4bVrefQb0tA+6Jj2rU0fxNEZVYthsYNXL+NNSU29pE07nso4H1NcdqfhTU7QvN5bbUPLR8gVfKpGsE3oeyabqaTRqQ4IPvU2qQR3lsyEZBFeE2uualpx25LAepxXSaX8Qtg23iOvv1FJQaKlBrU9K8Makfns7lv30J289x2NdWGBjzXis/ii0+3QX9rMpKnEig9Vr1XR71Ly0jljbcrAEGoatoS+5dkyenWo+e/FOdsZpvXBB5pAROr9RwRz9aejNnPAOOtTYyMbgD60mSseM8CmUpDd4IGCAe5HenKPmGCMkYA9KZjK/KBk9fapEXBwSCP1NBoOjtxGxBwzHgnv+FOaLdlUUF+3sKcS7JyDs6Djmk8wKdqZ39+O1MNSvHAQxDhm9hwDSXQ2oH+WNVO0KnJzU7MzRkAYOfvZ6CmOMDCbX2d8cD/69SVfuU1jMLKXZfMfqM8Y96gkdZJypb92noOpqzNFM8bDgDqzf0FLbxCJQsbDjqduSTQO/UjgAYEsr8feb+VESCQOFPAPHFPmizL882W74qNnZn8pCsYxgkcUXIbuRvarJOdqjaPvGqstiplYKA3v2FaDMFxHG2BjJPqajBwB8xCjuRRcky/7OznOOD60jafj5lGfer0kqoWJG9zyCOMU9JPMARifl4wKGkD2Plby/kGSOvWkTj29D0/z2q0uMehHYdf84/lTGQ7RjJA79f5fjXtHzxHuONrDLD1phz1yMjnFWDGeDnH07n/OaRoiDxzxkcf5/wAmgCsc5Oec0bW28HOKsqo28DAPQn/P0pPL5HufyoApsowetIVPernknAY8Z/X/ADzR5BHLA/5//VQBWj3dOcetTISc4HFSpbjqOp7n/P0p+zYMgYz/AJ/rQAxRhQe5PI/z+NKpKkjbyOgNOfJwOOPT/P1pShCnAzz1/wA/hSAY3HUf/Wo5B9Of1pM4QH/PvSr249v8/lQAbc5GTTgBySeOvtmnHkA5PHekAJGdwHHc/pQAfL6fQA0ozx0+lIpGeg4/WnbiecY74oAeQxOe1BXpjj6UDI9cUrHJHoetADSDtBFAGVxjJ7mnc4PBFEYXOW5HftQBEoBLE9eop+N5ycqO49qcepOeOuKQdjjjvQBGygKO5Hak2cHjkVIxOOuCPWmGTpyMd8UAQStJDIk0XyvGcriuw0LX2vVWM3RglHBU1yEhI+lVyDHLvRisg5BFZ1KSqI1p1HTZ7Fa2slyRvvXb6Cui0/w9aYDzBpD/ALbf0ryzw34z+z7YrxQrDgP2Nd7ZeJY7hVKSA1586bg9UenSmprRnc26W9tHshRY174GM01gZjsUAR+/Suet9SWTl5OfQGtBL7IweF7AVKkzojFFPU/CmmXYc+X+8PVlOAPc1x+peAslmtJBs7F+K9GilaQLxhB2qWZBIm0jaB3PFWjVSa6ngmq+G7uzVmeIlR/EK9G+DGrNLYTWEzEvbNhcn+E9P61satbxPA6MAQRiuK8ErJp3jeSCEfu5ozn2waqo7xM5xT1R7XIwABNLCd/SoIjvdd3J9K14bRPLDEHJ9K5Y6kPRFdY2IPAxTvJX+PH4VbFv6NUUikccVqQiPYq8rx7Ypkg2kYB56Y61KGCjnketIRnnOAepJpFpkMok4DE8jPyimRb0QhNo9N3Wp2IIwo3Z9Kb8gAD8t3JJNI0T0IdrgYdvlPUL3pCzImBJ5adcBakadkf5GCL2x1qN5d7DlTjpvP8ASkO7ZDJHwSJSW9SRgUxJmjVUTb67m45p8oRMMpR2PP3elRkPL82YwAPTH/66LBfQA4HKklj1YD+tR+Yo5yAT/wACNP2pIQpYuf7qL/WkywBAVkAPRRj9aVibld2fOQn4kYqOTe3Tn2B4FTuVYYcSOR03HIqCQ8Ebtg9MYzSsK4zzCFyVHHQChZAp3PIAwHA6ioGUEHaGx15piHax3Rr9Tnindi0PnkQruIbggYPv6/yP5inrF1wGG0AYxn/PI/8AHqkQAYEYzg5G49emD+i/nTyhAyhBU8Ajp2/+wr2z58g8nHC5/wA9P1x+dI6EEBfXj2z0/wDZam4KfINvTk9B/nK/lSSBWBY4VT+Qz/8ArH5UAQGPcTwFU9eOn+c/pQYsFiVK/T9R/P8AKpCB91yVHU5HT1/9m/KjdtzuH6Yz6j9G/OgCIIeeOR/P0/Q054wNoUZZugPX/PA/OldeOS2R6jHP+QOfegjKnGMDp/n/AL5oGNwpPG0joP8AP4j8qjcknpwR3/z9aecBeenoB2/yf0pJNrYzkN6f5/GgCMDv2+nX/OP1pCAB8nTpkjr/AJ4pTkEA8dv8/kKTdhcKBx3z/n1/SkA0fhjqR/n8aUgAkHk+o9aQ+3p/n+tKQenfH+f6UAGOPQEf5/nSL0Awc96U5xz069f8+9DfdHr04oEKowdwqRF7k4yO1NABAbIzjp7VIgHbqT/n+VAxwGTjPGOp9Kd0UjAKg9ff/IpGbntn6dv/ANVNZgcbRhT0NADyd3ZQBzjpTAu5hzwfWkQj7oyV70p4XaMA9c9/88UAMPQkE8fzpjNxjJx+lSMuQTzj0zUciHcBx1xigCJmz1OQKjLZU4z1p7YJ+UfjUZwBQA1mO3GKjJz1qU89aTYTz2oGQld3WnwyTQ/6mV0+hqcQk5OCBThD7c0b7gnbYtWPiDU7NgUkDgf3q63RfHqcJfIY2/vHkVxRh6ADmgwqxAIyO9ZSowl0NoYmcOp7Vp/ia3nQNHcqR7GtA6skp/1n4k14A0BiwySNGTzwaliu79WCQ3cxY8KoyST6Vi8M1szshj11R7VfahGqnLg07wLDFcatdXpQPtAjX+Z/pXJ+FfAvifXtj6hO9hZnnLj94w9l7fU17r4N8KWPhzT0gtlZip3GSQ5ZmPc1hNWVrm/tufW1i1pdhISZbhNiHtjnFanl4U7eF7VNNMirlyMVQmvl/hOcVikkNNyHOrKOT9RVdnA7cmmteDqT9AarSzbjk9famNJ9SZ5OmTz2FNBBycZbsO1V1ZSeuT7d6V26FyQPrSuaKJMwxgu2xT2Apg3SMx5Pue9QpIC42IXPuOKeJCGJYJk+pJ/lQyuUeocE4VePalZwSDvQj024FROeSGcZPYLUUkzAYOee/GPyFK4cpNI7HOG+XHO0DH61U2ZfJjL5/vtzTmkz1QFv7zU4hmx5pAX8qLhawyRUjPzQxpnpgkkVF8rAYUD3CcmrOFA+RCR61G4JPUsfT0pXJsQeWgP3mweSAOlQvGpOPnI9quOhGAFTPoBmqkyqxOFG7OSRgAUyWiBioHO8dqAqMvHmNjoSKZt2McFefepY5EzyzgDuvNK4WPnUgM6+W23pj2/zlfypw2scA9ensD/+sf8AfNAy5w524HPGOvX+Z59qVWJUg8eq9Prx24LenSvbPBEPzMDnr6fw5/8A1n8qTqu3BwBkj8yefxb8qfgklnTB57Y+vHb+OmnjqGB75GOR1/k3p1oAQk5w6555wfzH1+9SSIeCCSy9Se+P/wBX60/ZtBJOSBjr39vy/WmhcZCMSwHGf0x+S/nQBGRtRdpyf84/9loVd23oc9P8n2I/Kr1hp95fyiHT7eW4k/hEILY+uOn8P5V1Vn8MfFF4AxsYoF7CWUA4+n4n8qTkluUoSeyOFHPPrnIHb/OW/KkKYAbqf6/4cH869NT4PeIZMmWXT4geeZCf6fWrC/BrVsDOraduH97d7f4VHtI9ylRn2PJyhxxnA7/5/Cmkg54OM549P8/yr1wfBbVW/wCYtp+On8X+fSmN8EtXByNV07n13D/Pej2ke4/Yz7HkmWB6cjg+uaFBz6/Xv2/PpXq+h/CjzpJRqF/uMbFf9HHBx3yf8K6BfhJo0cTGQ3jgD/np/wDWodWI1QmzwfAHzMBxzj1/zzScdM/l617svww8PuU2rd7nPTzckfWp/wDhUOjdjdj/ALa//Wpe1iN4eaPBwVYoPujuf6/rUqKd2QfmH4/55Fe5r8IdIzy12frJ/wDWq1H8KNFUglLg44/1po9rEPq8zwMxnZj1/wA/1qMHaQGFfRcXwu0FQN1mW/3pG/xrrPCPgbR9PW5a306AM2AWdd2fzz6mhVU9hSoSirs+S1jdzhFYjtgE1NFZ3crbY7adifRCf5CvtRfD1inyx2kKjoAqAd6tJpcSZ2og6dF+pp85HIfFkHh/V7lgIdLvXX0ELY/lVy28C+J7riLR7wem9No/Wvs6PT1AIVAOPT2qf7DtIYLnH+zS5x8h8RX3grxFaXbWsmk3LOOSYwHU/iOKgu/COv2tq9zPpV0kMYyzbeg9cV9iPpsZlchBjcaZNpcckbI0YKsCCCOorJ1n2OhYaPc+JEjOB+fSpoYiflAzz9QK92sfBOk2t5L5dhAXWRsGXMnf0NdFFZC3ZY1sbXBHBRQv9Kl4pdENYKXVnzhHbSyHbFFI7Y6KpJq1FpGpXDYj0+5Zic/6o19GRW6+bt8kRN2wBVoQkNtddw9ah4t9EarA92fPNt4O16Zvl0+RQT/EwGP1rSh+G+tzEFzbRcY5cn+Qr32O2AGQAR6d6kECgZIFQ8TMtYOmjxLT/hPM8obUbxdmfuwryfxP+Fd54b8KaboCK1nYRtKODPIdzn8ccfhXY+QDjKkeuKaYowTuBP0rOVaUt2bQw8I/CitFfzRkbIIx/wACP+FTf2lesNo8se6rUTJlvl6enpViOIIu4D2rPmZbgl0K8jTu26aRm+tN+7n0/lVwqM7jgfhTBCM+3U0rlpFMZPqfelIO33PrVsxgOA340qJ87EjgdKC0isoOMAfNQwCDLfe96e4MUwORzRJkspPOaaRViMZCbiSFPYU0sc4XGMUrozOVxge3NQxZWRo8nPpTsOwSY3cg9PWncKvJGSOwqQR4OOvGeaSEFmYKvSiwEYi4BwT6luKeo7p27nFTpGQQWJJNDLknjp7UmiLiAllCnB+pA/lTWj2hjt2j2binrGSu7gAehxSMAPvcfjSsIhaMFflQgnqzGmSLGgIKIOOi8k1YLkLkszD3OBUDfMCVII745wKE7EtFaSIbCSgGegzVRkaFtzAg54qe4dQc5YL7/wBKi8xGUBh9GbJNU7MizjqfPBbjDMxx1K9Pz/779KN+zIwWI5OPlHfqff5x+NLuwfmJLDj8u35qeP8AaoyBk5O4dMn9Pb7v/j1eyeCO4DncM47Yx9f5N+dMwyq23nacenT/APZ9uvegHBIbLbeAD3/w5A9PvUucIPLA46E/of0X060AKnABUFgv8XQZ4x/JfTrW94J8N3HifWEtIQY7dfmlmXoi/wCJ+WsBMKflOBj5TnJHp/7L6GvoP4SafHpXgr7dIm2ScNcOT12/wj8gKicuWNzWlDnlY1Y00zwhYpp+kWsYn2jI/wDZmPc1D9r1KaEzXNy8cZ5CpxVHSEbULo3VzktM+foK19Ucy3X2fgQxgYHrXA25as9ayhaKMV2u7jlXkA9WbNTwssZxPbyN7hq1YIBt4FPa39qFSQ3Jldbuw8sAQlH/ANpciqN8wZGMSI3HatBrcNwVqQWQZMAYp+yRDdtR3g2Ldp+/ABZzj25rrFgGOlZXha2CWgRRkBj2rpBHVWIerM9LKFHZ0hjV26sFAJ+pqTyB6VfEdZ3iC1vJtLlXTSgueNoY4BoYrDhCD0xThbj0rJ8I2WtQtMdY8oL0XZxn8Mmun8qgLFEQD0ra0aILavjsew61w3iaz1+TUidOZfs20bRjOT3B5GPrXf8AhmGePRIVu+ZwPn2tu5q4GVa3KTmPBY/Lxg8inrFnPp/OrhjByM9uhFIIsSZ29R96tDmIfKHzdM4pLiMeSxYqABkk9BVpVyBg5GO/ekmX90SBggHtmgaOYKRhQfNB98YpCmKsyxlkK4Xkck9qaygLgdAK5jvPKb8eTqL5zkzNgjuCa05YgIg6/eT5qoazxNdAn5kmLAfjVwPm1ye61hLc7oq8UWZYIyPMXrwQD3qS4i2KknBHtUCPughzxwM1bmcMhXOR9OtJ6k2sM2jvn1BpB8wyw4HTNLExeEt2HA96mYgGNVwelSGxDtJXjjPWoZI3xhW79xV1yGYqOMcdO9Rog25JPTg0WFexB5K7QzdTQq8nrirYUKCkmCcU0qPMyv3AO1MVxrRDAzyM0Oi+VkAYzzz1pXJyjeuSBRPiOHydymQtyR6UgRBIo+0LhwFIPNMU7TLtAbBzxSOz7UbIJz16YNVw7KXyRzVF9B058yNyqnKtwaIzG067/lUcniqpYhnLcKDyBSLKAHYcZFFyntoXY2ja6faRtY/K3oM+lVhHC+pOzNiNF5J9agWbamTgAdMioIJc/dJD5Jzng0XuKzRemdWlPlkiMcHvmkVsTIVxt79hSRTmXeGkAXHQ8ZNNedUZQT+7x+NN6hfoX5HCLklcDjAFUzMHBJ3FR096qGZ52CxqQnQsalmZcjO7YvHXGaTJtbcWS6K8ImTj06VA1yd33unQA5qOSTOQI8sRhR/WhYJVQEuAxHIRTxUj0Q8yMwHGT6A5qN5GLBXYxpnkADNSGCQgn58e+FpqwMp3GNQMevJ/GnYnmQ3Bcjyo3Y+rcVWmR5D80mf9mrUjSE4Pl8cZByR+NR5Tbyo444bGaBHzku3gLyeinufTj8Bx709fvAqSSPlA/kP0X86YANo5HXHTge3vj5aUtu6EDd1xwPpj8V49q9o+eFUDzFMeeeF9T6f+y0vAJYYA9R+n81/KmgqxHU54XsOfp3GR+VSH5uX+XccD2/L03fp0oAbIC2MAhTnGTwP85H5dK+nvBccd74GtIU+69qEH4rivmBTkHAb3z2B//W35dK9u+CHiRJtOk0m4fFzbMflY8lTz+hyPwrKqrxOjDu0rG5p8htIP3g2tAcOPTB5rVv4g7rOnXGCfUVe1rRjK73NsufMXDp/e9xXLeHtX2OdL1bdHLCfLV34yB0B/xrj20Z6TvP3o9DpLFN4GOa0ksJpv9UhP0q1olvY20nnX9wy2/oiFia6mTxfpdtblNLtQG4Cl14/Gt4xVtWYynK/uq5yI8O6kQCLSUg+gqP7DcQlg8bKynBBHOa6VvGl+wYR/Z4/9oR8/zrk9Y1yWCGQE5ZgSGzySap8seok5y0aNXwzHm1B9ST+tbpTFZfhwCKzjyOdtJ4xmnXQ2+xyGJ2cK0gGSq9zWLKNdMN0walEdcT4D+2x3k6TXDT24QHc3Zs13YYde1A2MEdL5dP3Cl3CgQzy+a1NKH+hMcjG4/MvX/wDXWduFaemH/RMKVzkng/zqobmVbYt7cnnBBHSkAGRwc+nalzzyOMdaEPC4PHv3rQ5xV6A8H3ps2BC5wRj0FG7hdy4OeMUkzjyZPnxjv6UAYuz1psifISBTg498UplARskY2n+Vc9juPJNYh33t/J0HmED3q+9uYbRfmHKZ+lZ+q3JkS7BYALMxH59KumdX0sYPzba52tTsjJ2QiRkWkZ7FeKsNlUyeoqnHd/uRGxyEGPpUq3BMO58cnPNJWG2y3CVS0CvwcnPNOjP+k+YxGWTp2Gaog78BjwfmapXk+cEn5cg4/pSuIvlkWMYwJHJ/CmthWUZAUDJb0qhLIXbO7knpQ0u4YZsepNDYrF2WZdow2eTyeuKgL5dUDFVfg+wqrcXCrIAB2Hvio45AzHLZ29KTGlY0o3VnZWzhV45xVZ5jJcZ4wBVaSZjGUU/M5yaaWAAx0PHFIRLK4Cdyc8VEqkrnnGeW7j6VEZOrZBYngYqG4nCrtBOTTuO/QkhKCR8/MDnhhTZF3ybYgBnkkVXRcjJbYv8AOpopUyTt4HGaCuYsSIBEGcfL6Zqk0TM4kKhIz0461MwZ+mFUfw9z9aDIigNJIGPYY6Uxc1iMlIvuRSM/oRmowjt886rk9AT0/ClnuG2jlkQ9ieT+FESuxwq+WD1ZuSfwpC5h0m2IDfKWf+6owBUKq8z5UMwHoal8kZ+aQhfQ4yasBAMbBIR6scCgOawkdu8Yy22Nj3PJNSMpwWZpnJ59M0xpYYs7iN3s2ai89c5wcnrnJNGiE3ck8ssCWiwnoXqNsHlY069Mk0jspAO3AB78VGzh8hVUD0Uf1piuSbyclnZU9FQDNQuwUH5CWPTcaaXMYK4UHOSfvUiPhsgsc98YoYj5xABxxgng55/z1/SnevGSevrj/J/Smc8s3bI49/59W/KlJ3Dkjpj69f8AFvyr2jwCQNnGQEHRj1/zwT+VKrKV5PJHJz27/oW/Km853Meo6E5z/n5qQtgHIx2PfPr/AOzUAOA3AFuhOWHQe+P/AB7/AApsWoXmh6nbanYOyTxnBzwG9QR6ZzTi5GfmJAxkevr/ACb8+lMkVWUh8sDweRz/AJ2n8+lA07an0J8O/irp2tRpbXLCG6x80Mh6/wC6e9d9dWGka0gLiNn7FuGH0Ir4mubSW1cSRk7QeHXt/nrXWeHPiVrmkmNJpvtcC8bZPvY/3uv86xnRT2OqniLbn1PFoV5YIUsruX7P1Ecg3r/9aqF5Z38BLRWyyHP/ACzbj8q838P/ABrt2KrcrNB7n51/Mf4V6Ho/xF0rUVGJYJSfQ8/41zypWOuNa+qFlunO1XjELdCMEfzqjegTSRh33uWAHPvXXwazo94NrsOexwf51Ff6fpjxCa0EXnKcgqMGp5bF8/kW7OXy4lGe1WvtAZSrYIPY1zf24IcE4NSLfqf4qozOhhlSJdsaqo9FGKsC6965pb4etSrej1ouB0QuaeLn3rn1vB608Xg9aLgb63A9a2dKkJshnYRk8qeTXFC8HrW5o92n2QYGMsfmHIP/ANeqhuZVdjozKN45IOOBSeacAthj6isoXfo4I7/LSG6REycou7t3rQ5zVMy4GH2gHnP8qSWbEUhZlAxwfT61mNd8tgq3oDSPcja/yjkdaAKf2iori52Quc9jWc90C5IbPPXGM1T1S8EdhcPn7qE/pXOztRw+Q6TzPjDOzAepzRJfpb2gBORjoaw7PUo0tQ0h5xnBNU1nF7cAtkQKeT6+1c0t9Dqi9NTfsbp52wcksdx+laD3PmOACCq9cdPpWGbsAFIRtjP3mpq3e5QiN5cY7+tK1gcru50Yn6+nfFMku9zb+uO1YDajGo2hvkX9aadSGCQRg9B60hpnQNeooU8e2abJdg4YnOema537chBVmB/pTP7RUN8rbsdPaizKudA91tbLf/rNKbkLGAp+tc6dQRWDs3T16ZqtJq8bEgydfTpRYXMdT9sAzK3UdBSpc5TDNlm5J9BXFya6kl0IkfcBx9a0F1ABSWYfT1pWZLZ1CTKq7jzzxVQyCQMy8nPOegrn7nWI02rvwSOOada6oGi4NOxNzdkulRcAljSw3Uuz5QEB7mseOUuOTjPIqwlwkCnc4J/lTQXNcyJGm6RmY56ngVXNwZThV4PTArLSY3ko3EhAfzrbgSONMk7SOck80b7Be24Qxv1dtregGTV2OBACZGY/jVK61OC1TPHX86zhd3V8+VDRRZx05NDshq7Nee6t7cDZgEenJqpJfNNkKrH2pkFpGACQGc/xMcmrQjCnjrS1HoiBFlYjcAMc7RU6hw23apPqeac/ylu59c1E8mGPzAY9TRaw73FaMk87c/WkOSQP3ZA65NMaXc2MhsDrSbsg4xnH92mIeXx911XB6L/9emnYFJLZz6VEGZuSjEfkKkiD5ICgZ9WzRuSz5xC45OM+n8/5N+dP9emerDqff+TfnTCCB3wvGR/n2/WnKw4LAMR1HTOP8cfrXtHhgDt+Y9ccjr9c/kfzoyS7YBK9D7+v8j+dKwVcfxEcj0OPb3x/49T9zfwEEjgZHXHTj/gI/OgQpO04kIJ74749/fb7/eoUBZOhLAcHsSP8cD86aMLkLlgOh7n0/kv505WPBQYI+6f5fyT86AEK5O1CCw4B/Qf+ycVUurGGR2KDyyeQAPy/mv61cZgiDaOex/kfyKce1RmQBDngEd+3p+jD8qAMttOmU5hZW9OcHt/j/OiK8vLRxu3Aj+8KvvMG5JyD+n/1+T+VRMwOfMUHI6Z6ev8A7NQNNrY1tN8b6haYAmlCjtuyPyNdTp3xQnQASSKfqCv8jXnL26M33Bz0x6/5B/OmvYqT+7ZvpjP+e351LgmaKrJdT2m1+JttKAJ1Y+pWQH+YrTt/HmlSkZllQn+8n+BrwA2DggpIpBOB2/z1FNEN0vKMT9GqfZIpV5H0pD4r0+T7l9Cf94lf51owa3HIMxzRv/uuDXy+JdRhOAZePx9f8D+VSJq19Fyxb8RU+yLWIPqddV9dw/CpF1Ze7V8wReLdThXEUpU/U1bg8e67EADcK4H94E/1qfYlfWEfS41ZOu8Yrd0LVVezwJRu3k7cEHB9f/rV8rxfEfVlxvigf8K6vRPi1BaaWFvLaVrkyHKRj5QvqCT/AEH4040miZ1lJWPo4ahno4OMdaeuofLjcR/vHPavBIPjPp+PntrocjjAOBmtG3+L2hSY8ySdO3MZ96vlZlzI9vXUE55Xp689Kc19ySGJ4JwGFeSW3xO8OzcHU4wSP4lI7e9aFr480K5bZDqlsWORjdjnHoT/AJ/WlysfMjqZ70iZwxbOed4wfxFYXjHVltPDd9KzAYjI/PiubvfF2lJqNxDLqVtBIj4ZXJ4P61xHxU8UWtzo62FneRXDTMCfJYkAA96w9m27HV7VJXGDxFaFVQODgdKnXxCm0BCAPTNeQBXHIYj6Gn5n6eaw/wCBGqeGXchYt9j14+IBsALrtHbNRP4iTHDqPcmvJSZT96R/xJppDYyWb86X1Vdw+tvseoTeIIUO5pQx9WPAqrL4sgT7r7m9c15x5ZJ6kmjy6pYaJLxcux3j+LohyXBPtVd/GSgnaGI9q4vYKUKvoetUsPATxU2dPc+MJ5D8qmqLeJrtnJ6Z4rG2gc4604Lz05qlRguhm6831NdPEtxGBsQA+pPNWV8X3XVwScYHNYAQEDApyIpHKg0eyh2D20+5tQ+I5ZbgNO5VR711dh4mhCAbh+NedlFY4KgLn8v85prQgfdcg1MqEWXHEyW+p6ofFCsMRfMfrTrfVJ55Bu4OfrXliG4iP7qU5zjrVmLV9Qt/4uPUisnhexrHF90ezw6i6RqZGCge/NJN4pQt5FrhpOhOeBXj0niG9ddsmSD2zTrPxA9rMHWEZHvUfVpGn1qB7dphDuJpSZpic7m6D6VtJdAL8xAHtXjVn476CRWT+Vblp4rhmUEzxjPvzWMqMo9DaNWMup6ZHcg8L/OpUkBAJwT7muBt/ElsoBDs/wCtWk8UM6kQwSMfULWdrbmt77HdeaDuz09PWopJVUkgDPqTXIw6pfz4+VEHu1XFkuWG1mTJHalcaizY+2AMwUg+9OSd2BUOuPSqtvaNt+fDHrVk2wGMADjvRqJtE8TOMlpMD2NPSQ7Ww7deDgGoVTAC44pVU4wVwM1VhXPncEZymMDlQ36f+y09AB2zgZB7+2fx2fnUDNlsoNpPTHb0H6j8qXORxxjpjkj0/mvp0r2DwyeNgq/KwyRkD+X6hPzo6sPLU8/cx1Ppx3/g9agUg7RGACeh9PQ/hlfyoGAAycbumOAM+/fBK+vSgCUHoFXtgZ5z6f8Asn+FAYYAQkHjBGOP7uT2/g9OlRSHd6AH3wFz2/DI/LpSA7yFOQD0zwFz/wDr9vu0AO8zAATjgYOOg7c+2QPw61Hu4J+4GPTsB/kn8qdyyspGM9V/z9T69KYRkZfHX5iT/n/aoAaWB6LtI+8PX/PzUzJUfNnI6j/P0NLJ8rHd1HJ/r/I03PGMZHXOf8+h/OgBwPC8Hg/mf8j9aUc9Ppzzg9P8KZ24OT27/wCeg/OnjgkBhxwO5Pp/If4UAOJ3c8AE8cf59RUgwzb2B2N1BPT/ADk/4VEMA8Hgj8v85H5dKnhUPgEld3Bz7/8A7X6UAWI2wg8xR6NkfTP/ALN2o5X5mZQVABBzzj2+qH86ROOSDg9c9cHqP/Hm/KlVsDDfLjk88Egc5+u1vTrQBBJACgCgHsOOmOP/AIn86ckMMhA8tct3K+/+DD8qe5Ji8tQCO2Dxnp+u1aHIO1ScA/dxz1/+sy/lQBGtrbkMzRJt69MAdD1/7679qZJpkLFSAVGMcfxHB6dzyD+dWfO3AKxyOuM8Dv8A+zMO1PBIJwx3fTGcc/zUj8aBlFtKgzhXkz+B7/8A1xUX9lxkAiUgEZ/r/j+VavIOwEHHygenUfz2ntQu05J5DnPHp6fk3v0oAzH0U/wzevVe/PH6frUMmkSjGJEOcY/TH8xWwp4DtycZIHtgn/0E0E/wIMnoCRz3H9FoAwzps20OxXnnn/P1/KnxWLxyHcVO3OMd+v8AUVubVlJA4XOBx2J9fo/6VCVwegHRjj6A/wBDQBmeR27/AP1//riojEQQepH/AOutN4tu7kblGP5j+aimNGJHIOcZwPzI/qKQGa8fdckDgn3/AMikaHpjoa0/LyTgZ4z/ACP+NROm1WHccdPQf/Y0AUDEVHb86R1Oc4xj9KvNBzjbnPT9R/hTfL6E9OD/AC/xoApbTwOc9B/n8aTYfxq60bBR0GB/L/8AVQYsPgYz0/UigCoI84pSh6dulWlUAZIz3HOCOh/xpoT5fT9e3/1qAIAuRuIOMf0/+tTtpCntj/P9anKDec/dz0x1Gf8A69JjapBI46e3SgCBVOOME9eR06U8Ak7Seenr604qATwe/B+hp2OQDnnv7f5NADFUHsM57nHpTsYBGR06/hRtwB06dfwpzY3MFHAP+P8AnmgBpA3EN6/j1/SopED/AHl7d+vSpCefc89PpUbAHjv04/GgRXeD+4fzqfTrv7FcI00YkjznBpSMfnUbruGDz6/rQ1dWY02tUepaBqOnXMAaFY/cY5FdPZtAE3KF5rwOKWezl8yB2Q+oPWul0rxjPDtS6Td23LXLUoPdHbSrx2keyK8Qzu2896kieLnAA+lcRpfiO1uygE4Vv7p6100FxG4DZVx7VxuDTO1STWhux3A6I2e1SCX5TkHOevWsuJlwMdKsI3zfKPyNIC8DuYYp3zqMZAB9TUasMYPYdetPUj+8PxFAHzk6hThjgn7x9PX/ANm/KlUqwORyc7vY9/5t6dKaWAIGchT19cf/AKj+dDEZIJ9STjGf/wBeD6da9g8QUkkgv945yvUj1/mfypxwVxwMjHH68/ifX7tMwAnJyPy3Dnt/3169aTIBJ5AxjJ/X/wBmoAcDnJckDvjt9fzb06UDGADzkHJH6/8As3b8aUnYSJCcjrxj6/8As3p1pOTvVwAQDkdfr/JvXrQApA6sQA33ie/r9f4vWmkMoyeCOSD175GO3Ib060vRWzyRxwc59efwPfv0pTkDBP3ck5/z7H86AGlcLzuwOxPQ9/5H86YFxgtyRx+Xb9P1qdSVAB5RevTn/O0/nUZHGM7tv64//Z/WgBMY5zwB1A54/wDrgfnTWOB8vXtjt6f+y+lLn6ccf5/IfnTWPPyjHbpge39PSgABB4UEDtjtnp/MVNEA7lVx83GO/P8A+1+lQqN33Rx0AxwPf9RU8O052jJPA9s//tD8qALYO5tzlmVhltvO3PJ/Lc3ftSHG9XlGc/Ngce5x+TfnTNxxyP8A6wP/AO2fypN4KDeBzycdfUj/ANCoAV9ytheR3GeMjjv7qD360jLjGeGGVAAxz9OvQqe1LvKYA6gcn0x/9dfbrSFAV2gnB4U/p1/FaBjEGQS33T1wOgP/ANYn8qe0uVUgYOMsc9+ufzDfnTChZsYwpPXpj/IY/lTQShyPvDn+R/8AiqBFpWKrsOQegwOpxx+qrUvyFCuG3MQBu6YOQM+/zL+VUxvWQkkh17d+Of5rUobDY3FeCB79QP5LQMmQhvnAJBHJ9Bwf6tTcqiZOCwHPqe5/IofXrSAl8IrYQnjPbOf6OKWJsgFh985Oe4OD/wCzNQAYK7ggAHK49CMgY/IVL99iSMDB+pyf8HqLccgngAZJxz0HH5qaQ/IgwQeMDPqMj+goAUtkB8EAn5hnIxw3/wAV60bdq4I2/LwCOeAf6pRz8zcBWJUe/UD9GFKvzKC3I7D0yVP4D5j6UARsuMoOSTjHXPJH9RTE5cNgn5gSB6ZB/qalGFHzLj5eV9cAH/2U0Om1CFzgAgHA9CP/AGUUAQMhVAeePmxjp0/wNNYYJAGSARwOvUf0FWArOw9T29iev/jwprZaPIb5uCMd/un8e9AEG3PqBnn8T/8AZVHj5QwHHU4P0/qDU8ijYQCMgcgc9Af/AImmlMnCYzyP1PP6ikBCVIGMAcep9x/QUhwCMdM/1/8Ar9qlK7uhJA59PQ/1NRYIU56YH8v/AK1ADeNuew5+vTr+VGC2R6Dn9RSsCSAfTv8AiKOgVgckc9cY5H680AIpy3HTOOPr/wDXpOCue2Py6f4UYO3JweMfy/wppySQM5GR/OgBTyDweAcfrSAjuMe4PuKDjd+Pr7//AF6ax+UE88d/8+1AA3IOfp+n/wBamnO7k/5z/wDXoJPT8v1pM45/z2oATjH+fSjHzdOv+NHfGRxQMk5HJ6/yoAQqCORnj+lQywYOU6CrHBBwOP8A6xpepyc5z/U0xEdsSzhGO1+2e9b9lc6rageRKxHoTkVz7oHGO/Y+nSp7DUJbaULK7eX/ACrKcLm1OpynbWfifVYQBNaswH8S1t2HjSHAF0rxN/tLisbTLqO4jQbsg1uxWltJ8pVT6k1xySPRhdo1bXxXpzgk3UYz6mtO3120lAKTxkf73Wud/s3T8D9xGW9doqzDo9qcN5SA/QVkzW3c8gRhgFcDAwB19Mf+y0uS3TjbyCOo9Pp0Hp1pACQD93PH+fz/AEoHTIGCDxk/0/FfTpXrHhjwwHC/MM8dyfr69B6/eoU4JGQx6deDj398frUe4Acd+n9OP++fWlBO8MvOPu55+n8l/OgB7AqGA529OoBx/jj260oULgg7+OffHfH/AAE+vWkHyvkHOB068Dp9Og9OtPTgHbggHv3/AM7f1oAXDEKTjI5GT6f/ALJ/Ohwyk7gDt7/1x/wE/nTtmxT3A5Hoce//AAEfnTXJ4G7IA7DHQf12j86ABhtXlt2OOn+f7v61H075IOOf8+3607J3DceMYOPp/wDYj86icFCdoz268f54H50ANOVYgEcdMf59hR34PbPXp/nigjHzZ9h/n8qZk5GPw9vf+VAEi8kAdumO3+cip0VWI2/KG4HPr/8AtD8qgj5O31PGegz3/UVZjcthAcE8ZHv/APrH5UATnDoA5IJPcdAf5D5j+VNRlOGJPH3iB0HX/wCKpwAZRvJ2nnr0B/8A2/TtULElmYjGeG9gef6t3oGO3Mn3/vLwAefwx9VPbvT1IyoG4H7ox69B9ei1CGIOSASOT6Huf5GnqzKwJHK5PXqf/wBajrQBJIpYKiHP4f57MPyqLIYdR+fTOD/7M1SEFh8ucqOMDp1H/wATUTFWycnB/Dg5/wDihQIap2ckZ6H6Ec/0NAYjK5AwO/t/+zTD97HPPbHOP8tSBs4bj19z0z/WgZYIIQfNkgYHf1/wWpN/mAKV4PHHoc/n1WqocovXOBjn2x/8SakjYoMK+cZyAccjP/xIoAnJ3kHB2k5GfzP6MacmBKrbvQ5/AE/yNNAHzBWbA4Gevcfh2pGZZCV+6Dnge5P/AMX+lAAeATx8vB7c/wCUp7n5GU4IGRwOBwR/8TTM5G4nOT1PQZwf/ZjSCQptPJ29R68A/wA1NAD0Acg45Yg59cn0/wCB+9AYn5hjnkn24J/r6VC5IUqSSMHGPxGf/HRTiVf5TznoOwzkf1FADiNquB2HA5HI/wD2ac7AhgDycjGP94Y/lSIycFwGzg8ehI4/8ePb8aUOTtckZAB9+x5P4H/61AAF3MOV+Y9Owye//fXtURBYjuD6DvgE/wAjTlXClcfMvBxxjAP/AMTSnJUp17Bu5+8P6j1oAiZQnGeRwcfj/hUZXLHb09PbJ/xqYrggnABPPPYkdf8Avr2qORSccjGM8cc4B/xoAh7hjwM/l0/xppz1OeB/T/61SP8AcOQB6AD2/wDrUxv7v/6+/wDjSAawzkH149utJjnJPGevbr/9enL8pBHqCMfUf40mQMZ5IH+H+FADTggZyT/+qmEc8+/9acQduO4z8v501iMg9QeoJoATq3Prn+VIcY5PNJQeGPr0P50AH8XHc0D1yc4/pR6f57Cgc/5+tADjjqMcnj9aM8598nPeggA5PekHbt/kUAIR07/5FRyJuXtkVNwVPIGBTG6ceh/rTELp+oTWEmASVB6eldNZ6/JKVEZwT1JPSues7Fr+5CIDjPzMB0HNdJFpEMc8KRr8w61z1uU7MPKfTY2rC4vmIZSHX0IxW9aXl1jDxGk0u2CQqu3n1NbENuAQcA1wtno37nh4DFjnoR27nv8A+zflS4OeDg9OD0P1/H26UhIBKjlehP8An8fXrT1Py4J2+p/n/Nq9Y8IYowe47jH6Z/MflTl5zt6dv8/98+tCZOGbrk/h/nP6U7+HKggN078/5I/KgBEOAcDO3kZ49OP/AEH0qdccEDGOVB7+n1zhfzqBSfl2EggZBHr2/wDZfyqRNr4CY9h/L/2WgB/zRqCWIIPXr06fjwv50zf0wBkYx9O38h+dKhKqVByvbn/P+zUbZOAOg7j/AD/u0ANbK4x2PBxn/PQfnTGKnbwcjrn9P5CnOdv3Dn8Ov+flqLI52nP+f/1UALuyflPAPH+fypRgHAJ9eO3+eKbj5cr6f5/pSg8cc8ZGOPp/SgCVfmYbOp4x/L+YqeMKQc4ww+ufQf8Ajw/Kq0a9Ocdxz/n2qwnysPLPXgZ/T+a0ASkeYDtPBPA9j0P/AI8PypCN4zx+PYHt/wCPGlwzsVQFd/TPPXp/6EtIw78fMcc+/wDL7w9OlACKNxyw4PLAenU8fi1KPlTLFsdz19M/qp9KAA5JPRvmGOnP/wC0fypWY/fGMEg9fXB/q1AEiExrjBOOQPp/+xUTqM5249vbkZz+C0qqQQzH3IP4E5/JqVz8oJPQAfl/9dTQMgkVcbV6n9ev+IqJyGAbO3ceufz/APQv/rVPICpJxgr2Ptn/AOJqFlIcbOev9f8AAUANU8jPTvjtnH+Jp8UnOGx1BOfw/wDr0kiAfcXjnHPY5/xHpTMFj7N0x/n3oEWRMQQ4GGwMnHfj+qmguwHAUMvGc9Tgj/2UVDE2TuPfqR7/AP6zThk4Jbvk569s/wBaBk4f5WAY5PA/UY/VaQHBHAAbsPf/APaqvGdoGRz1z1B/ztqRSVBwcsOPYdf8BQA8DcfmyOAeD34P+NRltqjkDA/oP6rTn+YEgjrj+Y/qKY53EbeM8fX/ADuoAduIG0nHUcfiP6CnSPu+UcAnjn3PH61EGyRtAPTP6f8A16SPATOTkDPP+fagC0jEkHK9jjHc47f8CNKpJAOCCQM85z93PP4GoC5G7B9t2PTP+FG7OVUnHI579f8AEUATHJA6EKOnpx/9jSbSCRxnkc/8CFDMGJ54Occccnt/317U7cCVbB5PJPUj5T/U96AIZFLOwxxk4Pfr/wDXqLHHA44z+lWNu5AAMlfQew/+JNQOpGSD/nB/woAY44444x+n/wBamsDk4B7/ANakY5YgHjnn8/8AGmEAjOfTj8v8aQEZ+9g4PP8An+dMzgZ6n/8AVTu2eM//AKqawPsAM0AJzjHTH/16OR06nn+VB+nem44/z6UAH8NPHX6//XpvUnP/AOvrRnnjpQA8Hj/PtSLn5RngevTtQhPAA9O30ra0rQZrrDzZSLsO5pSkoq7KjBzdkY2CScZJqWO2kllSMxsCxwMg478139ho1vbKNkS59cc1cXS/PYAgBfaud4nsjqjhH1ZkWtlBplirL8zEdT1Jq9pEI8zzJeSa2U0SEqAV3Eepzir8FkkQAArllO52QgojbcqpHpWnFtZQQefaokt1BAHSlCmI5TBHpUGlkz//2Q==);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Rebecca Bassett, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_38_23136=[""].join("\n");
var outline_f22_38_23136=null;
var title_f22_38_23137="Patient information: Folliculitis (The Basics)";
var content_f22_38_23137=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div id=\"basics-graphics\">",
"      <span class=\"basics-box-top\">",
"      </span>",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-graphics-title.png\"/>",
"       <span class=\"openRelatedGraphics\" id=\"PI/17202\" rel=\"graphic_box\">",
"        <a href=\"#\" title=\"View All Related Graphics\">",
"         View All",
"        </a>",
"       </span>",
"      </h4>",
"      <ul>",
"       <li>",
"        <a class=\"graphic graphic_figure\" href=\"UTD.htm?17/18/17699\">",
"         Infected hair follicle",
"        </a>",
"       </li>",
"      </ul>",
"      <a href=\"#\" id=\"basics-seeall\">",
"       See All Graphics",
"      </a>",
"     </div>",
"     <script type=\"text/javascript\">",
"      if ($(\"#basics-graphics li\").length &lt;= 4) {",
"				$(\"#basics-seeall\").remove();",
"			} else {",
"				$(\"#basics-graphics li:gt(3)\").addClass(\"hidden\");",
"				$(\"#basics-seeall\").click(function(){",
"					$(\"#basics-graphics li.hidden\").removeClass(\"hidden\");",
"					$(this).remove();",
"					return false;",
"				});",
"			}",
"     </script>",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?19/63/20465\">",
"         Patient information: Boil (The Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Folliculitis (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/folliculitis-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H6662971\">",
"      <span class=\"h1\">",
"       What is folliculitis?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Folliculitis is a skin problem that happens when a hair follicle gets infected (",
"      <a class=\"graphic graphic_figure graphicRef66769 \" href=\"UTD.htm?17/18/17699\">",
"       figure 1",
"      </a>",
"      ). A hair follicle is a sac under the skin where a hair starts to grow.",
"     </p>",
"     <p>",
"      People tend to get folliculitis on the parts of their body that they shave. For example, men can get it in on their face, where their beard normally grows. Many men get &ldquo;razor bumps&rdquo; or &ldquo;shave bumps.&rdquo; The word doctors use for these bumps is &ldquo;Pseudofolliculitis barbae.&rdquo; Razor bumps are like folliculitis but are caused by ingrown hairs.",
"     </p>",
"     <p>",
"      Folliculitis can be caused by infected water in hot tubs, spas, or swimming pools.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H6662986\">",
"      <span class=\"h1\">",
"       What are the symptoms of folliculitis?",
"      </span>",
"      &nbsp;&mdash;&nbsp;The main symptom is a group of small, raised red bumps on your skin. These bumps can be tender or itchy, and they might have pus in them. Some of the bumps might have hair coming out of them.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H6663003\">",
"      <span class=\"h1\">",
"       What can I do on my own to treat it?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Wet a clean washcloth with warm water and put it on the bumps. When the cloth cools, reheat it with warm water and put it back on the area. Repeat these steps for 10 to 15 minutes, 3 times a day.",
"     </p>",
"     <p>",
"      Do not shave the area that has folliculitis. That will just irritate it more.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H6663018\">",
"      <span class=\"h1\">",
"       Should I see a doctor or nurse?",
"      </span>",
"      &nbsp;&mdash;&nbsp;See your doctor or nurse if the folliculitis does not go away after you treat it at home. You should also see your doctor or nurse if:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        The bumps get larger or more painful.",
"       </li>",
"       <li>",
"        The bumps go away but then come back.",
"       </li>",
"       <li>",
"        You get a fever.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H6663033\">",
"      <span class=\"h1\">",
"       Will I need tests?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Probably not. To make sure you do not have another skin condition, your doctor or nurse will ask about your symptoms and do an exam.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H6663048\">",
"      <span class=\"h1\">",
"       What other treatment might I have?",
"      </span>",
"      &nbsp;&mdash;&nbsp;If your folliculitis does not go away on its own, your doctor might prescribe an antibiotic cream. But most cases of folliculitis get better without treatment.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H6663063\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?19/63/20465?source=see_link\">",
"       Patient information: Boil (The Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"UTD.htm?22/38/23137?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 17202 Version 1.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-118.195.65.247-9F1D191359-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_38_23137=[""].join("\n");
var outline_f22_38_23137=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6662971\">",
"      What is folliculitis?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6662986\">",
"      What are the symptoms of folliculitis?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6663003\">",
"      What can I do on my own to treat it?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6663018\">",
"      Should I see a doctor or nurse?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6663033\">",
"      Will I need tests?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6663048\">",
"      What other treatment might I have?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6663063\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PI/17202\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li>",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?17/18/17699\">",
"      Infected hair follicle",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?19/63/20465?source=related_link\">",
"      Patient information: Boil (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f22_38_23138="Scabies axilla";
var content_f22_38_23138=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F60849&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F60849&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Scabies axilla",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 380px; height: 506px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Erythematous papules are present in the axilla of this child with scabies.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_38_23138=[""].join("\n");
var outline_f22_38_23138=null;
var title_f22_38_23139="Clocortolone: Drug information";
var content_f22_38_23139=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Clocortolone: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?30/14/30947?source=see_link\">",
"    see \"Clocortolone: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F152879\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Cloderm&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F152880\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Cloderm&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F152889\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Corticosteroid, Topical",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F152881\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Steroid responsive dermatoses: Topical: Apply sparingly and gently; rub into affected area from 1-4 times/day. Therapy should be discontinued when control is achieved; if no improvement is seen, reassessment of diagnosis may be necessary.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F152882\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F152867\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cream, topical, as pivalate:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cloderm&reg;: 0.1% (30 g, 45 g, 75 g, 90 g)",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F152855\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F152868\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Inflammation of corticosteroid-responsive dermatoses (intermediate-potency topical corticosteroid)",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F152895\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      International issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Cloderm: Brand name for clocortolone [U.S., Canada], but also brand name for alclometasone [Indonesia]; clobetasol [China, India, Malaysia, Singapore, Thailand]; clotrimazole [Germany]",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F152887\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermatologic: Itching, erythema",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Local: Burning, dryness, irritation, papular rash",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &lt;1% (Limited to important or life-threatening): Acneiform eruptions, hypertrichosis, hypopigmentation, maceration of skin, miliaria, perioral dermatitis, skin atrophy, striae",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F152872\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to clocortolone or any component of the formulation; viral, fungal, or tubercular skin lesions",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F152859\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Adrenal suppression: May cause hypercorticism or suppression of hypothalamic-pituitary-adrenal (HPA) axis, particularly in younger children or in patients receiving high doses for prolonged periods. HPA axis suppression may lead to adrenal crisis.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Contact dermatitis: Allergic contact dermatitis can occur, it is usually diagnosed by failure to heal rather than clinical exacerbation.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Kaposi's sarcoma: Prolonged treatment with corticosteroids has been associated with the development of Kaposi's sarcoma (case reports); if noted, discontinuation of therapy should be considered.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Systemic effects: Topical corticosteroids may be absorbed percutaneously. Absorption of topical corticosteroids may cause manifestations of Cushing's syndrome, hyperglycemia, or glycosuria. Absorption is increased by the use of occlusive dressings, application to denuded skin, or application to large surface areas.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pediatrics: Children may absorb proportionally larger amounts after topical application and may be more prone to systemic effects. HPA axis suppression, intracranial hypertension, and Cushing's syndrome have been reported in children receiving topical corticosteroids. Prolonged use may affect growth velocity; growth should be routinely monitored in pediatric patients.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299063\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F152863\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aldesleukin: Corticosteroids may diminish the antineoplastic effect of Aldesleukin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Corticorelin: Corticosteroids may diminish the therapeutic effect of Corticorelin. Specifically, the plasma ACTH response to corticorelin may be blunted by recent or current corticosteroid therapy.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: Corticosteroids may enhance the adverse/toxic effect of Deferasirox. Specifically, the risk for GI ulceration/irritation or GI bleeding may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hyaluronidase: Corticosteroids may diminish the therapeutic effect of Hyaluronidase.  Management: Patients receiving corticosteroids (particularly at larger doses) may not experience the desired clinical response to standard doses of hyaluronidase.  Larger doses of hyaluronidase may be required.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Telaprevir: Corticosteroids may decrease the serum concentration of Telaprevir. Telaprevir may increase the serum concentration of Corticosteroids.  Management: Concurrent use of telaprevir and systemic corticosteroids is not recommended.  When possible, consider alternatives.  If used together, employ extra caution and monitor closely for excessive corticosteroid effects and diminished telaprevir effects.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F152864\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F13277401\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Teratogenic effects have been observed in animals administered potent topical corticosteroids. Topical products are not recommended for extensive use, in large quantities, or for long periods of time in pregnant women.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F13277403\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion unknown/use caution",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F13277402\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     It is not known if topical application will result in detectable quantities in breast milk.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F152873\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Cream",
"     </b>",
"     (Cloderm Pump External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.1% (30 g): $168.58",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F152874\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Kaban (DE)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F152858\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Stimulates the synthesis of enzymes needed to decrease inflammation, suppress mitotic activity, and cause vasoconstriction",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F152871\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Percutaneous absorption is variable and dependent upon many factors including vehicle used, integrity of epidermis, dose, and use of occlusive dressings; small amounts enter circulatory system via skin",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Hepatic",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Urine and feces",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Goedert JJ, Vitale F, Lauria C, et al, &ldquo;Risk Factors for Classical Kaposi's Sarcoma,&rdquo;",
"      <i>",
"       J Natl Cancer Inst",
"      </i>",
"      , 2002, 94(22):1712-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?22/38/23139/abstract-text/12441327/pubmed\" id=\"12441327\" target=\"_blank\">",
"        12441327",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9278 Version 37.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-203.80.222.8-E8883B2495-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_38_23139=[""].join("\n");
var outline_f22_38_23139=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F152879\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F152880\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F152889\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F152881\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F152882\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F152867\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F152855\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F152868\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F152895\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F152887\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F152872\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F152859\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299063\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F152863\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F152864\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13277401\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13277403\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13277402\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F152873\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F152874\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F152858\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F152871\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9278\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9278|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?30/14/30947?source=related_link\">",
"      Clocortolone: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f22_38_23140="Regadenoson: Drug information";
var content_f22_38_23140=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Regadenoson: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?31/34/32291?source=see_link\">",
"    see \"Regadenoson: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F6139005\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Lexiscan&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F6156884\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Diagnostic Agent",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F6139064\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Myocardial perfusion imaging:",
"     </b>",
"     I.V.: 0.4 mg (5 mL) over ~10 seconds, followed immediately by a 5 mL saline flush.  Wait 10-20 seconds, then administer the radionuclide myocardial perfusion imaging agent.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F6139065\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F14210990\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment necessary.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F14210991\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment necessary.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F6139070\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution [preservative free]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Lexiscan&reg;: 0.08 mg/mL (5 mL) [contains edetate disodium, propylene glycol 150 mg/mL]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F6139007\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F6139067\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Administer over approximately 10 seconds into a peripheral vein using a &ge;22-gauge catheter or needle, followed immediately by a 5 mL saline flush. Wait 10-20 seconds, then administer the radionuclide myocardial perfusion imaging agent. The radionuclide may be injected directly into the same catheter as regadenoson.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F6139008\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Radionuclide myocardial perfusion imaging (MPI) in patients unable to undergo adequate exercise stress testing",
"    </p>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F6139020\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     &gt;10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Cardiovascular: Tachycardia (22%), flushing (16%), premature ventricular contractions (14%), chest discomfort (13%), angina or ST segment depression (12%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Central nervous system: Headache (26%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Respiratory: Dyspnea (11% to 28%), bronchoconstriction",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Cardiovascular: Chest pain (7%), premature atrial contractions (7%), systolic blood pressure decreased &gt;35 mm Hg (7%), systolic blood pressure increased &ge;180 mm Hg and &ge;20 mm Hg from baseline (5%), ventricular conduction abnormalities (6%), diastolic blood pressure decreased &gt;25 mm Hg (4%), first-degree AV block (PR prolongation &gt;220 msec; 3%), diastolic blood pressure increased &ge;30 mm Hg (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Central nervous system: Dizziness (8%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Gastrointestinal: Nausea (6%), abdominal discomfort (5%), abnormal taste (5%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Respiratory: Wheezing (&lt;1%; 1% to 3% in patients with asthma or COPD); respiratory adverse reactions overall (includes obstructive airway disorder, exertional dyspnea, tachypnea) (13% to 19% in patients with asthma or COPD)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Miscellaneous: Feeling hot (5%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     &lt;1% (Limited to important or life-threatening): Abdominal pain, anaphylaxis, angioedema, asystole, AV conduction abnormalities (other than AV blocks), cardiac arrest, diarrhea, fecal incontinence, heart block (includes second- and third-degree), hypertension, hypotension (symptomatic), myalgia, oxygen saturation decreased, QT prolongation (transient), rash, respiratory arrest, respiratory distress, seizure, syncope, throat tightness, transient ischemic attack, tremor, urticaria, vomiting",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F9848303\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Second- or third-degree heart block or sinus node dysfunction in patients without a functioning artificial pacemaker",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F6139014\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse events:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Myocardial ischemia: Pharmacological stress agents may produce myocardial ischemia resulting in life threatening ventricular arrhythmias, MI, and fatal cardiac arrest.  Equipment for resuscitation and trained personnel experienced in handling cardiac emergencies should always be immediately available prior to administration. If serious reactions occur, consider the use of aminophylline, an adenosine antagonist.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Conduction disturbances: Regadenoson depresses SA and AV node conduction and may produce first-, second-, or third-degree heart block, or sinus bradycardia. Third-degree heart block and asystole within minutes of administration have been reported. Use caution in patients with first-degree AV block or bundle branch block. Functional pacemaker must be in place to use in patients with second- or third-degree AV block or sinus node dysfunction.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Hypersensitivity reactions: Anaphylaxis, angioedema, cardiac and respiratory arrest, and other hypersensitivity reactions have occurred with regadenoson use. Equipment for resuscitation and trained personnel experienced in handling serious hypersensitivity reactions should always be immediately available prior to administration.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Hypertension: May produce hypertension; typically within  minutes of administration and usually resolves within 10-15 minutes. Effects may persist; in some patients hypertension continued for 45 minutes after administration. Use with caution in patients with underlying hypertension, especially when low-level exercise is used during MPI.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Hypotension: May produce profound vasodilation with subsequent hypotension especially in the elderly. Use with caution in patients with autonomic dysfunction, carotid stenosis (with cerebrovascular insufficiency), uncorrected hypovolemia, left main coronary artery stenosis, pericarditis, pericardial effusion and/or stenotic valvular heart disease. Syncope and transient ischemic attacks have been reported.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Respiratory disease: Regadenoson may cause bronchoconstriction in patients with asthma; should be used cautiously in patients with obstructive lung disease not associated with bronchoconstriction (eg, COPD/emphysema, bronchitis). Equipment for resuscitation and appropriate bronchodilator (eg, albuterol) therapy should always be immediately available prior to administration.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Dipyridamole: When possible, dipyridamole should be withheld for at least 2 days prior to regadenoson administration; concurrent use of dipyridamole increases the risk of adverse effects of regadenoson.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Theophylline derivatives: Patients should avoid consumption of any products containing theophylline derivatives (eg, aminophylline, caffeine) for at least 12 hours prior to regadenoson administration.  Aminophylline may be used to reverse any severe or persistent adverse reactions to regadenoson.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299988\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F6139024\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aminophylline: May diminish the vasodilatory effect of Regadenoson.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Caffeine: May diminish the vasodilatory effect of Regadenoson.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dipyridamole: May enhance the therapeutic effect of Regadenoson.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Theophylline: May diminish the vasodilatory effect of Regadenoson.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F6139027\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Food: Regadenoson&rsquo;s diagnostic effect may be decreased if used concurrently with caffeine. Management: Avoid food or drugs with caffeine for at least 12 hours prior to pharmacologic stress testing.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F6139009\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F6139010\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Animal studies have demonstrated embryo-fetal toxicity and maternal toxicity. There are no adequate and well-controlled studies in pregnant women. Use only if potential benefit outweighs risk to fetus.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F6139012\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/not recommended",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F6139013\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Due to the potential for serious adverse effects in the nursing infant, the manufacturer recommends interrupting nursing for 10 hours after administration.",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F6139066\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Avoid dietary caffeine for at least 12 hours prior to pharmacologic stress testing.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16321820\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Lexiscan Intravenous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.4 mg/5 mL (5 mL): $262.84",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F6139069\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Heart rate, blood pressure, continuous cardiac monitoring, oxygen saturation",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F12992806\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Rapiscan (CZ, EE, NL, PL, PT, SE)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F6139030\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Regadenoson, a low affinity agonist of the A",
"     <sub>",
"      2A",
"     </sub>",
"     adenosine receptor, increases coronary blood flow (CBF) and mimics the increase in CBF caused by exercise. Myocardial uptake of the radiopharmaceutical is proportional to CBF creating the contrast required to identify stenotic coronary arteries.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F6139033\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Distribution: 11.5 L",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metabolism: Unknown",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Half-life elimination: Initial phase: 2-4 minutes; Intermediate phase: 30 minutes; Terminal phase: 2 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Time to peak, plasma: 1-4 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Excretion: Urine (57% as unchanged drug)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      American Society of Nuclear Cardiology, &ldquo;Imaging Guidelines for Nuclear Cardiology Procedures: A Report of The American Society of Nuclear Cardiology Quality Assurance Committee,&rdquo;",
"      <i>",
"       J  Nucl Cardiol",
"      </i>",
"      , 2006, 13(6):e21-171.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Gordi T, Frohna P, Sun HL, et al, &ldquo;A Population Pharmacokinetic/Pharmacodynamic Analysis of Regadenoson, an Adenosine A2A-Receptor Agonist, in Healthy Male Volunteers,&rdquo;",
"      <i>",
"       Clin Pharmacokinet",
"      </i>",
"      , 2006, 45(12):1201-12.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?22/38/23140/abstract-text/17112296/pubmed\" id=\"17112296\" target=\"_blank\">",
"        17112296",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Iskandrian AE, Bateman TM, Belardinelli L, et al, &ldquo;Adenosine Versus Regadenoson Comparative Evaluation in Myocardial Perfusion Imaging: Results of the ADVANCE Phase 3 Multicenter International Trial,&rdquo;",
"      <i>",
"       J Nucl Cardiol",
"      </i>",
"      , 2007, 14(5):645-58.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?22/38/23140/abstract-text/17826318/pubmed\" id=\"17826318\" target=\"_blank\">",
"        17826318",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9462 Version 31.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-218.28.111.102-5CC63B1F68-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_38_23140=[""].join("\n");
var outline_f22_38_23140=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6139005\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6156884\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6139064\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6139065\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14210990\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14210991\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6139070\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6139007\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6139067\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6139008\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6139020\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9848303\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6139014\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299988\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6139024\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6139027\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6139009\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6139010\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6139012\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6139013\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6139066\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16321820\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6139069\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12992806\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6139030\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6139033\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9462\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9462|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?31/34/32291?source=related_link\">",
"      Regadenoson: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f22_38_23141="Potassium iodide: Patient drug information";
var content_f22_38_23141=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Potassium iodide: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/27/30134?source=see_link\">",
"     see \"Potassium iodide: Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?35/28/36293?source=see_link\">",
"     see \"Potassium iodide: Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F211985\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      iOSAT&trade; [OTC];",
"     </li>",
"     <li>",
"      SSKI&reg;;",
"     </li>",
"     <li>",
"      ThyroSafe&reg; [OTC];",
"     </li>",
"     <li>",
"      Thyroshield&reg; [OTC]",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10029324\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10029326\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat an overactive thyroid gland.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691567",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to stop thyroid cancer from radiation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691653",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to thin mucous so it can be taken from the body by coughing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2692146",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It may be given to you for other reasons. Talk with the doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10029325\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702771",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to potassium iodide or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2855825",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any of these health problems: Enlarged thyroid gland (goiter), high potassium levels, or kidney disease.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701080",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are pregnant or may be pregnant.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10029330\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697300",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have lung disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697313",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have myotonia congenital or TB (tuberculosis), talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698463",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your blood work checked often. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698528",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are taking a blood thinner, have your blood work checked. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697732",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use birth control that you can trust to stop pregnancy while taking this drug and for 1 month after stopping this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698411",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your baby's thyroid checked if you are using this drug and breast-feeding.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10029331\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698306",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696432",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Bad taste in your mouth. This most often goes back to normal.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698074",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling tired or weak.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10029333\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698655",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       A fast heartbeat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698663",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Flu-like signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699008",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad belly pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699042",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699105",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any bruising or bleeding.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699051",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad swelling.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698988",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Numbness or tingling in your hands or feet.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698658",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling very tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10029328\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695914",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take with or without food. Take with food if it causes an upset stomach.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705443",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Liquid (solution/syrup):",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695931",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take with water, milk, or juice.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694789",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not use if it turns brownish-yellow.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705383",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Expectorant:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694818",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Drink lots of noncaffeine liquids unless told to drink less liquid by your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705515",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Radiation exposure:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695893",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take this drug only when told by public health officials.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695778",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take once a day until the chance of being exposed to radiation ends.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s4231397",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       You may crush the tablet and mix it with water, low fat white or chocolate milk, orange juice, flat soda, or raspberry syrup.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10029329\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696457",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not change the dose or stop this drug. Talk with the doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10029334\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699264",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Protect from light.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10029335\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11439 Version 33.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-122.96.59.103-3B792D9370-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_38_23141=[""].join("\n");
var outline_f22_38_23141=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F211985\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10029324\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10029326\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10029325\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10029330\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10029331\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10029333\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10029328\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10029329\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10029334\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10029335\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?29/27/30134?source=related_link\">",
"      Potassium iodide: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?35/28/36293?source=related_link\">",
"      Potassium iodide: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f22_38_23142="Segmental anatomy of the liver";
var content_f22_38_23142=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F52260&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F52260&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Segmental anatomy of the liver",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 448px; height: 368px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Couinaud's segmental anatomy of the liver. Segments II to IV make up the left lobe and segments V to VIII constitute the right lobe.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Mulholland MW, Lillemoe KD. Greenfield's Surgery: Scientific Principles And Practice, Fourth Edition. Philadelphia: Lippincott Williams &amp; Wilkins, 2006. Copyright &copy; 2006 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_38_23142=[""].join("\n");
var outline_f22_38_23142=null;
var title_f22_38_23143="Microbiology and pathogenesis of Streptococcus pneumoniae";
var content_f22_38_23143=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Microbiology and pathogenesis of Streptococcus pneumoniae",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?22/38/23143/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/38/23143/contributors\">",
"     Elaine I Tuomanen, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?22/38/23143/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/38/23143/contributors\">",
"     Daniel J Sexton, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/38/23143/contributors\">",
"     Sheldon L Kaplan, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?22/38/23143/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/38/23143/contributors\">",
"     Anna R Thorner, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?22/38/23143/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 3, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Streptococcus pneumoniae occupies an important position in the history of microbiology:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The organism was first identified in 1881.",
"     </li>",
"     <li>",
"      Its role in causing lobar pneumonia was appreciated by the late 1880s.",
"     </li>",
"     <li>",
"      The central role of antibody in host defense against extracellular organisms was first described for the pneumococcus.",
"     </li>",
"     <li>",
"      The first recognition that antibody directed to the capsular polysaccharide of a bacteria could be protective was shown for the pneumococcus; this observation forms the basis for many current bacterial vaccines.",
"     </li>",
"     <li>",
"      The discovery of DNA as the material for genetic exchange was made from the pneumococcus.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    However, despite the extensive study of this pathogen and the availability of a vaccine covering 23 different serotypes, S. pneumoniae is currently the major invasive pathogen of children and older adults and is a principal cause of otitis media, pneumonia, bacteremia, and meningitis. The case-fatality rate for bacteremia in elderly patients is approximately 40 percent and approaches 35 percent for children with meningitis. An added significant challenge is the worldwide emergence of multiply antibiotic-resistant pneumococci. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/5/81?source=see_link\">",
"     \"Resistance of Streptococcus pneumoniae to beta-lactam antibiotics\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The microbiology and pathogenesis of S. pneumoniae infection will be reviewed here. The clinical syndromes of pneumococcal pneumonia and meningitis, as well as issues in vaccination against S. pneumoniae, are discussed separately. (See related topic reviews).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     MICROBIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;S. pneumoniae is a gram-positive, alpha-hemolytic bacterium. It is fastidious, growing best in 5 percent carbon dioxide, and requires a source of catalase (eg, blood) to grow on agar plates. The inability to make catalase has some clinical significance since, unlike other pyogenic organisms, catalase-negative bacteria generate",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?40/41/41617?source=see_link\">",
"     hydrogen peroxide",
"    </a>",
"    and are killed by the phagocytic cells of patients with chronic granulomatous disease. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/38/43620?source=see_link&amp;anchor=H4#H4\">",
"     \"Primary disorders of phagocytic function: An overview\", section on 'Chronic granulomatous disease'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In the laboratory, pneumococci are identified by sensitivity to optochin and to lysis by bile salts (deoxycholate). The ability of deoxycholate and penicillin to dissolve the cell wall of the organism depends upon the presence of an autolytic enzyme in pneumococci [",
"    <a class=\"abstract\" href=\"UTD.htm?22/38/23143/abstract/1\">",
"     1",
"    </a>",
"    ]. This autolytic enzyme causes the organism, when grown in high density, to undergo a characteristic autolysis that can kill the entire culture. As an example, when a blood culture is allowed to grow for 24 to 48 hours without sampling or subculturing, the positive growth observed at six hours can be reversed by autolysis. The natural ability to undergo DNA transformation and autolysis in the stationary phase are attributes that pneumococci share with Haemophilus influenzae and Neisseria meningitidis, two other common invasive bacteria.",
"   </p>",
"   <p>",
"    The complete genomic sequence of S. pneumoniae serotype 4, a clinical isolate from a patient with meningitis, was placed online by the Institute for Genetic Research in November, 1997. This was the first gram-positive genome to be sequenced in its entirety. A detailed annotation of 2236 potential coding regions, of which 64 percent have been assigned a potential biologic role, has been published [",
"    <a class=\"abstract\" href=\"UTD.htm?22/38/23143/abstract/2\">",
"     2",
"    </a>",
"    ]. The complete genome of an important laboratory strain R6 and a variety of clinical strains have been described [",
"    <a class=\"abstract\" href=\"UTD.htm?22/38/23143/abstract/3\">",
"     3",
"    </a>",
"    ]. The striking feature of these comparisons is the tremendous diversity within strains of S. pneumoniae. DNA composition of clinical isolates can vary by as much as 20 percent and still be classified as pneumococcus. This diversity is localized to regions of the chromosome that alter the virulence of the strain [",
"    <a class=\"abstract\" href=\"UTD.htm?22/38/23143/abstract/4,5\">",
"     4,5",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of features of S. pneumoniae mediate its ability to produce infection, including surface components that enhance virulence and provoke a host inflammatory reaction. The following discussion will emphasize the pathogenetic mechanisms of the organism and host responses. The steps involved in the bacteriologic and pathologic progression of pneumococcal pneumonia are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/4/13386?source=see_link\">",
"     \"Pneumococcal pneumonia in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Capsule",
"    </span>",
"    &nbsp;&mdash;&nbsp;The surface capsular polysaccharide of S. pneumoniae provokes a type-specific protective immune response and serves as the basis for serotyping of these organisms; currently &gt;90 different pneumococcal serotypes have been identified. Serotypes 6, 14, 18, 19, and 23 are the most prevalent, accounting for between 60 and 80 percent of infections depending upon the area of the world.",
"   </p>",
"   <p>",
"    The capsular polysaccharide is the major antiphagocytic surface element of pneumococci and the major protective antigen. The capsule locus has been sequenced [",
"    <a class=\"abstract\" href=\"UTD.htm?22/38/23143/abstract/6\">",
"     6",
"    </a>",
"    ]. A study has identified the galU gene of S. pneumoniae as an essential gene for the biosynthesis of capsular polysaccharide [",
"    <a class=\"abstract\" href=\"UTD.htm?22/38/23143/abstract/7\">",
"     7",
"    </a>",
"    ]. The gene has been cloned and sequenced; knock-out mutants of pneumococcus types 1 and 3 lacking this gene are incapable of synthesizing a detectable capsule.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Adherence",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pneumococci, like other Streptococcus species, avidly adhere to epithelial cells of the nasopharynx (",
"    <a class=\"graphic graphic_picture graphicRef52746 \" href=\"UTD.htm?37/45/38623\">",
"     picture 1",
"    </a>",
"    ); this adherence does not usually produce a symptomatic infection. Like other streptococci that use fibrillar structures to contact human cells, a minority of pneumococci display pili to facilitate adherence [",
"    <a class=\"abstract\" href=\"UTD.htm?22/38/23143/abstract/8\">",
"     8",
"    </a>",
"    ].&nbsp;",
"   </p>",
"   <p>",
"    The pneumococcus also exports several proteins, which are noncovalently linked to the bacterial cell wall scaffold, in order to traffic from one body site to the other. These proteins recognize and bridge to human cell carbohydrates or the receptor for platelet activating factor, creating a direct contact between bacteria and human cells over a large area [",
"    <a class=\"abstract\" href=\"UTD.htm?22/38/23143/abstract/9,10\">",
"     9,10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Different, multiple ligand-receptor pairings occur at each body site [",
"    <a class=\"abstract\" href=\"UTD.htm?22/38/23143/abstract/9\">",
"     9",
"    </a>",
"    ]. As examples, sialic acid is a prominent receptor in the conjunctiva, eustachian tube and nasopharynx, while the disaccharide N-acetylgalactosamine b1-4 galactose is prominent in the lower respiratory tract. The latter sugar is recognized by a wide variety of pulmonary bacterial pathogens, suggesting this may be the basic \"catch all\" ligand for bacteria in the lung. Competitive inhibition of adherence by sugars has led to reduced pneumonia and bacteremia in animal models [",
"    <a class=\"abstract\" href=\"UTD.htm?22/38/23143/abstract/11\">",
"     11",
"    </a>",
"    ] and may spare the use of antibiotics in some clinical settings. Receptor analogs also might be designed to halt the progression of colonization or disease.",
"   </p>",
"   <p>",
"    Conversely, disease can be potentiated by exposing receptors. Both in vitro and in vivo, preceding influenza infection strongly predisposes to invasive pneumococcal infection [",
"    <a class=\"abstract\" href=\"UTD.htm?22/38/23143/abstract/12\">",
"     12",
"    </a>",
"    ]. It appears that the influenza neuraminidase exposes receptors for pneumococci during infection [",
"    <a class=\"abstract\" href=\"UTD.htm?22/38/23143/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Invasion",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pneumococci invade cells poorly, up to tenfold less than other streptococci [",
"    <a class=\"abstract\" href=\"UTD.htm?22/38/23143/abstract/14\">",
"     14",
"    </a>",
"    ]. Clinical isolates exhibit a wide variability in invasive capacity [",
"    <a class=\"abstract\" href=\"UTD.htm?22/38/23143/abstract/15\">",
"     15",
"    </a>",
"    ]. Invasion is promoted by the cell wall, adhesins, and the cytotoxin pneumolysin; in comparison, invasion is inhibited by capsular polysaccharide.",
"   </p>",
"   <p>",
"    Phosphorylcholine is an unusual component and a key feature of the pneumococcal cell wall. Phosphorylcholine recognizes the host cell and also acts as a docking station for proteins bridging to the host cell. Intact pneumococci use phosphorylcholine to tether to the platelet activating factor (PAF) receptor, thereby inserting the bacteria into the PAF receptor uptake pathway in an endocytic vacuole [",
"    <a class=\"abstract\" href=\"UTD.htm?22/38/23143/abstract/16\">",
"     16",
"    </a>",
"    ]. Bacterial phosphorylcholine recognition of the PAF receptor is an example of mimicry since the natural ligand PAF itself contains phosphorylcholine.",
"   </p>",
"   <p>",
"    To initiate uptake of pneumococci, human cells must become activated and upregulate the PAF receptor on their surfaces [",
"    <a class=\"abstract\" href=\"UTD.htm?22/38/23143/abstract/16\">",
"     16",
"    </a>",
"    ]. PAF receptors may also be upregulated in sickle cell disease, which may play an important role in the predisposition of such patients to invasive pneumococcal infection [",
"    <a class=\"abstract\" href=\"UTD.htm?22/38/23143/abstract/17\">",
"     17",
"    </a>",
"    ]. On the other hand, blockade or genetic deletion of PAF receptors impairs cellular uptake and protects against invasive infection [",
"    <a class=\"abstract\" href=\"UTD.htm?22/38/23143/abstract/16,17\">",
"     16,17",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/11/42170?source=see_link&amp;anchor=H21#H21\">",
"     \"Overview of the clinical manifestations of sickle cell disease\", section on 'Bacteremia'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Antecedent viral infection has long been known to predispose to bacterial pneumonia by unclear mechanisms. One study showed that adenovirus-infected cells in vitro displayed increased binding and uptake of adherent but not poorly adherent S. pneumoniae strains compared to uninfected cells, probably via viral upregulation of receptors [",
"    <a class=\"abstract\" href=\"UTD.htm?22/38/23143/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Once in the endocytic vacuole, pneumococci are subsequently transported to the basolateral cell surface, resulting in net transcytosis of the bacterium across the cell (for instance from the blood into the cerebrospinal fluid) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/38/23143/abstract/14\">",
"     14",
"    </a>",
"    ]. Transcytosis without passing between cells or inducing cytotoxicity appears to be unique to pneumococci, as compared to other meningeal pathogens, and is initiated by binding to the PAF receptor [",
"    <a class=\"abstract\" href=\"UTD.htm?22/38/23143/abstract/14\">",
"     14",
"    </a>",
"    ]. Invasion is partially inhibited by PAF receptor antagonists [",
"    <a class=\"abstract\" href=\"UTD.htm?22/38/23143/abstract/14\">",
"     14",
"    </a>",
"    ]. Mice deficient in PAF receptor fail to develop pneumonia and meningitis in the face of bacteremia [",
"    <a class=\"abstract\" href=\"UTD.htm?22/38/23143/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Regulatory mechanisms",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pneumococci use many regulatory mechanisms to change their surfaces in response to new host environments. Spontaneous phase variation changes gene expression when the bacteria transit between the mucosal surface and the bloodstream, altering the surface coat to avoid host defenses. As an example, the amount of surface phosphorylcholine in pneumococci is decreased when the organism enters the bloodstream; phosphorylcholine is useful in attaching to the lung but detrimental in the blood, where C-reactive protein can bind and opsonize the bacterium. Other pulmonary pathogens, such as H. influenzae, pseudomonas, and mycoplasma, also can modulate the amount of surface phosphorylcholine [",
"    <a class=\"abstract\" href=\"UTD.htm?22/38/23143/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Pneumococci change the proteins they express after exposure to heat shock, as occurs when they translocate from the nasal mucosa to the lungs, the brain, and the blood during infection. The S. pneumoniae heat shock protein, ClpP, appears to regulate the expression of pneumococcal virulence proteins, including pneumolysin and the capsular polysaccharide. In a murine model, ClpP was required for colonization of the nasopharynx and for survival in host macrophages [",
"    <a class=\"abstract\" href=\"UTD.htm?22/38/23143/abstract/21\">",
"     21",
"    </a>",
"    ]. Immunization of mice with ClpP elicited a protective immune response against fatal systemic challenge with S. pneumoniae, making ClpP a potential vaccine candidate for human pneumococcal disease.",
"   </p>",
"   <p>",
"    Pneumococci also can sense the density of other pneumococci in the environment and establish communication between the bacterial cells using small peptides similar to eukaryotic hormones [",
"    <a class=\"abstract\" href=\"UTD.htm?22/38/23143/abstract/22\">",
"     22",
"    </a>",
"    ]. These peptides signal all the bacteria, as a unified group, to undergo DNA transformation, adherence, or autolysis.",
"   </p>",
"   <p>",
"    Pneumococci secrete a potent cytotoxin, pneumolysin, which binds to cholesterol and can indiscriminately form pores in membranes, thereby killing any cell [",
"    <a class=\"abstract\" href=\"UTD.htm?22/38/23143/abstract/23\">",
"     23",
"    </a>",
"    ]. In addition, pneumolysin promotes intraalveolar replication of pneumococci, the penetration of pneumococci from the alveoli into the interstitium, and dissemination of the organisms into the bloodstream [",
"    <a class=\"abstract\" href=\"UTD.htm?22/38/23143/abstract/24\">",
"     24",
"    </a>",
"    ]. These effects are attenuated in pneumolysin-deficient strains [",
"    <a class=\"abstract\" href=\"UTD.htm?22/38/23143/abstract/24\">",
"     24",
"    </a>",
"    ]. Pneumolysin is an important factor leading to neuronal loss during meningitis [",
"    <a class=\"abstract\" href=\"UTD.htm?22/38/23143/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Host inflammatory response",
"    </span>",
"    &nbsp;&mdash;&nbsp;Gram-negative bacilli stimulate the host inflammatory response via endotoxin. A major unanswered question is how gram-positive bacteria, which do not have endotoxin, initiate this response. Pneumococci produce at least three hemolysins, one being the widely active cytolysin pneumolysin. When pneumococcal cell wall, cytoplasm, and capsular polysaccharide are compared for inflammatory capacity, cell wall has the highest specific activity [",
"    <a class=\"abstract\" href=\"UTD.htm?22/38/23143/abstract/10\">",
"     10",
"    </a>",
"    ]. This activity is not diminished by the overlying capsule on the native bacteria. The signs and symptoms of infection induced by cell wall mimic those of intact bacteria in animal models of meningitis, pneumonia, and otitis media, suggesting that the cell wall is an important virulence determinant [",
"    <a class=\"abstract\" href=\"UTD.htm?22/38/23143/abstract/10\">",
"     10",
"    </a>",
"    ]. Clinical strains with defects in the release of cell wall fragments induce an attenuated pattern of disease [",
"    <a class=\"abstract\" href=\"UTD.htm?22/38/23143/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The teichoic acid and lipoteichoic acid of the cell wall contribute strongly to host defense responses associated with acute inflammation. These components have the following effects [",
"    <a class=\"abstract\" href=\"UTD.htm?22/38/23143/abstract/10\">",
"     10",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Activate the alternative pathway of the complement cascade",
"     </li>",
"     <li>",
"      Bind the acute phase reactant C-reactive protein",
"     </li>",
"     <li>",
"      Activate procoagulant activity on the surface of endothelial cells",
"     </li>",
"     <li>",
"      Induce production of cytokines, nitric oxide, and platelet activating factor upon binding to epithelial and endothelial cells and macrophages",
"     </li>",
"     <li>",
"      Initiate the influx of neutrophils",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Cell walls are recognized by the innate immune system in several ways. Cell wall binding proteins in serum bind specific wall fragments and present them to human cell receptors [",
"    <a class=\"abstract\" href=\"UTD.htm?22/38/23143/abstract/27\">",
"     27",
"    </a>",
"    ]. The most prominent receptor on many cell types is Toll-like receptor 2 [",
"    <a class=\"abstract\" href=\"UTD.htm?22/38/23143/abstract/28\">",
"     28",
"    </a>",
"    ]. Downstream signaling leads to translocation of NF-kB and production of cytokines to initiate inflammation. Evidence suggests that a cell wall binding protein also exists in the human cell cytoplasm, Nod-2 [",
"    <a class=\"abstract\" href=\"UTD.htm?22/38/23143/abstract/29-31\">",
"     29-31",
"    </a>",
"    ]. Its precise roll in signaling is yet to be determined, but the Nod proteins suggest that a complex biology for cell wall components is yet to be uncovered.",
"   </p>",
"   <p>",
"    The cell wall components induce a strong interleukin (IL)-1 response, exceeding that of endotoxin by at least tenfold. Glycopeptides in the cell wall have numerous bioactivities including induction of slow wave sleep, killing respiratory ciliated cells, and promoting blood-brain barrier permeability. Viable pneumococci also induce apoptosis in several cell types in the brain and lung [",
"    <a class=\"abstract\" href=\"UTD.htm?22/38/23143/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The factors mediating the influx of neutrophils are in part organ-specific. As an example, P-selectin mediates rolling or slowing of neutrophils, while intercellular adhesion molecule-1 (ICAM-1) contributes to the firm adhesion and emigration of neutrophils. Neutrophil emigration into the peritoneum during S. pneumoniae-induced peritonitis is markedly reduced in mice with mutations in either P-selectin or ICAM-1 and is abolished in double mutants [",
"    <a class=\"abstract\" href=\"UTD.htm?22/38/23143/abstract/33\">",
"     33",
"    </a>",
"    ]. In contrast, neutrophil emigration into the alveoli during S. pneumoniae-induced pneumonia is not impaired in double mutants. This is consistent with the observation that in the lungs, pneumococci induce neutrophil efflux in two ways: one dependent upon the CD18 family of leukocyte adhesion molecules and the other by an unknown mechanism independent of CD18 [",
"    <a class=\"abstract\" href=\"UTD.htm?22/38/23143/abstract/34\">",
"     34",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Attenuating the acute host response to pneumococci has direct clinical application in improving the outcome of disease. A major change in the therapy of meningitis arose from the observation that pneumococcal cell wall pieces are as bioactive as intact bacteria [",
"    <a class=\"abstract\" href=\"UTD.htm?22/38/23143/abstract/35\">",
"     35",
"    </a>",
"    ]. This observation provided an explanation for an increased host inflammatory response during antibiotic therapy and a rationale for reducing this unwanted side effect. Over the first few hours of antibiotic therapy of bacterial meningitis, the leukocyte density in cerebrospinal fluid can increase one to two orders of magnitude [",
"    <a class=\"abstract\" href=\"UTD.htm?22/38/23143/abstract/36\">",
"     36",
"    </a>",
"    ]. This burst is sufficient to injure host tissues as evidenced by the significant attenuation of damage upon the inhibition of leukocyte recruitment [",
"    <a class=\"abstract\" href=\"UTD.htm?22/38/23143/abstract/37\">",
"     37",
"    </a>",
"    ]. The use of steroids during the early phase of antibiotic therapy to inhibit this response has become accepted for pneumococcal meningitis in adults. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/34/23080?source=see_link\">",
"     \"Dexamethasone to prevent neurologic complications of bacterial meningitis in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    To truly affect the outcome of meningitis, the bacterial host interactions that cause neuronal death must be interrupted. In this context, the ability of pneumococci to induce human cell apoptosis is important. Evidence indicates that the inflammatory response to pneumococci leads to caspase-dependent human cell death, while direct toxicity of pneumolysin and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?40/41/41617?source=see_link\">",
"     hydrogen peroxide",
"    </a>",
"    cause caspase-independent human cell death [",
"    <a class=\"abstract\" href=\"UTD.htm?22/38/23143/abstract/25,38,39\">",
"     25,38,39",
"    </a>",
"    ]. Both mechanisms may be inhibited in vitro and in vivo by treatment with a phosphatidylcholine analog, citicoline [",
"    <a class=\"abstract\" href=\"UTD.htm?22/38/23143/abstract/40\">",
"     40",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11090376\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Streptococcus pneumoniae occupies an important position in the history of microbiology:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      The organism was first identified in 1881.",
"     </li>",
"     <li>",
"      Its role in causing lobar pneumonia was appreciated by the late 1880s.",
"     </li>",
"     <li>",
"      The central role of antibody in host defense against extracellular organisms was first described for the pneumococcus.",
"     </li>",
"     <li>",
"      The first recognition that antibody directed to the capsular polysaccharide of a bacteria could be protective was shown for the pneumococcus; this observation forms the basis for many bacterial vaccines.",
"     </li>",
"     <li>",
"      The discovery of DNA as the material for genetic exchange was made from the pneumococcus. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Despite the extensive study of this pathogen and the availability of a vaccine covering 23 different serotypes, S. pneumoniae is currently the major invasive pathogen of children and older adults and is a principal cause of otitis media, pneumonia, bacteremia, and meningitis. An added significant challenge is the worldwide emergence of multiply antibiotic-resistant pneumococci. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      S. pneumoniae is a gram-positive, alpha-hemolytic bacterium. It is fastidious, growing best in 5 percent carbon dioxide, and requires a source of catalase (eg, blood) to grow on agar plates. The inability to make catalase has clinical significance since, unlike other pyogenic organisms, catalase-negative bacteria generate",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?40/41/41617?source=see_link\">",
"       hydrogen peroxide",
"      </a>",
"      and are killed by the phagocytic cells of patients with chronic granulomatous disease. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Microbiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A striking feature of S. pneumoniae is the tremendous diversity among different strains. DNA composition of clinical isolates can vary by as much as 20 percent and still be classified as pneumococcus. This diversity is localized to regions of the chromosome that alter the virulence of the strain. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Microbiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The surface capsular polysaccharide of S. pneumoniae provokes a type-specific protective immune response and serves as the basis for serotyping of these organisms; currently &gt;90 different pneumococcal serotypes have been identified. Serotypes 6, 14, 18, 19, and 23 are the most prevalent, accounting for between 60 and 80 percent of infections depending upon the area of the world. The capsular polysaccharide is the major antiphagocytic surface element of pneumococci and the major protective antigen. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Capsule'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Pneumococci, like other Streptococcus species, avidly adhere to epithelial cells of the nasopharynx; this adherence does not usually produce a symptomatic infection. Like other streptococci that use fibrillar structures to contact human cells, a minority of pneumococci display pili to facilitate adherence (",
"      <a class=\"graphic graphic_picture graphicRef52746 \" href=\"UTD.htm?37/45/38623\">",
"       picture 1",
"      </a>",
"      ). The pneumococcus also exports several proteins, which are noncovalently linked to the bacterial cell wall scaffold, in order to traffic from one body site to the other. These proteins recognize and bridge to human cell carbohydrates or the receptor for platelet activating factor, creating a direct contact between bacteria and human cells. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Adherence'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      To initiate uptake of pneumococci, human cells must become activated and upregulate the platelet activating factor receptor on their surface. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Invasion'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Pneumococci use many regulatory mechanisms to change their surfaces in response to new host environments. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Regulatory mechanisms'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Pneumococci secrete a potent cytotoxin, pneumolysin, which binds to cholesterol and can indiscriminately form pores in membranes, thereby killing any eukaryotic cell. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Regulatory mechanisms'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The teichoic acid and lipoteichoic acid of the cell wall contribute strongly to host defense responses associated with acute inflammation. These components have the following effects:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Activate the alternative pathway of the complement cascade",
"     </li>",
"     <li>",
"      Bind the acute phase reactant C-reactive protein",
"     </li>",
"     <li>",
"      Activate procoagulant activity on the surface of endothelial cells",
"     </li>",
"     <li>",
"      Induce production of cytokines, nitric oxide, and platelet activating factor upon binding to epithelial and endothelial cells and macrophages",
"     </li>",
"     <li>",
"      Initiate the influx of neutrophils (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Host inflammatory response'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/38/23143/abstract/1\">",
"      Tomasz A, Albino A, Zanati E. Multiple antibiotic resistance in a bacterium with suppressed autolytic system. Nature 1970; 227:138.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/38/23143/abstract/2\">",
"      Tettelin H, Nelson KE, Paulsen IT, et al. Complete genome sequence of a virulent isolate of Streptococcus pneumoniae. Science 2001; 293:498.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/38/23143/abstract/3\">",
"      Hoskins J, Alborn WE Jr, Arnold J, et al. Genome of the bacterium Streptococcus pneumoniae strain R6. J Bacteriol 2001; 183:5709.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/38/23143/abstract/4\">",
"      Obert C, Sublett J, Kaushal D, et al. Identification of a Candidate Streptococcus pneumoniae core genome and regions of diversity correlated with invasive pneumococcal disease. Infect Immun 2006; 74:4766.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/38/23143/abstract/5\">",
"      Blomberg C, Dagerhamn J, Dahlberg S, et al. Pattern of accessory regions and invasive disease potential in Streptococcus pneumoniae. J Infect Dis 2009; 199:1032.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/38/23143/abstract/6\">",
"      Caimano MJ, Hardy GG, Yother J. Capsule genetics in Streptococcus pneumoniae and a possible role for transposition in the generation of the type 3 locus. Microb Drug Resist 1998; 4:11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/38/23143/abstract/7\">",
"      Mollerach M, L&oacute;pez R, Garc&iacute;a E. Characterization of the galU gene of Streptococcus pneumoniae encoding a uridine diphosphoglucose pyrophosphorylase: a gene essential for capsular polysaccharide biosynthesis. J Exp Med 1998; 188:2047.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/38/23143/abstract/8\">",
"      Barocchi MA, Ries J, Zogaj X, et al. A pneumococcal pilus influences virulence and host inflammatory responses. Proc Natl Acad Sci U S A 2006; 103:2857.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/38/23143/abstract/9\">",
"      Cundell D, Masure HR, Tuomanen EI. The molecular basis of pneumococcal infection: a hypothesis. Clin Infect Dis 1995; 21 Suppl 3:S204.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/38/23143/abstract/10\">",
"      Tuomanen EI, Austrian R, Masure HR. Pathogenesis of pneumococcal infection. N Engl J Med 1995; 332:1280.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/38/23143/abstract/11\">",
"      Id&auml;np&auml;&auml;n-Heikkil&auml; I, Simon PM, Zopf D, et al. Oligosaccharides interfere with the establishment and progression of experimental pneumococcal pneumonia. J Infect Dis 1997; 176:704.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/38/23143/abstract/12\">",
"      McCullers JA, Rehg JE. Lethal synergism between influenza virus and Streptococcus pneumoniae: characterization of a mouse model and the role of platelet-activating factor receptor. J Infect Dis 2002; 186:341.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/38/23143/abstract/13\">",
"      McCullers JA, Bartmess KC. Role of neuraminidase in lethal synergism between influenza virus and Streptococcus pneumoniae. J Infect Dis 2003; 187:1000.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/38/23143/abstract/14\">",
"      Ring A, Weiser JN, Tuomanen EI. Pneumococcal trafficking across the blood-brain barrier. Molecular analysis of a novel bidirectional pathway. J Clin Invest 1998; 102:347.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/38/23143/abstract/15\">",
"      Brueggemann AB, Peto TE, Crook DW, et al. Temporal and geographic stability of the serogroup-specific invasive disease potential of Streptococcus pneumoniae in children. J Infect Dis 2004; 190:1203.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/38/23143/abstract/16\">",
"      Cundell DR, Gerard NP, Gerard C, et al. Streptococcus pneumoniae anchor to activated human cells by the receptor for platelet-activating factor. Nature 1995; 377:435.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/38/23143/abstract/17\">",
"      Miller ML, Gao G, Pestina T, et al. Hypersusceptibility to invasive pneumococcal infection in experimental sickle cell disease involves platelet-activating factor receptor. J Infect Dis 2007; 195:581.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/38/23143/abstract/18\">",
"      H&aring;kansson A, Kidd A, Wadell G, et al. Adenovirus infection enhances in vitro adherence of Streptococcus pneumoniae. Infect Immun 1994; 62:2707.",
"     </a>",
"    </li>",
"    <li>",
"     Tuomanen, E. Pneumococcus. ASM Press, Washington DC, 2004.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/38/23143/abstract/20\">",
"      Weiser JN, Pan N, McGowan KL, et al. Phosphorylcholine on the lipopolysaccharide of Haemophilus influenzae contributes to persistence in the respiratory tract and sensitivity to serum killing mediated by C-reactive protein. J Exp Med 1998; 187:631.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/38/23143/abstract/21\">",
"      Kwon HY, Ogunniyi AD, Choi MH, et al. The ClpP protease of Streptococcus pneumoniae modulates virulence gene expression and protects against fatal pneumococcal challenge. Infect Immun 2004; 72:5646.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/38/23143/abstract/22\">",
"      Tomasz A. Control of the competent state in Pneumococcus by a hormone-like cell product: an example for a new type of regulatory mechanism in bacteria. Nature 1965; 208:155.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/38/23143/abstract/23\">",
"      Mitchell TJ, Andrew PW. Biological properties of pneumolysin. Microb Drug Resist 1997; 3:19.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/38/23143/abstract/24\">",
"      Rubins JB, Charboneau D, Paton JC, et al. Dual function of pneumolysin in the early pathogenesis of murine pneumococcal pneumonia. J Clin Invest 1995; 95:142.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/38/23143/abstract/25\">",
"      Braun JS, Sublett JE, Freyer D, et al. Pneumococcal pneumolysin and H(2)O(2) mediate brain cell apoptosis during meningitis. J Clin Invest 2002; 109:19.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/38/23143/abstract/26\">",
"      Tuomanen E, Pollack H, Parkinson A, et al. Microbiological and clinical significance of a new property of defective lysis in clinical strains of pneumococci. J Infect Dis 1988; 158:36.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/38/23143/abstract/27\">",
"      Weber JR, Freyer D, Alexander C, et al. Recognition of pneumococcal peptidoglycan: an expanded, pivotal role for LPS binding protein. Immunity 2003; 19:269.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/38/23143/abstract/28\">",
"      Yoshimura A, Lien E, Ingalls RR, et al. Cutting edge: recognition of Gram-positive bacterial cell wall components by the innate immune system occurs via Toll-like receptor 2. J Immunol 1999; 163:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/38/23143/abstract/29\">",
"      Girardin SE, Sansonetti PJ, Philpott DJ. Intracellular vs extracellular recognition of pathogens--common concepts in mammals and flies. Trends Microbiol 2002; 10:193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/38/23143/abstract/30\">",
"      Girardin SE, Travassos LH, Herv&eacute; M, et al. Peptidoglycan molecular requirements allowing detection by Nod1 and Nod2. J Biol Chem 2003; 278:41702.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/38/23143/abstract/31\">",
"      Pauleau AL, Murray PJ. Role of nod2 in the response of macrophages to toll-like receptor agonists. Mol Cell Biol 2003; 23:7531.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/38/23143/abstract/32\">",
"      Tuomanen EI, Masure HR. Molecular and cellular biology of pneumococcal infection. Microb Drug Resist 1997; 3:297.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/38/23143/abstract/33\">",
"      Bullard DC, Qin L, Lorenzo I, et al. P-selectin/ICAM-1 double mutant mice: acute emigration of neutrophils into the peritoneum is completely absent but is normal into pulmonary alveoli. J Clin Invest 1995; 95:1782.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/38/23143/abstract/34\">",
"      Doerschuk CM, Winn RK, Coxson HO, Harlan JM. CD18-dependent and -independent mechanisms of neutrophil emigration in the pulmonary and systemic microcirculation of rabbits. J Immunol 1990; 144:2327.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/38/23143/abstract/35\">",
"      Tuomanen E, Tomasz A, Hengstler B, Zak O. The relative role of bacterial cell wall and capsule in the induction of inflammation in pneumococcal meningitis. J Infect Dis 1985; 151:535.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/38/23143/abstract/36\">",
"      T&auml;uber MG, Doroshow CA, Hackbarth CJ, et al. Antibacterial activity of beta-lactam antibiotics in experimental meningitis due to Streptococcus pneumoniae. J Infect Dis 1984; 149:568.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/38/23143/abstract/37\">",
"      Tuomanen EI, Saukkonen K, Sande S, et al. Reduction of inflammation, tissue damage, and mortality in bacterial meningitis in rabbits treated with monoclonal antibodies against adhesion-promoting receptors of leukocytes. J Exp Med 1989; 170:959.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/38/23143/abstract/38\">",
"      Braun JS, Novak R, Herzog KH, et al. Neuroprotection by a caspase inhibitor in acute bacterial meningitis. Nat Med 1999; 5:298.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/38/23143/abstract/39\">",
"      Braun JS, Novak R, Murray PJ, et al. Apoptosis-inducing factor mediates microglial and neuronal apoptosis caused by pneumococcus. J Infect Dis 2001; 184:1300.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/38/23143/abstract/40\">",
"      Zweigner J, Jackowski S, Smith SH, et al. Bacterial inhibition of phosphatidylcholine synthesis triggers apoptosis in the brain. J Exp Med 2004; 200:99.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7023 Version 4.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-125.39.66.147-0E3ADE63EF-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_38_23143=[""].join("\n");
var outline_f22_38_23143=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H11090376\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      MICROBIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Capsule",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Adherence",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Invasion",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Regulatory mechanisms",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Host inflammatory response",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11090376\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ID/7023\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/7023|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?37/45/38623\" title=\"picture 1\">",
"      Pneumococcal adherence EM",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/34/23080?source=related_link\">",
"      Dexamethasone to prevent neurologic complications of bacterial meningitis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/11/42170?source=related_link\">",
"      Overview of the clinical manifestations of sickle cell disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/4/13386?source=related_link\">",
"      Pneumococcal pneumonia in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/38/43620?source=related_link\">",
"      Primary disorders of phagocytic function: An overview",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/5/81?source=related_link\">",
"      Resistance of Streptococcus pneumoniae to beta-lactam antibiotics",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f22_38_23144="Condylomata acuminata (anogenital warts)";
var content_f22_38_23144=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Condylomata acuminata (anogenital warts)",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?22/38/23144/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/38/23144/contributors\">",
"     Elizabeth Breen, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/38/23144/contributors\">",
"     Ronald Bleday, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?22/38/23144/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/38/23144/contributors\">",
"     Ted Rosen, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?22/38/23144/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/38/23144/contributors\">",
"     Abena O Ofori, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?22/38/23144/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jul 16, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Anogenital warts (condylomata acuminata) are the most common viral sexually transmitted disease in the United States. Although condylomata affect both genders, data from office visits for warts obtained from the 1994 to 1998 National Ambulatory Medical Care Survey showed that women accounted for 67 percent of the patient population [",
"    <a class=\"abstract\" href=\"UTD.htm?22/38/23144/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Condylomata acuminata in children are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/29/26072?source=see_link&amp;anchor=H12#H12\">",
"     \"Vulvovaginal complaints in the prepubertal child\", section on 'Condylomata acuminata'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     ETIOLOGY AND ASSOCIATION WITH MALIGNANCY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Condyloma acuminatum is caused by human papilloma virus (HPV) infection. HPV encompasses a family of highly infectious and primarily sexually transmitted double-stranded DNA viruses. The incubation period after exposure ranges from three weeks to eight months. Most infections are transient and cleared within two years [",
"    <a class=\"abstract\" href=\"UTD.htm?22/38/23144/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Individuals with condylomata acuminata are at an increased risk for anogenital cancers [",
"    <a class=\"abstract\" href=\"UTD.htm?22/38/23144/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. In a large Danish cohort study of 16,155 men and 32,933 women, individuals who were diagnosed with condylomata acuminata were at increased risk for anogenital and head and neck cancers for greater than ten years following the diagnosis (anal [SIR for men, 21.5; SIR for women, 7.8], vulvar [SIR, 14.8], vaginal [SIR, 5.9], cervical [SIR, 1.5], penile [SIR, 8.2], and head and neck cancer [SIR, 2.8], including subsites of head and neck cancer with confirmed HPV association [SIR for men, 3.5; SIR for women, 4.8]) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/38/23144/abstract/4\">",
"     4",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/32/35337?source=see_link\">",
"     \"Cervical cancer screening tests: Techniques and test characteristics of cervical cytology and human papillomavirus testing\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/33/1562?source=see_link\">",
"     \"Anal intraepithelial neoplasia: Diagnosis, screening, prevention, and treatment\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There are over 70 distinct HPV subtypes; approximately 35 types are specific for the anogenital epithelium and have varying potentials to cause malignant change, such as cervical or anal cancer (",
"    <a class=\"graphic graphic_table graphicRef76394 \" href=\"UTD.htm?0/27/443\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/38/23144/abstract/5\">",
"     5",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/53/26455?source=see_link\">",
"     \"Virology of human papillomavirus infections and the link to cancer\"",
"    </a>",
"    .) HPV serotypes 16 and 18 are most commonly associated with squamous cell carcinoma. Low-risk subtypes, such as HPV 6 and 11, do not integrate into the host genome and are most frequently associated with benign condyloma and low grade intraepithelial neoplasia (",
"    <a class=\"graphic graphic_table graphicRef82294 \" href=\"UTD.htm?27/25/28059\">",
"     table 2",
"    </a>",
"    ). Intermediate risk subtypes can cause high grade dysplasia which persists but rarely progresses to the invasive stage. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/32/35337?source=see_link\">",
"     \"Cervical cancer screening tests: Techniques and test characteristics of cervical cytology and human papillomavirus testing\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     RISK FACTORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acquisition of condylomata is related to sexual activity.",
"    <span class=\"nowrap\">",
"     Digital/anal,",
"    </span>",
"    <span class=\"nowrap\">",
"     oral/anal",
"    </span>",
"    and",
"    <span class=\"nowrap\">",
"     digital/vaginal",
"    </span>",
"    contact probably can also spread the virus, as may fomites [",
"    <a class=\"abstract\" href=\"UTD.htm?22/38/23144/abstract/6\">",
"     6",
"    </a>",
"    ]. The disease is also more common in immunosuppressed individuals [",
"    <a class=\"abstract\" href=\"UTD.htm?22/38/23144/abstract/7,8\">",
"     7,8",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Women",
"    </span>",
"    &nbsp;&mdash;&nbsp;Disease in women is primarily caused by vaginal intercourse. Anal condylomata can occur by extension from vulvar or perineal infection or by receptive anal intercourse. The risk of disease increases with the number of sexual partners. A population-based case-control study including 94 women with incident and 55 women with recurrent condyloma found women with five or more partners within the previous five years were over seven times more likely to have incident condyloma and over 12 times more likely to have recurrent condyloma compared to women with only one sexual partner during the same time period [",
"    <a class=\"abstract\" href=\"UTD.htm?22/38/23144/abstract/9\">",
"     9",
"    </a>",
"    ]. An increased risk of incident condyloma was also associated with a history of any sexually transmitted disease or oral herpes.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Men",
"    </span>",
"    &nbsp;&mdash;&nbsp;In men, the preputial cavity or penile shaft can be affected through heterosexual or homosexual activity. Perianal lesions may occur among heterosexual men, although most such lesions are observed among men who have sex with men. The risk of disease increases with the number of sexual partners [",
"    <a class=\"abstract\" href=\"UTD.htm?22/38/23144/abstract/10\">",
"     10",
"    </a>",
"    ], as described above for women.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     HIV infected individuals",
"    </span>",
"    &nbsp;&mdash;&nbsp;The prevalence of condyloma is higher in patients who are HIV positive or who have other forms of sexually transmitted diseases [",
"    <a class=\"abstract\" href=\"UTD.htm?22/38/23144/abstract/11-14\">",
"     11-14",
"    </a>",
"    ]. In an illustrative study, the prevalence of condylomata acuminata in 385 HIV-1 positive and 341 HIV-1 negative women was 7 and 1 percent, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?22/38/23144/abstract/14\">",
"     14",
"    </a>",
"    ]. Lower CD4 T lymphocyte count (&lt;500",
"    <span class=\"nowrap\">",
"     cells/&micro;L)",
"    </span>",
"    and frequent injection of drugs were also risk factors for development of vulvovaginal or perianal lesions. Similar results were reported in a subsequent study, which also noted that highly active antiretroviral therapy was associated with lower rates of these lesions [",
"    <a class=\"abstract\" href=\"UTD.htm?22/38/23144/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Symptoms associated with condylomata acuminata vary depending upon the number of lesions and their location. Patients with a small number of warts are often asymptomatic. Other patients may have pruritus, bleeding, burning, tenderness, vaginal discharge (women), or pain.",
"   </p>",
"   <p>",
"    Condylomata can occasionally form large exophytic masses that can interfere with defecation, intercourse, or vaginal delivery. Lesions involving the proximal anal canal may also cause stricturing.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of condylomata can usually be made by visual inspection of the affected area. The lesions, which are skin-colored or pink, range from smooth flattened papules to a verrucous, papilliform appearance (",
"    <a class=\"graphic graphic_picture graphicRef55494 \" href=\"UTD.htm?17/24/17794\">",
"     picture 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The extent of involvement should be documented by physical examination and anoscopy, sigmoidoscopy, colposcopy,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    vaginal speculum examination, as appropriate. High-resolution anoscopy is being used increasingly to permit improved visualization of the tissue [",
"    <a class=\"abstract\" href=\"UTD.htm?22/38/23144/abstract/16\">",
"     16",
"    </a>",
"    ]. In addition, application of 5 percent",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/36/19011?source=see_link\">",
"     acetic acid",
"    </a>",
"    causes lesions to turn white, which facilitates identification but is not specific.",
"   </p>",
"   <p>",
"    A biopsy can be considered when the diagnosis is uncertain, in those who do not respond to therapy, in immunocompromised patients, in those with large lesions, or in the presence of atypical features (",
"    <a class=\"graphic graphic_table graphicRef80917 \" href=\"UTD.htm?6/39/6779\">",
"     table 3",
"    </a>",
"    ). Some authorities recommend a routine biopsy to search for dysplasia [",
"    <a class=\"abstract\" href=\"UTD.htm?22/38/23144/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Differential diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Condyloma acuminatum (",
"    <a class=\"graphic graphic_picture graphicRef55494 \" href=\"UTD.htm?17/24/17794\">",
"     picture 1",
"    </a>",
"    ) should be distinguished from another form of condylomata (condyloma lata), which is caused by secondary syphilis infection. Lesions in condyloma lata appear flat and velvety (",
"    <a class=\"graphic graphic_picture graphicRef56162 \" href=\"UTD.htm?22/28/22979\">",
"     picture 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Micropapillomatosis of the vulva is a normal variant. The papillary projections each arise from an individual base, in contrast to condyloma acuminatum where multiple papillae arise from a single base. Painful verrucous perianal lesions have been described in association with herpes simplex in patients with AIDS [",
"    <a class=\"abstract\" href=\"UTD.htm?22/38/23144/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Squamous cell carcinoma of the anogenital area can exist concurrently with condylomata acuminata. Suspicious lesions (particularly those which are ulcerated) should be biopsied. Lesions that do not respond after three provider administered treatments or have not resolved after six months should be reevaluated with consideration of biopsy to confirm the diagnosis [",
"    <a class=\"abstract\" href=\"UTD.htm?22/38/23144/abstract/19\">",
"     19",
"    </a>",
"    ]. Patients who are immunocompromised, or over 40 years of age, or have large, pigmented, or atypical lesions also warrant a higher index of suspicion of malignancy.",
"   </p>",
"   <p>",
"    Additional conditions which should be considered include hymenal remnants and vulvar intraepithelial neoplasia (in women), molluscum contagiosum (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/43/6842?source=see_link\">",
"     \"Molluscum contagiosum\"",
"    </a>",
"    ), skin tags, and angiofibromas (",
"    <a class=\"graphic graphic_picture graphicRef68899 \" href=\"UTD.htm?37/49/38678\">",
"     picture 3",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment of condyloma acuminatum involves one of three major approaches: chemical or physical destruction, immunologic therapy, or surgical excision (",
"    <a class=\"graphic graphic_algorithm graphicRef68884 \" href=\"UTD.htm?4/26/4518\">",
"     algorithm 1",
"    </a>",
"    ). Limited experience with topical antimicrobial therapy has also been reported. The preferred approach depends upon the number and extent of the lesions. In general, all therapies for genital warts are somewhat unsatisfactory due to recurrence rates of 30 to 70 percent within six months of treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?22/38/23144/abstract/20\">",
"     20",
"    </a>",
"    ]. However, spontaneous regression is also possible, and has been reported to occur within three months in 20 to 30 percent of cases.",
"   </p>",
"   <p>",
"    There is no evidence to suggest that one treatment is significantly superior to another or appropriate for all patients and all types of warts [",
"    <a class=\"abstract\" href=\"UTD.htm?22/38/23144/abstract/19\">",
"     19",
"    </a>",
"    ]. If a clinician has",
"    <a class=\"drug drug_general\" href=\"UTD.htm?7/39/7794?source=see_link\">",
"     trichloroacetic acid",
"    </a>",
"    or podophyllin available in their office practice, then it would be most efficient for the clinician to provide an initial treatment of the warts at the diagnostic visit, and then to prescribe home treatments (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/59/20406?source=see_link\">",
"     imiquimod",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/34/23074?source=see_link\">",
"     podofilox",
"    </a>",
"    ) or examine the patient in follow-up to see how the initial treatment worked. For clinicians without trichloroacetic acid or podophyllin in their office, the patient could first try home treatments (imiquimod or podofilox). However, we suggest initially referring patients with very large condylomata (eg, 1 to 2 cm at the base) to a surgeon (gynecologist or anorectal surgeon) because surgical treatment is probably going to be needed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Chemical agents",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chemical agents include podophyllin,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?7/39/7794?source=see_link\">",
"     trichloroacetic acid",
"    </a>",
"    , and",
"    <span class=\"nowrap\">",
"     5-",
"     <a class=\"drug drug_general\" href=\"UTD.htm?32/32/33280?source=see_link\">",
"      fluorouracil",
"     </a>",
"     /epinephrine",
"    </span>",
"    gel (",
"    <a class=\"graphic graphic_table graphicRef74829 \" href=\"UTD.htm?14/57/15259\">",
"     table 4",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Podophyllin",
"    </span>",
"    &nbsp;&mdash;&nbsp;Podophyllin, an extract of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?30/8/30851?source=see_link\">",
"     Podophyllum",
"    </a>",
"    peltatum, contains the antimitotic agent podophyllotoxin, which arrests the cell cycle in metaphase and leads to cell death. Podophyllin solution when used topically as a single agent once or twice a week has limited success in clearing warts (from 20 to 50 percent clearance at three months) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/38/23144/abstract/21\">",
"     21",
"    </a>",
"    ]. It is usually used as a 25 percent solution in combination with another treatment method such as cryotherapy. The solution is applied to a small area of skin, allowed to dry, and then washed off within six hours of application. Large areas should not be treated in a single application because of potential neurotoxicity and pain when the area becomes necrotic. Podophyllin should never be applied to the cervix or vaginal epithelium because of risk of chemical burns.",
"   </p>",
"   <p>",
"    The drug is teratogenic and must not be used in pregnancy or suspected pregnancy. It is not indicated for internal (eg, mucosal) use. Adverse effects range from mild skin irritation to ulceration and pain depending upon the concentration used and the length of time over which it is applied to the skin.",
"   </p>",
"   <p>",
"    A similar agent, 0.5 percent",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/34/23074?source=see_link\">",
"     podofilox",
"    </a>",
"    (podophyllotoxin) can be self-administered. It is applied to palpable external warts twice daily for three days, followed by a four day rest period, and then repeated up to four times. The surface area treated and the volume of medication per application should not exceed 10 cm(2) and 0.5 mL, respectively. A randomized trial comparing self-administration of podophyllotoxin solution or cream (0.5 and 0.15 percent, respectively) to 25 percent podophyllin administered in a clinic found that self treatment of anogenital warts with podophyllotoxin showed greater efficacy and cost-effectiveness than clinic based treatment with podophyllin [",
"    <a class=\"abstract\" href=\"UTD.htm?22/38/23144/abstract/22\">",
"     22",
"    </a>",
"    ]. However, recurrence of warts within 12 weeks of study entry occurred in 43 percent of all initially cleared subjects, without significant differences among the treatment groups.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Trichloroacetic acid",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?7/39/7794?source=see_link\">",
"     Trichloroacetic acid",
"    </a>",
"    (80 to 90 percent concentration) physically destroys the wart tissue by protein coagulation. Clearance rates and adverse effects are similar to podophyllin. Repeated application is required. However, in contrast to podophyllin, trichloroacetic acid can be used for internal lesions [",
"    <a class=\"abstract\" href=\"UTD.htm?22/38/23144/abstract/23\">",
"     23",
"    </a>",
"    ] and during pregnancy, when it is considered first line therapy. The solution is highly caustic and should not be applied to skin surrounding the lesion; a barrier of petroleum jelly helps to protect unaffected areas nearby.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     5-fluorouracil epinephrine gel",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/32/33280?source=see_link\">",
"     Fluorouracil",
"    </a>",
"    is a pyrimidine antimetabolite that interferes with DNA synthesis by blocking the methylation of deoxyuridylic acid, leading to cell death. A gel consisting of 5-fluorouracil and epinephrine can be injected intralesionally. One study evaluated the safety and efficacy of this treatment in 401 patients randomly assigned to receive",
"    <span class=\"nowrap\">",
"     fluorouracil/epinephrine",
"    </span>",
"    gel, fluorouracil gel alone, or placebo [",
"    <a class=\"abstract\" href=\"UTD.htm?22/38/23144/abstract/24\">",
"     24",
"    </a>",
"    ]. Each lesion was injected once per week for up to six weeks, and patients were followed for three months. The complete response rate was higher in patients treated with",
"    <span class=\"nowrap\">",
"     fluorouracil/epinephrine",
"    </span>",
"    gel than fluorouracil gel without epinephrine or placebo, 61 versus 43 and 5 percent, respectively. However, the recurrence rate in patients with complete response to drug therapy was 50 to 60 percent at three months.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Immune modulation",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/59/20406?source=see_link\">",
"     Imiquimod",
"    </a>",
"    and interferon alfa are the two immune modulating agents that have been used (",
"    <a class=\"graphic graphic_table graphicRef74829 \" href=\"UTD.htm?14/57/15259\">",
"     table 4",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Imiquimod",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/59/20406?source=see_link\">",
"     Imiquimod",
"    </a>",
"    is a positive immune response modifier, which acts by local cytokine induction. When applied topically as a 5 percent cream, it has shown significant effect in clearing warts (72 to 84 percent of patients show some response, with complete clearance rates of 40 to 70 percent) with few recurrences (5 to 19 percent) in limited clinical experience [",
"    <a class=\"abstract\" href=\"UTD.htm?22/38/23144/abstract/23,25-28\">",
"     23,25-28",
"    </a>",
"    ]. Most patients who do not clear still have a significant reduction in lesion size. Imiquimod has also been used for treatment of vulvar and anal intraepithelial neoplasia [",
"    <a class=\"abstract\" href=\"UTD.htm?22/38/23144/abstract/29,30\">",
"     29,30",
"    </a>",
"    ]",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/59/20406?source=see_link\">",
"     Imiquimod",
"    </a>",
"    is not indicated for internal use. The cream is applied and left in place for six to ten hours, and then washed off. There are two regimens approved by the US Food and Drug Administration:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Application of a 5 percent cream three times per week for up to 16 weeks",
"     </li>",
"     <li>",
"      Application of a 3.75 percent cream once per day for up to 8 weeks",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/59/20406?source=see_link\">",
"     Imiquimod",
"    </a>",
"    was initially approved using the thrice weekly regimen. The daily regimen was subsequently developed to shorten the overall treatment duration. No studies have directly compared the two regimens. The results of two controlled trials of the 3.75 percent cream have been reported by the manufacturer as part of the drug&rsquo;s labeling information [",
"    <a class=\"abstract\" href=\"UTD.htm?22/38/23144/abstract/31\">",
"     31",
"    </a>",
"    ]. In those studies, 601 patients were treated with the 3.75 percent cream or placebo for up to eight weeks. Patients were followed for an additional 12 weeks after stopping the medication. Complete clearance of genital warts within 16 weeks of starting the medication was seen in 37 percent of women and 19 percent of men. In the placebo arm, the rates were 14 and 4 percent, respectively. Whether the differences were statistically significant was not reported.",
"   </p>",
"   <p>",
"    The major side effect is mild to moderate local erythema.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Interferon alfa",
"    </span>",
"    &nbsp;&mdash;&nbsp;Primary systemic therapy with interferon can achieve complete resolution of the anal condyloma in 25 to 80 percent of patients, but is frequently associated with interferon-related side effects and recurrence [",
"    <a class=\"abstract\" href=\"UTD.htm?22/38/23144/abstract/32,33\">",
"     32,33",
"    </a>",
"    ]. Interferon may also be given intralesionally [",
"    <a class=\"abstract\" href=\"UTD.htm?22/38/23144/abstract/34\">",
"     34",
"    </a>",
"    ]. Interferon is not FDA approved for treatment of anogenital warts, but is widely used for this purpose.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In one study, 203 patients with untreated anogenital condyloma were randomly assigned to one of four treatment groups with varying doses of interferon (3 million units IM daily for three weeks or 3 million units SQ three times per week for four weeks), diathermocoagulation, or no treatment [",
"      <a class=\"abstract\" href=\"UTD.htm?22/38/23144/abstract/33\">",
"       33",
"      </a>",
"      ]. After six months, the overall complete response rate was similar for patients receiving interferon compared to diathermocoagulation (57 versus 82 percent respectively, compared to 8 percent for untreated patients). However, the disease recurred significantly more often in patients who were treated with interferon (15 versus 4 percent).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Local or systemic treatment with interferon may also decrease the likelihood of recurrence following surgical excision or ablative therapy, but is uncommonly used in clinical practice [",
"    <a class=\"abstract\" href=\"UTD.htm?22/38/23144/abstract/35,36\">",
"     35,36",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In one study, 81 patients with condylomata acuminata who had undergone treatment with either 5-",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/32/33280?source=see_link\">",
"       fluorouracil",
"      </a>",
"      cream or laser ablation were randomized to adjuvant alpha-interferon therapy or no additional treatment [",
"      <a class=\"abstract\" href=\"UTD.htm?22/38/23144/abstract/35\">",
"       35",
"      </a>",
"      ]. At the end of eight weeks, recurrences were less common in patients who had received interferon (6 versus 24 percent).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6935408\">",
"    <span class=\"h3\">",
"     Sinecatechins",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/35/15923?source=see_link\">",
"     Sinecatechins",
"    </a>",
"    (eg, Veregen&trade;) is a botanical drug product for self-administered topical treatment of external anogenital warts. The active ingredient is kunecatechins, which is a mixture of catechins and other components of green tea. The exact mechanism of action of catechins is unknown, but they have both antioxidant and immune enhancing activity. A detailed review of the antiviral, antioxidant, and immunostimulatory properties of green tea catechins is available elsewhere [",
"    <a class=\"abstract\" href=\"UTD.htm?22/38/23144/abstract/37\">",
"     37",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In two randomized phase III clinical trials, 15 or 10 percent Veregen&trade; ointment or placebo was applied to anogenital warts in men and women three times daily until complete clearance of all warts or for up to 16 weeks [",
"    <a class=\"abstract\" href=\"UTD.htm?22/38/23144/abstract/38-41\">",
"     38-41",
"    </a>",
"    ]. Veregen&trade; was more effective than placebo in achieving complete clearance (54 to 57 versus 34 to 35 percent). Fewer than 10 percent of subjects developed new or recurrent warts [",
"    <a class=\"abstract\" href=\"UTD.htm?22/38/23144/abstract/40\">",
"     40",
"    </a>",
"    ]. Five percent of subjects discontinued the drug due to side effects and almost 90 percent reported local application site reactions, some of which were severe (pruritus, erythema, pain, inflammation, ulceration). Veregen&trade; costs about $257 for one 15 gram tube.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Surgery",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ablative or excisional surgical therapy may be considered when medical therapy has failed or when warts are amenable to surgical removal. Cryotherapy can be performed in an appropriately equipped office, but laser and excisional therapy require an operating room and thus are usually a last resort after other methods have failed. However, very large lesions may be considered for excisional surgery as an initial approach.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Cryotherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cryotherapy can be performed in the office by the application of liquid nitrogen spray, a swab soaked in liquid nitrogen, or by placing a",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/29/11732?source=see_link\">",
"     nitrous oxide",
"    </a>",
"    cooled cryoprobe on the lesion. This procedure is safe in pregnancy. This method causes pain during application and variable localized inflammation afterward. Clearance rates at three months are 63 to 92 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?22/38/23144/abstract/23\">",
"     23",
"    </a>",
"    ], and again repeated application is required.",
"   </p>",
"   <p>",
"    The ice ball should extend 2 to 3 mm beyond an external lesion and 5 mm beyond cervical warts.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/29/11732?source=see_link\">",
"     Nitrous oxide",
"    </a>",
"    should not be used in the vagina, but is preferred to liquid nitrogen for cervical warts because it produces better freezing of cervical tissue.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Laser therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Laser therapy (CO2 or NdYag) is carried out in the operating room or ambulatory surgical facility and requires anesthesia. A colposcope is useful for directing laser therapy in women. The tissue absorbs the laser energy, which is converted to heat energy, vaporizing the wart. Tissue destruction should not go beyond 1 mm in depth.",
"   </p>",
"   <p>",
"    This technique has rates of wart clearance which approach 100 percent over one year [",
"    <a class=\"abstract\" href=\"UTD.htm?22/38/23144/abstract/42\">",
"     42",
"    </a>",
"    ]; however, recurrence can be up to 45 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?22/38/23144/abstract/23\">",
"     23",
"    </a>",
"    ]. Adverse events include scarring and pain. The laser operator is also at risk for developing mucosal warts. This is the most expensive method of treating warts [",
"    <a class=\"abstract\" href=\"UTD.htm?22/38/23144/abstract/43\">",
"     43",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     Excisional procedures",
"    </span>",
"    &nbsp;&mdash;&nbsp;Knife or scissor excision requires anesthesia and involves routine surgical risks such as infection and hemorrhage. The three-month clearance rates are 36 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?22/38/23144/abstract/23\">",
"     23",
"    </a>",
"    ]. The area of the lesion is excised down to normal skin or mucosa, and the roots of the lesions are cauterized. Care should be taken to assure that cauterization does not extend into the subcutaneous or submucosal fat. Excessive cauterization increases the risk of dysfunction from development of a stricture. Excised condylomata should be examined pathologically to exclude the presence of squamous cell carcinoma.",
"   </p>",
"   <p>",
"    In pregnant women, large lesions can obstruct the vagina and may be lacerated during vaginal delivery. Such lesions should be treated aggressively or the patient delivered by cesarean section.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Topical antimicrobials",
"    </span>",
"    &nbsp;&mdash;&nbsp;A newer approach beginning to appear in the literature involves topical application of antimicrobials, including",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/2/20517?source=see_link\">",
"     cidofovir",
"    </a>",
"    and bacillus Calmette-Guerin (BCG). Both therapies require further study.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h3\">",
"     Cidofovir",
"    </span>",
"    &nbsp;&mdash;&nbsp;After undergoing cellular phosphorylation,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/2/20517?source=see_link\">",
"     cidofovir",
"    </a>",
"    competitively inhibits the incorporation of dCTP into viral DNA by viral DNA polymerase. Incorporation of the drug disrupts further chain elongation. (See",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/2/20517?source=see_link\">",
"     \"Cidofovir: Drug information\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A double-blind, randomized trial compared topical",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/2/20517?source=see_link\">",
"     cidofovir",
"    </a>",
"    gel containing 1 percent drug to a placebo gel in 30 patients with condylomata acuminata [",
"    <a class=\"abstract\" href=\"UTD.htm?22/38/23144/abstract/44\">",
"     44",
"    </a>",
"    ]. Patients were treated once daily for five days every other week for a maximum of six cycles with follow-up of six months for complete responders. Patients receiving cidofovir were more likely than placebo recipients to have a complete (47 versus 0 percent) or partial (37 versus 18 percent) response; five patients in the placebo group had progression of lesions compared to zero receiving cidofovir. One complete responder had a recurrence of lesions in the same location 120 days after finishing treatment. Four patients discontinued cidofovir applications.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h3\">",
"     Bacillus Calmette-Guerin",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ten patients were treated with topical BCG in one series with response in six at a mean of nine months follow-up, partial response in one, and no response in three [",
"    <a class=\"abstract\" href=\"UTD.htm?22/38/23144/abstract/45\">",
"     45",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Infrared coagulation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Infrared coagulation achieves tissue coagulation by focusing a narrow beam of infrared light delivered through a probe. The technique (Redfield Corporation, Rochelle Park, NJ) is approved for treatment of hemorrhoids, removal of tattoos, treatment of chronic rhinitis, ablation of common warts and anogenital condyloma. In one of the largest studies, successful treatment was described 61 of 74 (82 percent) women with condylomata acuminata of the genital tract [",
"    <a class=\"abstract\" href=\"UTD.htm?22/38/23144/abstract/46\">",
"     46",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h1\">",
"     VULVAR AND VAGINAL WARTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment of vulvar and vaginal warts, including the treatment of anogenital warts in women who are pregnant, is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/34/27178?source=see_link\">",
"     \"Treatment of vulvar and vaginal warts\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?16/13/16594?source=see_link\">",
"       \"Patient information: Genital warts (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?5/22/5475?source=see_link\">",
"       \"Patient information: Human papillomavirus (HPV) vaccine (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?37/45/38610?source=see_link\">",
"       \"Patient information: Human papillomavirus (HPV) vaccine (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?3/60/4035?source=see_link\">",
"       \"Patient information: Genital warts in women (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Anogenital warts (condylomata acuminata) are the most common viral sexually transmitted disease in the United States.",
"     </li>",
"     <li>",
"      It is caused by human papilloma virus (HPV) infection. HPV encompasses a family of highly infectious and primarily sexually transmitted double-stranded DNA viruses. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Etiology and association with malignancy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Acquisition of condylomata is related to sexual activity.",
"      <span class=\"nowrap\">",
"       Digital/anal,",
"      </span>",
"      <span class=\"nowrap\">",
"       oral/anal",
"      </span>",
"      and",
"      <span class=\"nowrap\">",
"       digital/vaginal",
"      </span>",
"      contact probably can also spread the virus, as may fomites. The disease is also more common in immunosuppressed individuals. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Risk factors'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Symptoms vary depending upon the number of lesions and their location. Patients with a small number of warts are often asymptomatic. Other patients may have pruritus, bleeding, burning, tenderness, vaginal discharge (women), or pain. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Clinical manifestations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The diagnosis of condylomata can usually be made by visual inspection of the affected area. The lesions, which are skin-colored or pink, range from smooth flattened papules to a verrucous, papilliform appearance (",
"      <a class=\"graphic graphic_picture graphicRef55494 \" href=\"UTD.htm?17/24/17794\">",
"       picture 1",
"      </a>",
"      ).&nbsp;(See",
"      <a class=\"local\" href=\"#H8\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Treatment involves one of three major approaches: chemical or physical destruction, immunologic therapy, or surgical excision. We agree with the approach summarized in the algorithm (",
"      <a class=\"graphic graphic_algorithm graphicRef68884 \" href=\"UTD.htm?4/26/4518\">",
"       algorithm 1",
"      </a>",
"      ). The preferred approach depends upon the number and extent of the lesions.",
"     </li>",
"     <li>",
"      In patients with recurrence following successful initial treatment, we suggest either excisional or fulguration therapy (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). An acceptable alternative is cryotherapy but we prefer the combination of",
"      <span class=\"nowrap\">",
"       excision/fulguration",
"      </span>",
"      since it allows us to obtain a biopsy of at least part of the specimen. After the area heals, we generally use \"adjuvant\" treatment. We typically start this therapy four weeks after excision and most commonly use",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/59/20406?source=see_link\">",
"       Imiquimod",
"      </a>",
"      5 percent cream (Aldara) applied three times per week for 12 weeks.",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/38/23144/abstract/1\">",
"      Fleischer AB Jr, Parrish CA, Glenn R, Feldman SR. Condylomata acuminata (genital warts): patient demographics and treating physicians. Sex Transm Dis 2001; 28:643.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/38/23144/abstract/2\">",
"      Burk RD, Kelly P, Feldman J, et al. Declining prevalence of cervicovaginal human papillomavirus infection with age is independent of other risk factors. Sex Transm Dis 1996; 23:333.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/38/23144/abstract/3\">",
"      Chua KL, Hjerpe A. Persistence of human papillomavirus (HPV) infections preceding cervical carcinoma. Cancer 1996; 77:121.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/38/23144/abstract/4\">",
"      Blomberg M, Friis S, Munk C, et al. Genital warts and risk of cancer: a Danish study of nearly 50 000 patients with genital warts. J Infect Dis 2012; 205:1544.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/38/23144/abstract/5\">",
"      Pfister H. The role of human papillomavirus in anogenital cancer. Obstet Gynecol Clin North Am 1996; 23:579.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/38/23144/abstract/6\">",
"      Palefsky JM. Cutaneous and genital HPV-associated lesions in HIV-infected patients. Clin Dermatol 1997; 15:439.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/38/23144/abstract/7\">",
"      de la Fuente SG, Ludwig KA, Mantyh CR. Preoperative immune status determines anal condyloma recurrence after surgical excision. Dis Colon Rectum 2003; 46:367.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/38/23144/abstract/8\">",
"      Schneider V, Kay S, Lee HM. Immunosuppression as a high-risk factor in the development of condyloma acuminatum and squamous neoplasia of the cervix. Acta Cytol 1983; 27:220.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/38/23144/abstract/9\">",
"      Habel LA, Van Den Eeden SK, Sherman KJ, et al. Risk factors for incident and recurrent condylomata acuminata among women. A population-based study. Sex Transm Dis 1998; 25:285.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/38/23144/abstract/10\">",
"      Van Den Eeden SK, Habel LA, Sherman KJ, et al. Risk factors for incident and recurrent condylomata acuminata among men. A population-based study. Sex Transm Dis 1998; 25:278.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/38/23144/abstract/11\">",
"      Ciobotaru B, Leiman G, St John T, et al. Prevalence and risk factors for anal cytologic abnormalities and human papillomavirus infection in a rural population of HIV-infected males. Dis Colon Rectum 2007; 50:1011.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/38/23144/abstract/12\">",
"      Piketty C, Darragh TM, Da Costa M, et al. High prevalence of anal human papillomavirus infection and anal cancer precursors among HIV-infected persons in the absence of anal intercourse. Ann Intern Med 2003; 138:453.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/38/23144/abstract/13\">",
"      Beck DE, Jaso RG, Zajac RA. Surgical management of anal condylomata in the HIV-positive patient. Dis Colon Rectum 1990; 33:180.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/38/23144/abstract/14\">",
"      Conley LJ, Ellerbrock TV, Bush TJ, et al. HIV-1 infection and risk of vulvovaginal and perianal condylomata acuminata and intraepithelial neoplasia: a prospective cohort study. Lancet 2002; 359:108.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/38/23144/abstract/15\">",
"      Massad LS, Silverberg MJ, Springer G, et al. Effect of antiretroviral therapy on the incidence of genital warts and vulvar neoplasia among women with the human immunodeficiency virus. Am J Obstet Gynecol 2004; 190:1241.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/38/23144/abstract/16\">",
"      Tramujas da Costa e Silva I, de Lima Ferreira LC, Santos Gimenez F, et al. High-resolution anoscopy in the diagnosis of anal cancer precursor lesions in renal graft recipients. Ann Surg Oncol 2008; 15:1470.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/38/23144/abstract/17\">",
"      Metcalf AM, Dean T. Risk of dysplasia in anal condyloma. Surgery 1995; 118:724.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/38/23144/abstract/18\">",
"      Nadal SR, Calore EE, Manzione CR, et al. Hypertrophic herpes simplex simulating anal neoplasia in AIDS patients: report of five cases. Dis Colon Rectum 2005; 48:2289.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/38/23144/abstract/19\">",
"      American College of Obstetricians and Gynecologists. ACOG Practice Bulletin. Clinical Management Guidelines for Obstetrician-Gynecologists. Number 61, April 2005. Human papillomavirus. Obstet Gynecol 2005; 105:905.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/38/23144/abstract/20\">",
"      Jablonska S. Traditional therapies for the treatment of condylomata acuminata (genital warts). Australas J Dermatol 1998; 39 Suppl 1:S2.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/38/23144/abstract/21\">",
"      Greene I. Therapy for genital warts. Dermatol Clin 1992; 10:253.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/38/23144/abstract/22\">",
"      Lacey CJ, Goodall RL, Tennvall GR, et al. Randomised controlled trial and economic evaluation of podophyllotoxin solution, podophyllotoxin cream, and podophyllin in the treatment of genital warts. Sex Transm Infect 2003; 79:270.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/38/23144/abstract/23\">",
"      Maw RD. Treatment of anogenital warts. Dermatol Clin 1998; 16:829.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/38/23144/abstract/24\">",
"      Swinehart JM, Sperling M, Phillips S, et al. Intralesional fluorouracil/epinephrine injectable gel for treatment of condylomata acuminata. A phase 3 clinical study. Arch Dermatol 1997; 133:67.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/38/23144/abstract/25\">",
"      Beutner KR, Spruance SL, Hougham AJ, et al. Treatment of genital warts with an immune-response modifier (imiquimod). J Am Acad Dermatol 1998; 38:230.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/38/23144/abstract/26\">",
"      Gunter J. Genital and perianal warts: new treatment opportunities for human papillomavirus infection. Am J Obstet Gynecol 2003; 189:S3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/38/23144/abstract/27\">",
"      O'Mahony C, Law C, Gollnick HP, Marini M. New patient-applied therapy for anogenital warts is rated favourably by patients. Int J STD AIDS 2001; 12:565.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/38/23144/abstract/28\">",
"      Wagstaff AJ, Perry CM. Topical imiquimod: a review of its use in the management of anogenital warts, actinic keratoses, basal cell carcinoma and other skin lesions. Drugs 2007; 67:2187.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/38/23144/abstract/29\">",
"      van Seters M, van Beurden M, ten Kate FJ, et al. Treatment of vulvar intraepithelial neoplasia with topical imiquimod. N Engl J Med 2008; 358:1465.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/38/23144/abstract/30\">",
"      Kreuter A, Brockmeyer NH, Weissenborn SJ, et al. Penile intraepithelial neoplasia is frequent in HIV-positive men with anal dysplasia. J Invest Dermatol 2008; 128:2316.",
"     </a>",
"    </li>",
"    <li>",
"     file://www.gracewaypharma.com/sites/default/files/products/Zyclara%20Full%20PI.pdf (Accessed on April 08, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/38/23144/abstract/32\">",
"      Reichman RC, Oakes D, Bonnez W, et al. Treatment of condyloma acuminatum with three different interferon-alpha preparations administered parenterally: a double-blind, placebo-controlled trial. J Infect Dis 1990; 162:1270.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/38/23144/abstract/33\">",
"      Benedetti Panici P, Scambia G, Baiocchi G, et al. Randomized clinical trial comparing systemic interferon with diathermocoagulation in primary multiple and widespread anogenital condyloma. Obstet Gynecol 1989; 74:393.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/38/23144/abstract/34\">",
"      Dinsmore W, Jordan J, O'Mahony C, et al. Recombinant human interferon-beta in the treatment of condylomata acuminata. Int J STD AIDS 1997; 8:622.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/38/23144/abstract/35\">",
"      Klutke JJ, Bergman A. Interferon as an adjuvant treatment for genital condyloma acuminatum. Int J Gynaecol Obstet 1995; 49:171.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/38/23144/abstract/36\">",
"      Fleshner PR, Freilich MI. Adjuvant interferon for anal condyloma. A prospective, randomized trial. Dis Colon Rectum 1994; 37:1255.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/38/23144/abstract/37\">",
"      Meltzer SM, Monk BJ, Tewari KS. Green tea catechins for treatment of external genital warts. Am J Obstet Gynecol 2009; 200:233.e1.",
"     </a>",
"    </li>",
"    <li>",
"     Drug Information: Veregen (kunecatechins). www.centerwatch.com/patient/drugs/dru938.html (Accessed on November 06, 2007).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/38/23144/abstract/39\">",
"      Veregen: a botanical for treatment of genital warts. Med Lett Drugs Ther 2008; 50:15.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/38/23144/abstract/40\">",
"      Tatti S, Swinehart JM, Thielert C, et al. Sinecatechins, a defined green tea extract, in the treatment of external anogenital warts: a randomized controlled trial. Obstet Gynecol 2008; 111:1371.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/38/23144/abstract/41\">",
"      Stockfleth E, Beti H, Orasan R, et al. Topical Polyphenon E in the treatment of external genital and perianal warts: a randomized controlled trial. Br J Dermatol 2008; 158:1329.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/38/23144/abstract/42\">",
"      Bellina JH. The use of the carbon dioxide laser in the management of condyloma acuminatum with eight-year follow-up. Am J Obstet Gynecol 1983; 147:375.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/38/23144/abstract/43\">",
"      Kraus SJ, Stone KM. Management of genital infection caused by human papillomavirus. Rev Infect Dis 1990; 12 Suppl 6:S620.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/38/23144/abstract/44\">",
"      Snoeck R, Bossens M, Parent D, et al. Phase II double-blind, placebo-controlled study of the safety and efficacy of cidofovir topical gel for the treatment of patients with human papillomavirus infection. Clin Infect Dis 2001; 33:597.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/38/23144/abstract/45\">",
"      B&ouml;hle A, B&uuml;ttner H, Jocham D. Primary treatment of condylomata acuminata with viable bacillus Calmette-Guerin. J Urol 2001; 165:834.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/38/23144/abstract/46\">",
"      Bekassy Z, Westr&ouml;m L. Infrared coagulation in the treatment of condyloma acuminata in the female genital tract. Sex Transm Dis 1987; 14:209.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2554 Version 14.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1005-122.72.76.133-7EC3A6EE76-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_38_23144=[""].join("\n");
var outline_f22_38_23144=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H28\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      ETIOLOGY AND ASSOCIATION WITH MALIGNANCY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      RISK FACTORS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Women",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Men",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      HIV infected individuals",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Differential diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Chemical agents",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Podophyllin",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Trichloroacetic acid",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - 5-fluorouracil epinephrine gel",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Immune modulation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Imiquimod",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Interferon alfa",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6935408\">",
"      - Sinecatechins",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Surgery",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Cryotherapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Laser therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - Excisional procedures",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Topical antimicrobials",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      - Cidofovir",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      - Bacillus Calmette-Guerin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Infrared coagulation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      VULVAR AND VAGINAL WARTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DERM/2554\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DERM/2554|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?4/26/4518\" title=\"algorithm 1\">",
"      Approach anogenital condyloma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DERM/2554|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?17/24/17794\" title=\"picture 1\">",
"      Anal condyloma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?22/28/22979\" title=\"picture 2\">",
"      Condyloma lata",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?37/49/38678\" title=\"picture 3\">",
"      Pearly penile papules",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DERM/2554|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?0/27/443\" title=\"table 1\">",
"      Risk of cervical CA with HPV",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?27/25/28059\" title=\"table 2\">",
"      Clinical manifestations of HPV",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?6/39/6779\" title=\"table 3\">",
"      Indications biopsy genital wart",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?14/57/15259\" title=\"table 4\">",
"      Rx genital warts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/33/1562?source=related_link\">",
"      Anal intraepithelial neoplasia: Diagnosis, screening, prevention, and treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/32/35337?source=related_link\">",
"      Cervical cancer screening tests: Techniques and test characteristics of cervical cytology and human papillomavirus testing",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?20/2/20517?source=related_link\">",
"      Cidofovir: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/43/6842?source=related_link\">",
"      Molluscum contagiosum",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?16/13/16594?source=related_link\">",
"      Patient information: Genital warts (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?3/60/4035?source=related_link\">",
"      Patient information: Genital warts in women (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?37/45/38610?source=related_link\">",
"      Patient information: Human papillomavirus (HPV) vaccine (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?5/22/5475?source=related_link\">",
"      Patient information: Human papillomavirus (HPV) vaccine (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/34/27178?source=related_link\">",
"      Treatment of vulvar and vaginal warts",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/53/26455?source=related_link\">",
"      Virology of human papillomavirus infections and the link to cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/29/26072?source=related_link\">",
"      Vulvovaginal complaints in the prepubertal child",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f22_38_23145="Septic dural sinus thrombosis";
var content_f22_38_23145=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Septic dural sinus thrombosis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?22/38/23145/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/38/23145/contributors\">",
"     Frederick S Southwick, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?22/38/23145/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/38/23145/contributors\">",
"     Stephen B Calderwood, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?22/38/23145/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/38/23145/contributors\">",
"     Anna R Thorner, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?22/38/23145/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Sep 14, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Septic dural sinus thrombosis is an uncommon disease with only several hundred cases reported in the English medical literature during the antibiotic era. Since this disorder is rare, each clinician is likely to encounter only one or a few cases during his or her career. The combination of lack of familiarity and the myriad of potential symptoms and signs often leads to misinterpretation of the clinical manifestations. Delay in both diagnosis and treatment are the rule.",
"   </p>",
"   <p>",
"    Dural sinus thrombosis encompasses three basic syndromes:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Cavernous sinus thrombosis",
"     </li>",
"     <li>",
"      Lateral sinus thrombosis",
"     </li>",
"     <li>",
"      Superior sagittal sinus thrombosis",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The manifestations of each syndrome are unique because the anatomy of the specific sites differs. Thus, the clinician must be familiar with the anatomy of the dural sinuses in order to understand the clinical manifestations of each entity. All three syndromes result in severe headaches, and headache is the usual complaint that brings the patient to the clinician. An exception to this rule is the elderly patient (over age 65 years), who more commonly presents with an alteration in mental status without antecedent headache [",
"    <a class=\"abstract\" href=\"UTD.htm?22/38/23145/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     SEPTIC CAVERNOUS SINUS THROMBOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The cavernous sinus is the most frequent dural sinus to become infected and thrombosed (",
"    <a class=\"graphic graphic_figure graphicRef65634 \" href=\"UTD.htm?9/15/9461\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/38/23145/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Pathogenesis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The cavernous sinuses are the most centrally located of the dural sinuses, positioned just lateral to the base of the sella turcica and to the sphenoid air sinuses. These irregularly shaped sinuses contain multiple trabeculae that act as sieves to trap bacteria, and this characteristic explains the higher risk of infection of the cavernous sinuses as compared with the other dural sinuses. The cavernous sinuses are connected by two intercavernous sinuses that pass anteriorly and posteriorly to the sella turcica and the pituitary gland.",
"   </p>",
"   <p>",
"    A number of cranial nerves are located in fibrous sheaths along the lateral wall of each cavernous sinus: the oculomotor nerve (cranial nerve III), the trochlear nerve (cranial nerve IV), and the ophthalmic (V",
"    <sub>",
"     1",
"    </sub>",
"    ) and maxillary branches (V",
"    <sub>",
"     2",
"    </sub>",
"    ) of the trigeminal nerve. The abducens nerve (cranial nerve VI) is located more medially, near the internal carotid artery that also tracks through the cavernous sinus [",
"    <a class=\"abstract\" href=\"UTD.htm?22/38/23145/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The cavernous sinuses receive blood from the facial veins and pterygoid plexus via the inferior and superior ophthalmic veins. Infections of the face including the nose, orbits, tonsils, and soft palate can spread to the cavernous sinus by this route.",
"   </p>",
"   <p>",
"    Three sites of primary infection are the most likely to lead to septic cavernous sinus thrombosis:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Facial infections involving what has been termed the danger zone (medial third of the face, ie, the areas around the eyes and nose) that drains into the ophthalmic veins. Nasal furuncles are the most common facial infection to produce this complication, particularly if the furuncle is squeezed or drained in the absence of antibiotic coverage.",
"     </li>",
"     <li>",
"      Sphenoid",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      ethmoid sinus infections have increasingly been reported with cavernous sinus thrombosis. Infection can arise via the emissary veins or, in the case of sphenoid sinusitis, can spread by breaking through the lateral air sinus wall [",
"      <a class=\"abstract\" href=\"UTD.htm?22/38/23145/abstract/2,4,5\">",
"       2,4,5",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?38/48/39688?source=see_link\">",
"       \"Acute sinusitis and rhinosinusitis in adults: Clinical manifestations and diagnosis\"",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      Ethmoid sinus infection can extend laterally to the orbit and subsequently spread to the cavernous sinus via the superior ophthalmic vein. Sphenoid sinus infection is particularly difficult to diagnose, and treatment is often delayed, providing time for the infection to spread to the cavernous sinus [",
"      <a class=\"abstract\" href=\"UTD.htm?22/38/23145/abstract/4\">",
"       4",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Dental infection less commonly can result in this complication; infection spreads to the cavernous sinus via the pterygoid venous plexus [",
"      <a class=\"abstract\" href=\"UTD.htm?22/38/23145/abstract/6\">",
"       6",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?16/30/16873?source=see_link\">",
"       \"Epidemiology, pathogenesis, and clinical manifestations of odontogenic infections\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Otitis media and its related complication, mastoiditis, rarely result in cavernous sinus disease despite the frequency of these infections as a cause in the preantibiotic era (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/60/29642?source=see_link&amp;anchor=H27#H27\">",
"     \"Acute otitis media in children: Epidemiology, microbiology, clinical manifestations, and complications\", section on 'Complications and sequelae'",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/38/23145/abstract/7,8\">",
"     7,8",
"    </a>",
"    ]. Mastoid infection can spread first to the lateral and sigmoid sinuses before reaching the cavernous sinuses via the inferior and superior petrosal sinuses. Infection can spread in a retrograde direction in this manner, depending upon the pressure gradients, because the dural sinuses contain no valves.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Clinical manifestations",
"    </span>",
"    &nbsp;&mdash;&nbsp;The early symptoms of cavernous sinus thrombosis are not specific, but the presence of cranial nerve signs (particularly lateral gaze palsy) on physical examination in a patient with headache should alert the clinician to the possibility of the diagnosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Symptoms",
"    </span>",
"    &nbsp;&mdash;&nbsp;Headache is the most common early symptom and generally precedes fever and periorbital edema by several days. Rarely, cavernous sinus infection can be a subacute or chronic process; in this case, headache can be present for several months prior to the onset of eye findings [",
"    <a class=\"abstract\" href=\"UTD.htm?22/38/23145/abstract/4\">",
"     4",
"    </a>",
"    ]. The character of the headache is generally sharp; the pain progressively increases in severity, interferes with sleep, and is not relieved by pain medications. The pain is generally localized to the dermatomes enervated by the ophthalmic and maxillary branches of the fifth cranial nerve. Thus, it is usually unilateral, involving the retroorbital and frontal areas with occasional radiation to the occipital region [",
"    <a class=\"abstract\" href=\"UTD.htm?22/38/23145/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The severe nature of the headache is the most common reason for patients to seek medical attention. Clinicians frequently misdiagnose the pain as migraine headache when the patient presents early in the course of the disorder, before the onset of neurological deficits.",
"   </p>",
"   <p>",
"    Other symptoms that often accompany headache in this disorder include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Eye swelling that begins as a unilateral process but within 24 to 48 hours spreads via the intercavernous sinuses to produce swelling in the other eye",
"     </li>",
"     <li>",
"      Diplopia, which occurs as oculomotor deficits develop",
"     </li>",
"     <li>",
"      Alterations in mental status such as drowsiness, confusion, and coma can rapidly follow eye complaints. A depressed mental status occurs more commonly in elderly patients and in fatal cases.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Less common complaints include photophobia, eye tearing, and ptosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Physical examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;When cavernous sinus septic thrombophlebitis is fully manifest, the physical findings are dramatic. Fever and the classic constellation of bilateral ptosis, proptosis, chemosis, and ocular muscle paralysis are present in the majority of such cases. However, the physical findings may be considerably subtler. A careful eye and neurologic examination, with particular attention to the cranial nerves, is necessary in order to make a diagnosis at an earlier stage.",
"   </p>",
"   <p>",
"    Periorbital edema may be the earliest physical finding. Exophthalmos and chemosis are thought to result from occlusion of the ophthalmic veins, and generally occur just before or at the same time as ophthalmoplegia. Fundoscopic exam is abnormal in two-thirds of patients. Papilledema or dilated tortuous retinal veins are noted.",
"   </p>",
"   <p>",
"    Ophthalmoplegia is an important finding and results from dysfunction of cranial nerve III (oculomotor nerve) enervating the medial, superior, inferior recti, and the inferior oblique eye muscles; cranial nerve IV (trochlear nerve) enervating the superior oblique muscle responsible for downward gaze, especially when the eye is adducted (turned inward); and cranial nerve VI (abducens nerve) enervating the lateral rectus muscle responsible for lateral gaze. These nerves are damaged by the extensive inflammation of the infected cavernous sinus. The following signs should be sought:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Lateral gaze palsy (isolated cranial nerve VI dysfunction) may precede full-blown ophthalmoplegia, particularly in cases of chronic sphenoid sinusitis. Unlike cranial nerves III and IV that are located in the lateral wall of the cavernous sinus and are protected by a fibrous sheath, the abducens nerve is situated medially in the cavernous sinus and is surrounded by blood, making it more susceptible to inflammatory damage.",
"     </li>",
"     <li>",
"      Drooping of the eyelid (ptosis), dilation of the pupil (mydriasis), and eye muscle weakness results from cranial nerve III dysfunction. Total palsy of the nerve leads to an eye that is facing down and lateral. Cranial nerve III also enervates the levator palpebrae superioris muscle, which raises the eyelid, and contains parasympathetic fibers to the ciliary ganglion that regulates the sphincter muscle of the iris.",
"     </li>",
"     <li>",
"      Hypo or hyperesthesia in the dermatomes served by the ophthalmic (V",
"      <sub>",
"       1",
"      </sub>",
"      ) and maxillary (V",
"      <sub>",
"       2",
"      </sub>",
"      ) branches of the fifth cranial nerve (trigeminal nerve) can be subtle but is virtually always present. To test for these, pain and light touch should be examined on the forehead, dorsum of the nose, and cornea (V",
"      <sub>",
"       1",
"      </sub>",
"      ) and the upper lip, lateral nose, and upper cheek (V",
"      <sub>",
"       2",
"      </sub>",
"      ).",
"     </li>",
"     <li>",
"      Loss of visual acuity can arise from papilledema. Blindness caused by compression of the optic nerve by a mycotic aneurysm of the intercavernous segment of the internal",
"      <span class=\"nowrap\">",
"       carotid/ophthalmic",
"      </span>",
"      artery has been reported [",
"      <a class=\"abstract\" href=\"UTD.htm?22/38/23145/abstract/9\">",
"       9",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Differential diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Septic cavernous sinus thrombosis can be difficult to differentiate from orbital cellulitis. Clinical characteristics that increase the probability of involvement of the cavernous sinus include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Dilated pupil or pupils",
"     </li>",
"     <li>",
"      Visual loss",
"     </li>",
"     <li>",
"      Papilledema",
"     </li>",
"     <li>",
"      Fifth cranial nerve dysfunction",
"     </li>",
"     <li>",
"      Bilateral eye involvement",
"     </li>",
"     <li>",
"      Inflammatory cells in the cerebrospinal fluid (CSF)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    High resolution CT or MRI can readily differentiate between the two diseases (see below).",
"   </p>",
"   <p>",
"    Other conditions that can mimic septic cavernous sinus thrombosis include: intraorbital abscess, allergic blepharitis, intracavernous carotid artery aneurysm or arteriovenous fistula, granulomatous inflammation of the superior orbital vein and cavernous sinus (Tolosa-Hunt syndrome), polyarteritis nodosa associated with cerebral venous sinus thrombosis (Cogan syndrome), nasopharyngeal tumor, meningioma and trauma.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The results of a lumbar puncture can be supportive, but imaging studies are necessary to establish the diagnosis of septic cavernous sinus thrombosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     General laboratories and lumbar puncture",
"    </span>",
"    &nbsp;&mdash;&nbsp;The peripheral white blood cell count (WBC) is commonly elevated, suggesting an acute bacterial infection. Lumbar puncture is recommended for differentiating periorbital cellulitis from septic cavernous sinus thrombosis and may yield the offending pathogen. Lumbar puncture reveals inflammatory cells in 75 percent of cases. In half of these cases, the CSF profile is most suggestive of a parameningeal focus (elevated WBC with a predominance of polymorphonuclear neutrophils [PMNs]",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    mononuclear cells, normal glucose, elevated or occasionally normal protein, culture negative). In one-third of patients, the CSF formula is identical to that found in bacterial meningitis (elevated WBC with a predominance of PMN, low glucose, high protein, culture positive) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/38/23145/abstract/2,10\">",
"     2,10",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Microbiology",
"    </span>",
"    &nbsp;&mdash;&nbsp;The organisms associated with septic cavernous sinus thrombosis reflect the primary sites of infection. Staphylococcus aureus accounts for 70 percent of all infections and is the etiologic pathogen in nearly all cases associated with facial infection or sphenoid sinusitis. Community-acquired methicillin-resistant S. aureus is being reported with increasing frequency [",
"    <a class=\"abstract\" href=\"UTD.htm?22/38/23145/abstract/11\">",
"     11",
"    </a>",
"    ]. Streptococci (including S. pneumoniae, S. milleri, and viridans group streptococci) are less commonly found. Anaerobes are occasionally cultured, including Bacteroides spp and Fusobacterium spp, and are most often found with accompanying sinus, dental, or tonsillar infections [",
"    <a class=\"abstract\" href=\"UTD.htm?22/38/23145/abstract/2,12-14\">",
"     2,12-14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Fungal pathogens have been less commonly reported and include Rhizopus spp [",
"    <a class=\"abstract\" href=\"UTD.htm?22/38/23145/abstract/2,10,15\">",
"     2,10,15",
"    </a>",
"    ] and other agents of mucormycosis [",
"    <a class=\"abstract\" href=\"UTD.htm?22/38/23145/abstract/16\">",
"     16",
"    </a>",
"    ], Aspergillus spp [",
"    <a class=\"abstract\" href=\"UTD.htm?22/38/23145/abstract/17\">",
"     17",
"    </a>",
"    ], and Schizophyllum commune [",
"    <a class=\"abstract\" href=\"UTD.htm?22/38/23145/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Imaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;High-resolution orbital computed tomography (CT) scan with contrast or magnetic resonance imaging (MRI) with gadolinium enhancement both readily demonstrate septic cavernous vein thrombosis (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef71777 \" href=\"UTD.htm?33/40/34434\">",
"     image 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/38/23145/abstract/19,20\">",
"     19,20",
"    </a>",
"    ]. The early venous phase following administration of contrast demonstrates regions of decreased or irregular enhancement, thickening of the lateral walls, and bulging of the sinus [",
"    <a class=\"abstract\" href=\"UTD.htm?22/38/23145/abstract/21,22\">",
"     21,22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Carotid angiography, when performed, demonstrates narrowing or complete obstruction of the intercavernous segment of the carotid artery. This segment of the carotid artery spasms and may even thrombose in response to the intense inflammation present in the infected cavernous sinus. MRI and CT scan also readily demonstrate narrowing or occlusion of the internal carotid artery and are now the preferred imaging techniques.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;The mainstay of therapy for septic cavernous sinus thrombosis is antibiotics, although anticoagulation, glucocorticoids, and surgery are appropriate adjunctive treatments in selected cases.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Antibiotics",
"    </span>",
"    &nbsp;&mdash;&nbsp;High-dose intravenous antibiotics should be instituted emergently and directed at the probable organisms causing this type of infection. (See",
"    <a class=\"local\" href=\"#H10\">",
"     'Microbiology'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Because thrombus may limit the penetration of antibiotics, prolonged high dose intravenous antibiotics are recommended. A minimum of three weeks of treatment is generally required to assure sterilization.",
"   </p>",
"   <p>",
"    Empiric therapy should include coverage for community-acquired methicillin-resistant Staphylococcus aureus with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/41/42649?source=see_link\">",
"     vancomycin",
"    </a>",
"    (30",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    IV in two equally divided doses with adjustment for reduced renal function). If susceptibility testing reveals methicillin-sensitive S. aureus, vancomycin should be replaced with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/36/1608?source=see_link\">",
"     nafcillin",
"    </a>",
"    (2 g IV every four hours) or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/15/8437?source=see_link\">",
"     oxacillin",
"    </a>",
"    (2 g IV every four hours). An agent with activity against S. aureus should be combined with a third- or fourth-generation cephalosporin, either",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/17/10521?source=see_link\">",
"     ceftriaxone",
"    </a>",
"    (2 g IV every 12 hours) or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/33/16919?source=see_link\">",
"     cefepime",
"    </a>",
"    (2 g IV every 8 to 12 hours); the latter agent is preferred if Pseudomonas coverage is desired. Anaerobic coverage should be added if a dental or sinus infection is suspected. Intravenous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/38/20065?source=see_link\">",
"     metronidazole",
"    </a>",
"    (500 mg every eight hours) is highly effective for this purpose. For brain abscess, higher doses of metronidazole (15",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    loading dose followed by 7.5",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    every six hours) are recommended.",
"   </p>",
"   <p>",
"    Antifungal therapy is rarely required and should only be utilized if invasive fungal infection is proven by biopsy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24487009\">",
"    <span class=\"h4\">",
"     MRSA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Given substantial rates of methicillin-resistant Staphylococcus aureus (MRSA) infections,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/41/42649?source=see_link\">",
"     vancomycin",
"    </a>",
"    (30 to 60",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day in two or three divided doses IV if renal function is normal) should be used as initial therapy when S. aureus is suspected or proven [",
"    <a class=\"abstract\" href=\"UTD.htm?22/38/23145/abstract/23,24\">",
"     23,24",
"    </a>",
"    ]. If susceptibility testing reveals methicillin-sensitive S. aureus, therapy should be changed to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/36/1608?source=see_link\">",
"     nafcillin",
"    </a>",
"    (2 g IV every four hours) or&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/15/8437?source=see_link\">",
"     oxacillin",
"    </a>",
"    (2 g IV every four hours). If the organism is methicillin-resistant, vancomycin should be continued and dosed to achieve serum trough concentrations of 15 to 20",
"    <span class=\"nowrap\">",
"     mcg/mL.",
"    </span>",
"    A significant drawback to vancomycin is its poor penetration into the cerebrospinal fluid (CSF) of approximately 1 and 5 percent with uninflamed and inflamed meninges, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?22/38/23145/abstract/24-27\">",
"     24-27",
"    </a>",
"    ].",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/31/10746?source=see_link\">",
"     Rifampin",
"    </a>",
"    can be added to vancomycin at a dose of 600 mg orally once daily or 300 to 450 mg twice daily because it achieves bactericidal concentrations in the cerebrospinal fluid regardless of meningeal inflammation [",
"    <a class=\"abstract\" href=\"UTD.htm?22/38/23145/abstract/23,24,28\">",
"     23,24,28",
"    </a>",
"    ], although there are few data to support this [",
"    <a class=\"abstract\" href=\"UTD.htm?22/38/23145/abstract/29-31\">",
"     29-31",
"    </a>",
"    ]. &nbsp;",
"    <br/>",
"    <br/>",
"    Based upon case reports and case series of patients with central nervous system (CNS) infections caused by MRSA, alternatives to vancomycin include",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/3/14393?source=see_link\">",
"     linezolid",
"    </a>",
"    (600 mg IV or orally twice daily) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/38/23145/abstract/11,32-34\">",
"     11,32-34",
"    </a>",
"    ],",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/58/5034?source=see_link\">",
"     trimethoprim-sulfamethoxazole",
"    </a>",
"    (5",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    IV every 8 to 12 hours) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/38/23145/abstract/24,35,36\">",
"     24,35,36",
"    </a>",
"    ], and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/10/20646?source=see_link\">",
"     daptomycin",
"    </a>",
"    (6",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    IV once daily) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/38/23145/abstract/37,38\">",
"     37,38",
"    </a>",
"    ]. Although there are insufficient data regarding the efficacy of these regimens for the treatment of CNS infections caused by MRSA, these agents are reasonable alternatives when vancomycin cannot be used or is ineffective. Further studies are needed to establish the benefit of these agents for the treatment of CNS infections. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/60/15306?source=see_link&amp;anchor=H108515050#H108515050\">",
"     \"Treatment of bacterial meningitis caused by specific pathogens in adults\", section on 'Staphylococcus aureus'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Anticoagulation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The use of anticoagulants in septic cavernous sinus thrombosis is controversial and there are limited data on this issue. A prospective trial has not been performed due to the rarity of the syndrome. One retrospective study demonstrated a significant reduction in mortality in patients with unilateral involvement who presented early and who received",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    &nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?22/38/23145/abstract/2\">",
"     2",
"    </a>",
"    ]. In a second retrospective analysis, the addition of early anticoagulation to antibiotic treatment did not affect mortality but did decrease morbidity, including ophthalmoplegia, blindness, stroke, hypopituitarism, and seizures [",
"    <a class=\"abstract\" href=\"UTD.htm?22/38/23145/abstract/39\">",
"     39",
"    </a>",
"    ]. Complications associated with heparinization have been rare.",
"   </p>",
"   <p>",
"    Based upon these limited observations, and pending better prospective data, we suggest early heparinization in patients with unilateral cavernous sinus thrombosis. The use of anticoagulation in patients with cavernous sinus thrombosis who have associated intracerebral hemorrhage secondary to venous infarction is even less well studied, but careful anticoagulation in such patients may be appropriate. In contrast, anticoagulation is contraindicated in patients with spontaneous intracerebral hemorrhage (eg, hypertensive intracerebral hemorrhage).",
"   </p>",
"   <p>",
"    The related condition of aseptic acute cerebral venous thrombosis is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/16/9482?source=see_link&amp;anchor=H7#H7\">",
"     \"Treatment and prognosis of cerebral venous thrombosis\", section on 'Acute antithrombotic treatment'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Constant infusion",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    anticoagulation should be used, adjusting the dose to maintain a partial thromboplastin time ratio of 1.5 to 2.5 [",
"    <a class=\"abstract\" href=\"UTD.htm?22/38/23145/abstract/40\">",
"     40",
"    </a>",
"    ]. There are no reports of low molecular weight heparin being used in this setting; however, hemorrhagic complications have been observed in two patients who were receiving low molecular weight heparin for septic lateral sinus thrombosis [",
"    <a class=\"abstract\" href=\"UTD.htm?22/38/23145/abstract/41\">",
"     41",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The duration of anticoagulation has not been determined. We suggest that anticoagulation should be continued until the infection, as well as the symptoms and signs of cavernous sinus thrombosis, have resolved or significantly improved. This is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/16/9482?source=see_link&amp;anchor=H16#H16\">",
"     \"Treatment and prognosis of cerebral venous thrombosis\", section on 'Duration of antithrombotic treatment'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Oral anticoagulants should be avoided in the acute phase of the illness because of the difficulty in rigorously maintaining safe anticoagulation levels.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Glucocorticoids",
"    </span>",
"    &nbsp;&mdash;&nbsp;Glucocorticoids may prove helpful in reversing the inflammatory damage to the cranial nerves and in reducing subsequent cranial nerve dysfunction. They should be instituted only after appropriate antibiotic coverage. These agents may also be helpful in reducing orbital congestion and preventing Addisonian crisis in cases where infection has spread to the pituitary gland.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/4/33856?source=see_link\">",
"     Dexamethasone",
"    </a>",
"    10 mg IV every six hours is commonly recommended.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Surgery",
"    </span>",
"    &nbsp;&mdash;&nbsp;Surgical drainage of documented sphenoid sinus infection should be strongly considered, and, if done, should be performed emergently [",
"    <a class=\"abstract\" href=\"UTD.htm?22/38/23145/abstract/42\">",
"     42",
"    </a>",
"    ]. Debridement of the infected sphenoid can be followed by rapid improvement.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H93003671\">",
"    <span class=\"h2\">",
"     Prevention",
"    </span>",
"    &nbsp;&mdash;&nbsp;It is vital for clinicians to recognize and aggressively treat sphenoid sinus infection before there is spread to the cavernous sinus [",
"    <a class=\"abstract\" href=\"UTD.htm?22/38/23145/abstract/4\">",
"     4",
"    </a>",
"    ]. In recent years, the use of sinus CT scans has markedly enhanced the ability to diagnose this dangerous air sinus infection. Caregivers should also treat serious infections of the midfacial region urgently because delays in treatment can result in tracking of infection from the face through the venous system to the cavernous sinus.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Outcome",
"    </span>",
"    &nbsp;&mdash;&nbsp;The overall mortality rate associated with septic cavernous sinus thrombosis is 30 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?22/38/23145/abstract/2\">",
"     2",
"    </a>",
"    ]. Infection can spread to the meninges and even to the pituitary gland despite appropriate antimicrobial therapy. An additional 30 percent of patients suffer serious sequelae including persistent oculomotor weakness, blindness, hemiparesis, or pituitary insufficiency. The morbidity and mortality (50 percent, respectively) are particularly high in cases of cavernous sinus thrombosis associated with sphenoid sinus infection [",
"    <a class=\"abstract\" href=\"UTD.htm?22/38/23145/abstract/2,4\">",
"     2,4",
"    </a>",
"    ]. The diagnosis and therapy are more commonly delayed in sphenoid sinus disease compared with facial or dental infection. The delay in diagnosing spheroid sinus infection results in more extensive cavernous sinus involvement at the time of presentation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     SEPTIC LATERAL SINUS THROMBOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Lateral sinus thrombosis is now uncommon. Early institution of antibiotic treatment for otitis media often prevents progression to mastoiditis and subsequent spread to the lateral sinus. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/60/29642?source=see_link&amp;anchor=H27#H27\">",
"     \"Acute otitis media in children: Epidemiology, microbiology, clinical manifestations, and complications\", section on 'Complications and sequelae'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Pathogenesis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Septic lateral sinus thrombosis is exclusively associated with infection of the mastoid air cells [",
"    <a class=\"abstract\" href=\"UTD.htm?22/38/23145/abstract/2,43\">",
"     2,43",
"    </a>",
"    ]. Infection spreads from this site directly to the epidural space overlying the lateral sinus or spreads via emissary veins. The majority of individuals have a right dominant venous circulation in which the superior sagittal sinus drains into the right lateral sinus. Less commonly, a left dominant circulation is present. Occlusion of the dominant lateral sinus interferes with venous drainage of the superior sagittal sinus. Because the arachnoid villi responsible for CSF resorption drain into this sinus, thrombosis of the dominant lateral dural sinus results in communicating hydrocephalus, sometimes called otitic hydrocephalus.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Clinical manifestations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Septic lateral sinus thrombosis has a subacute onset. Symptoms generally begin several weeks before hospitalization.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     Symptoms",
"    </span>",
"    &nbsp;&mdash;&nbsp;Earache is generally the first symptom, persisting for several weeks prior to the onset of headache. Failure to seek medical attention or treatment with inappropriate antibiotics results in spread of the infection to the mastoid and subsequently to the epidural space. Headache generally is severe, persistent, and localized to the fronto-temporo-occipital region on the side of the ear infection. Pain is thought to be a manifestation of a developing epidural abscess, irritation of the fifth cranial nerve, or thrombosis of the lateral sinus. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/40/17033?source=see_link\">",
"     \"Epidural abscess\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Nausea and vomiting develop in nearly half of cases and can be mistaken for severe gastroenteritis. This manifestation may reflect irritation of the brainstem or elevated CSF pressure. Other symptoms include vertigo, diplopia, photophobia, and neck stiffness. Some patients develop cough productive of bloody sputum that results from septic pulmonary emboli (see below).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h3\">",
"     Physical findings",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fever is present in 80 percent of cases, and patients often appear toxic. An abnormal ear examination is found in virtually all patients; 40 percent have a ruptured tympanic membrane and 20 percent a dull, erythematous tympanic membrane. Posterior auricular swelling is found in over half of the cases and is caused by occlusion of the mastoid emissary veins. This finding is called the Gresinger sign.",
"   </p>",
"   <p>",
"    Bilateral papilledema (the result of elevated CSF pressure) is also present in half of the cases and may be associated with retinal hemorrhage. Accompanying loss of visual acuity develops in 15 percent. Unilateral sixth nerve dysfunction is reported in over a third of cases and is thought to be caused by compression of the nerve by swelling of the inferior petrosal sinus within the closed space of Dorello's canal.",
"   </p>",
"   <p>",
"    Otitis media, sixth nerve paralysis, and fifth cranial nerve irritation (temporoparietal and retroorbital pain) is known as Gradenigo syndrome. When present, this symptom complex provides strong evidence for lateral sinus thrombosis or inflammation of the petrous ridge of the temporal bone [",
"    <a class=\"abstract\" href=\"UTD.htm?22/38/23145/abstract/44\">",
"     44",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Nuchal rigidity is present in one-third of patients and is probably the result of meningeal inflammation. Depression in mental status is noted in 14 percent of cases.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mastoid radiographs are abnormal in all patients, showing increased density with loss of mastoid trabeculae, bony sclerosis and lytic lesions of the temporal and parietal bones. Magnetic resonance imaging (MRI) is the diagnostic study of choice. T1-weighted images can readily detect methemoglobin in thrombosed vessels resulting in a marked increase in signal intensity. MR gadolinium angiography can also be used to assess venous flow. Three-dimensional MR gradient-echo cerebral venography has been shown to be superior to two-dimensional MR [",
"    <a class=\"abstract\" href=\"UTD.htm?22/38/23145/abstract/45\">",
"     45",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Lumbar puncture should be performed in all cases after MRI or CT has excluded the possibility of brain abscess. CSF pressures are commonly elevated to the range of 450 to 500 mmH2O in 75 percent of cases. Increased CSF pressure results from interference with CSF resorption by arachnoid villi draining into the superior sagittal sinus. The CSF formula is normal in two-thirds of cases, and reflects parameningeal inflammation in the other third. (See",
"    <a class=\"local\" href=\"#H9\">",
"     'General laboratories and lumbar puncture'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Chest radiography rarely reveals rounded densities. These lesions are caused by septic emboli passing from the lateral sinus into the internal jugular vein and then passing into the pulmonary venous circulation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Microbiology",
"    </span>",
"    &nbsp;&mdash;&nbsp;The principal pathogens associated with this complication reflect the bacteriology of chronic otitis media. Proteus spp are most common, followed by S. aureus, Escherichia coli, and anaerobes (Bacteroides fragilis and anaerobic streptococci) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/38/23145/abstract/2\">",
"     2",
"    </a>",
"    ]. Pseudomonas is often cultured from the external ear canal, and cultures of this site cannot be relied upon. However, this organism has also been identified in intraoperative cultures [",
"    <a class=\"abstract\" href=\"UTD.htm?22/38/23145/abstract/43,46\">",
"     43,46",
"    </a>",
"    ]. Infection is often polymicrobial, containing both aerobes and anaerobes.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;The mainstays of treatment of septic lateral sinus thrombosis are antibiotics and, in the absence of rapid defervescence, surgery.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h3\">",
"     Antibiotics",
"    </span>",
"    &nbsp;&mdash;&nbsp;High-dose intravenous antibiotics need to be administered immediately [",
"    <a class=\"abstract\" href=\"UTD.htm?22/38/23145/abstract/2,47,48\">",
"     2,47,48",
"    </a>",
"    ]. A regimen containing a third- or fourth-generation cephalosporin (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/17/10521?source=see_link\">",
"     ceftriaxone",
"    </a>",
"    2 g IV every 12 hours or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/33/16919?source=see_link\">",
"     cefepime",
"    </a>",
"    2 g IV every 8 to 12 hours) and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/38/20065?source=see_link\">",
"     metronidazole",
"    </a>",
"    (500 mg IV every eight hours) should be initiated pending cultures. Imipenem (500 mg IV every six hours) or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/38/32359?source=see_link\">",
"     meropenem",
"    </a>",
"    (1 g IV every eight hours) are acceptable alternatives. Methicillin-resistant S. aureus is rare; however, in the acutely ill patient, the empiric addition of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/41/42649?source=see_link\">",
"     vancomycin",
"    </a>",
"    (30",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    IV per day in two divided doses, not to exceed 2 g per 24 hours unless serum concentrations are inappropriately low) may be warranted.",
"   </p>",
"   <p>",
"    Once the results of intraoperative cultures are available, therapy should be changed to target the identified organisms based upon their antibiotic sensitivities. Antibiotic regimens for methicillin-resistant Staphylococcus aureus infection are discussed above. (See",
"    <a class=\"local\" href=\"#H24487009\">",
"     'MRSA'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h3\">",
"     Surgery",
"    </span>",
"    &nbsp;&mdash;&nbsp;Radical mastoidectomy should be strongly considered in all patients who fail to defervesce within 12 to 24 hours of the initiation of antibiotic treatment. During surgery, the area overlying the lateral sinus should be explored so that infected granulation tissue or purulent collections can be drained. Removal of thrombus from the lateral sinus is not recommended because recanalization or the development of collateral venous drainage occurs once the infection has been controlled [",
"    <a class=\"abstract\" href=\"UTD.htm?22/38/23145/abstract/49\">",
"     49",
"    </a>",
"    ]. Similarly, ligation of the jugular vein, a common procedure in the preantibiotic era, is not recommended.",
"   </p>",
"   <p>",
"    Not all cases of lateral sinus thrombosis require mastoidectomy with drainage. In one pediatric series, three of five patients responded quickly to antibiotic therapy and myringotomy, fully recovering without more aggressive surgical intervention [",
"    <a class=\"abstract\" href=\"UTD.htm?22/38/23145/abstract/50\">",
"     50",
"    </a>",
"    ]. However, in the absence of prompt defervescence, surgical intervention is recommended.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h3\">",
"     Anticoagulation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The role of anticoagulation in septic lateral sinus thrombosis remains controversial, and there are limited data on this issue. A previously reported patient with lateral sinus thrombosis and cortical vein thrombosis suffered a fatal hemorrhage while receiving",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?22/38/23145/abstract/2\">",
"     2",
"    </a>",
"    ]. In recent series, the majority of patients with acute aseptic dural sinus thrombosis received anticoagulation without apparent ill effects (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/16/9482?source=see_link\">",
"     \"Treatment and prognosis of cerebral venous thrombosis\"",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The stimulus precipitating thrombosis in septic cases is self-limited, resolving with antibiotic treatment, and thrombotic vessels subsequently often undergo recanalization. Until better prospective data are available, the clinician will need to balance the potential benefits of anticoagulation with the small risk of intracerebral hemorrhage.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h3\">",
"     Other",
"    </span>",
"    &nbsp;&mdash;&nbsp;Serial lumbar punctures every 48 hours may be required to lower the CSF pressure and relieve papilledema. Persistent communicating hydrocephalus may require placement of a ventricular shunt.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h2\">",
"     Outcome",
"    </span>",
"    &nbsp;&mdash;&nbsp;The outcome is usually favorable in this disease. There have been no reported fatalities in the last decade. The majority of patients fully recover, although 10 to 15 percent suffer chronic sequelae including otitic hydrocephalus, decreased visual acuity, impaired hearing, and rarely, residual hemiparesis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h1\">",
"     SEPTIC SUPERIOR SAGITTAL SINUS THROMBOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The superior sagittal sinus is the largest venous channel in the brain. In addition to arachnoid villi (responsible for CSF resorption), multiple cortical veins empty into this venous channel [",
"    <a class=\"abstract\" href=\"UTD.htm?22/38/23145/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. Given the large size of the superior sagittal sinus, septic thrombotic occlusion is very rare.",
"   </p>",
"   <p>",
"    The most common infection associated with complete occlusion of the superior sagittal sinus is bacterial meningitis. Thrombosis of the anterior segment has been associated with frontal bacterial sinusitis occasionally. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/38/31335?source=see_link\">",
"     \"Epidemiology of bacterial meningitis in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/48/39688?source=see_link\">",
"     \"Acute sinusitis and rhinosinusitis in adults: Clinical manifestations and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A case of methicillin-resistant Staphylococcus aureus causing septic superior sagittal sinus thrombosis following facial plastic surgery has been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?22/38/23145/abstract/51\">",
"     51",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Septic thrombosis of the superior sagittal sinus results in hemorrhagic infarcts, due to cortical vein thrombosis, and communicating hydrocephalus. When combined with the cerebral edema associated with meningitis, massive brain infarction in most cases quickly leads to transtentorial brainstem herniation [",
"    <a class=\"abstract\" href=\"UTD.htm?22/38/23145/abstract/52\">",
"     52",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Diagnosis is made most readily by MRI. As discussed above, this diagnostic technique readily demonstrates thrombus formation and decreased venous flow. As observed for lateral sinus thrombosis, three-dimensional MR has proved to be superior to two-dimensional MR angiography [",
"    <a class=\"abstract\" href=\"UTD.htm?22/38/23145/abstract/53\">",
"     53",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H23\">",
"     'Diagnosis'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    The outcome of complete occlusion of the superior sagittal sinus is universally fatal. Occlusion of the anterior segment in association with frontal sinusitis presents with mild to moderate headache and spontaneously resolves following the development of collateral venous channels. Although anticoagulants and thrombolytic therapy are often administered in aseptic superior sagittal sinus thrombosis, their role in septic disease has not been defined, and given the extensive intracerebral hemorrhage and the rapid progression to death, they are unlikely to be of benefit. Antibiotics, if begun early for bacterial meningitis, can prevent this complication from occurring; however, once occlusion has occurred, initiation of antibiotics is unlikely to be of significant benefit for this complication. Coverage with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/41/42649?source=see_link\">",
"     vancomycin",
"    </a>",
"    (30",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    IV in two equally divided doses with adjustment for reduced renal function) and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/17/10521?source=see_link\">",
"     ceftriaxone",
"    </a>",
"    (2 g IV every 12 hours) can be used for empiric therapy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/17/22810?source=see_link\">",
"     \"Initial therapy and prognosis of bacterial meningitis in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1319409772\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Septic dural sinus thrombosis is an uncommon disease. The combination of lack of familiarity and the myriad of potential symptoms and signs often leads to misinterpretation of the clinical manifestations. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Dural sinus thrombosis encompasses three basic syndromes:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Cavernous sinus thrombosis",
"     </li>",
"     <li>",
"      Lateral sinus thrombosis",
"     </li>",
"     <li>",
"      Superior sagittal sinus thrombosis (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1319410488\">",
"    <span class=\"h2\">",
"     Septic cavernous sinus thrombosis",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The cavernous sinus is the most frequent dural sinus to become infected and thrombosed (",
"      <a class=\"graphic graphic_figure graphicRef65634 \" href=\"UTD.htm?9/15/9461\">",
"       figure 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Septic cavernous sinus thrombosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The most likely sites of primary infection to lead to septic cavernous sinus thrombosis include facial infections involving the danger zone (medial third of the face), sphenoid",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      ethmoid sinus infections, and less commonly, dental infections. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Pathogenesis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The early symptoms of cavernous sinus thrombosis are not specific, but the presence of cranial nerve signs (particularly lateral gaze palsy) on physical examination in a patient with headache should alert the clinician to the possibility of the diagnosis. Headache is the most common early symptom and generally precedes fever and periorbital edema by several days. Other common clinical manifestations include eye swelling, diplopia, and changes in mental status. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Clinical manifestations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The results of a lumbar puncture can be supportive, but imaging studies are necessary to establish the diagnosis of septic cavernous sinus thrombosis (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef71777 \" href=\"UTD.htm?33/40/34434\">",
"       image 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The organisms associated with septic cavernous sinus thrombosis reflect the primary sites of infection. Staphylococcus aureus accounts for 70 percent of all infections and is the etiologic pathogen in nearly all cases associated with facial infection or sphenoid sinusitis. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Microbiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The mainstay of therapy for septic cavernous sinus thrombosis is antibiotics, although anticoagulation, glucocorticoids, and surgery are appropriate adjunctive treatments in selected cases. Empiric therapy should include coverage for community-acquired methicillin-resistant Staphylococcus aureus with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?41/41/42649?source=see_link\">",
"       vancomycin",
"      </a>",
"      (30",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      IV in two equally divided doses with adjustment for reduced renal function). If susceptibility testing reveals methicillin-sensitive S. aureus, vancomycin should be replaced with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?1/36/1608?source=see_link\">",
"       nafcillin",
"      </a>",
"      (2 g IV every four hours) or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?8/15/8437?source=see_link\">",
"       oxacillin",
"      </a>",
"      (2 g IV every four hours). An agent with activity against S. aureus should be combined with a third- or fourth-generation cephalosporin, either",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/17/10521?source=see_link\">",
"       ceftriaxone",
"      </a>",
"      (2 g IV every 12 hours) or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/33/16919?source=see_link\">",
"       cefepime",
"      </a>",
"      (2 g IV every 8 to 12 hours); the latter agent is preferred if Pseudomonas coverage is desired. Anaerobic coverage with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/38/20065?source=see_link\">",
"       metronidazole",
"      </a>",
"      (500 mg IV every eight hours) should be added if a dental or sinus infection is suspected. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      It is vital for clinicians to recognize and aggressively treat sphenoid sinus infection before there is spread to the cavernous sinus. Surgical drainage of documented sphenoid sinus infection should be strongly considered, and, if done, should be performed emergently. (See",
"      <a class=\"local\" href=\"#H93003671\">",
"       'Prevention'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H16\">",
"       'Surgery'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1319410496\">",
"    <span class=\"h2\">",
"     Septic lateral sinus thrombosis",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Lateral sinus thrombosis is uncommon. Early institution of antibiotic treatment for otitis media often prevents progression to mastoiditis and subsequent spread to the lateral sinus. Earache is generally the first symptom, persisting for several weeks prior to the onset of headache. Failure to seek medical attention or treatment with inappropriate antibiotics results in spread of the infection to the mastoid and subsequently to the epidural space. Headache generally is severe, persistent, and localized to the fronto-temporo-occipital region on the side of the ear infection. (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Septic lateral sinus thrombosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      If the diagnosis is made, a regimen containing a third- or fourth-generation cephalosporin (",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/17/10521?source=see_link\">",
"       ceftriaxone",
"      </a>",
"      2 g IV every 12 hours or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/33/16919?source=see_link\">",
"       cefepime",
"      </a>",
"      2 g IV every 8 to 12 hours) and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/38/20065?source=see_link\">",
"       metronidazole",
"      </a>",
"      (500 mg every eight hours) should be initiated pending cultures. Imipenem (500 mg IV every six hours) or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/38/32359?source=see_link\">",
"       meropenem",
"      </a>",
"      (1 g IV every eight hours) are acceptable alternatives. Methicillin-resistant S. aureus is rare; however, in the acutely ill patient, the empiric addition of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?41/41/42649?source=see_link\">",
"       vancomycin",
"      </a>",
"      (30",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      IV per day in two divided doses, not to exceed 2 g per 24 hours unless serum concentrations are inappropriately low) may be warranted. (See",
"      <a class=\"local\" href=\"#H26\">",
"       'Antibiotics'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Radical mastoidectomy should be strongly considered in all patients who fail to defervesce within 12 to 24 hours of the initiation of antibiotic treatment. During surgery, the area overlying the lateral sinus should be explored so that infected granulation tissue or purulent collections can be drained. (See",
"      <a class=\"local\" href=\"#H27\">",
"       'Surgery'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1319410581\">",
"    <span class=\"h2\">",
"     Septic superior sagittal sinus thrombosis",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Given the large size of the superior sagittal sinus, septic thrombotic occlusion is very rare. The most common infection associated with complete occlusion of the superior sagittal sinus is bacterial meningitis. Thrombosis of the anterior segment has been associated with frontal bacterial sinusitis occasionally. Complete occlusion of the superior sagittal sinus is universally fatal. (See",
"      <a class=\"local\" href=\"#H31\">",
"       'Septic superior sagittal sinus thrombosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Antibiotics, if begun early for bacterial meningitis, can prevent septic superior sagittal sinus thrombosis from occurring; however, once occlusion has occurred, initiation of antibiotics is unlikely to be of significant benefit for this complication. Coverage with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?41/41/42649?source=see_link\">",
"       vancomycin",
"      </a>",
"      (30",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      IV in two equally divided doses with adjustment for reduced renal function) and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/17/10521?source=see_link\">",
"       ceftriaxone",
"      </a>",
"      (2 g IV every 12 hours) can be used for empiric therapy. (See",
"      <a class=\"local\" href=\"#H31\">",
"       'Septic superior sagittal sinus thrombosis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/38/23145/abstract/1\">",
"      Ferro JM, Canh&atilde;o P, Bousser MG, et al. Cerebral vein and dural sinus thrombosis in elderly patients. Stroke 2005; 36:1927.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/38/23145/abstract/2\">",
"      Southwick FS, Richardson EP Jr, Swartz MN. Septic thrombosis of the dural venous sinuses. Medicine (Baltimore) 1986; 65:82.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/38/23145/abstract/3\">",
"      Harris FS, Rhoton AL. Anatomy of the cavernous sinus. A microsurgical study. J Neurosurg 1976; 45:169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/38/23145/abstract/4\">",
"      Lew D, Southwick FS, Montgomery WW, et al. Sphenoid sinusitis. A review of 30 cases. N Engl J Med 1983; 309:1149.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/38/23145/abstract/5\">",
"      Sadun F, Feldon SE, Weiss MH, Krieger MD. Septic cavernous sinus thrombosis following transsphenoidal craniotomy. Case report. J Neurosurg 1996; 85:949.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/38/23145/abstract/6\">",
"      Kahn JB, Baharestani S, Beck HC, et al. Orbital dissemination of Lemierre syndrome from gram-positive septic emboli. Ophthal Plast Reconstr Surg 2011; 27:e67.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/38/23145/abstract/7\">",
"      Park SN, Yeo SW, Suh BD. Cavernous sinus thrombophlebitis secondary to petrous apicitis: a case report. Otolaryngol Head Neck Surg 2003; 128:284.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/38/23145/abstract/8\">",
"      Dubey SP, Larawin V, Molumi CP. Intracranial spread of chronic middle ear suppuration. Am J Otolaryngol 2010; 31:73.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/38/23145/abstract/9\">",
"      Quisling SV, Mawn LA, Larson TC 3rd. Blindness associated with enlarging mycotic aneurysm after cavernous sinus thrombosis. Ophthalmology 2003; 110:2036.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/38/23145/abstract/10\">",
"      Bengel D, Susa M, Schreiber H, et al. Early diagnosis of rhinocerebral mucormycosis by cerebrospinal fluid analysis and determination of 16s rRNA gene sequence. Eur J Neurol 2007; 14:1067.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/38/23145/abstract/11\">",
"      Naesens R, Ronsyn M, Druw&eacute; P, et al. Central nervous system invasion by community-acquired meticillin-resistant Staphylococcus aureus. J Med Microbiol 2009; 58:1247.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/38/23145/abstract/12\">",
"      Cannon ML, Antonio BL, McCloskey JJ, et al. Cavernous sinus thrombosis complicating sinusitis. Pediatr Crit Care Med 2004; 5:86.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/38/23145/abstract/13\">",
"      Watkins LM, Pasternack MS, Banks M, et al. Bilateral cavernous sinus thromboses and intraorbital abscesses secondary to Streptococcus milleri. Ophthalmology 2003; 110:569.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/38/23145/abstract/14\">",
"      Westhout F, Hasso A, Jalili M, et al. Lemierre syndrome complicated by cavernous sinus thrombosis, the development of subdural empyemas, and internal carotid artery narrowing without cerebral infarction. Case report. J Neurosurg 2007; 106:53.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/38/23145/abstract/15\">",
"      Peter L, Krolak-Salmon P, Pignat JC, et al. [Rhinocerebral mucormycosis]. Rev Neurol (Paris) 2005; 161:214.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/38/23145/abstract/16\">",
"      Chitsaz S, Bagheri J, Mandegar MH, et al. Extensive sino-orbital zygomycosis after heart transplantation: a case report. Transplant Proc 2009; 41:2927.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/38/23145/abstract/17\">",
"      Dev&egrave;ze A, Facon F, Latil G, et al. Cavernous sinus thrombosis secondary to non-invasive sphenoid aspergillosis. Rhinology 2005; 43:152.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/38/23145/abstract/18\">",
"      Roh ML, Tuazon CU, Mandler R, et al. Sphenocavernous syndrome associated with Schizophyllum commune infection of the sphenoid sinus. Ophthal Plast Reconstr Surg 2005; 21:71.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/38/23145/abstract/19\">",
"      Ebright JR, Pace MT, Niazi AF. Septic thrombosis of the cavernous sinuses. Arch Intern Med 2001; 161:2671.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/38/23145/abstract/20\">",
"      Lee JH, Lee HK, Park JK, et al. Cavernous sinus syndrome: clinical features and differential diagnosis with MR imaging. AJR Am J Roentgenol 2003; 181:583.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/38/23145/abstract/21\">",
"      Schuknecht B, Simmen D, Y&uuml;ksel C, Valavanis A. Tributary venosinus occlusion and septic cavernous sinus thrombosis: CT and MR findings. AJNR Am J Neuroradiol 1998; 19:617.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/38/23145/abstract/22\">",
"      Ellie E, Houang B, Louail C, et al. CT and high-field MRI in septic thrombosis of the cavernous sinuses. Neuroradiology 1992; 34:22.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/38/23145/abstract/23\">",
"      Tunkel AR, Hartman BJ, Kaplan SL, et al. Practice guidelines for the management of bacterial meningitis. Clin Infect Dis 2004; 39:1267.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/38/23145/abstract/24\">",
"      Liu C, Bayer A, Cosgrove SE, et al. Clinical practice guidelines by the infectious diseases society of america for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children. Clin Infect Dis 2011; 52:e18.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/38/23145/abstract/25\">",
"      Pfausler B, Spiss H, Beer R, et al. Treatment of staphylococcal ventriculitis associated with external cerebrospinal fluid drains: a prospective randomized trial of intravenous compared with intraventricular vancomycin therapy. J Neurosurg 2003; 98:1040.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/38/23145/abstract/26\">",
"      Jorgenson L, Reiter PD, Freeman JE, et al. Vancomycin disposition and penetration into ventricular fluid of the central nervous system following intravenous therapy in patients with cerebrospinal devices. Pediatr Neurosurg 2007; 43:449.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/38/23145/abstract/27\">",
"      Wang Q, Shi Z, Wang J, et al. Postoperatively administered vancomycin reaches therapeutic concentration in the cerebral spinal fluid of neurosurgical patients. Surg Neurol 2008; 69:126.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/38/23145/abstract/28\">",
"      Nau R, Prange HW, Menck S, et al. Penetration of rifampicin into the cerebrospinal fluid of adults with uninflamed meninges. J Antimicrob Chemother 1992; 29:719.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/38/23145/abstract/29\">",
"      Perlroth J, Kuo M, Tan J, et al. Adjunctive use of rifampin for the treatment of Staphylococcus aureus infections: a systematic review of the literature. Arch Intern Med 2008; 168:805.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/38/23145/abstract/30\">",
"      von Specht M, Gardella N, Tagliaferri P, et al. Methicillin-resistant Staphylococcus aureus in community-acquired meningitis. Eur J Clin Microbiol Infect Dis 2006; 25:267.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/38/23145/abstract/31\">",
"      Pintado V, Meseguer MA, Fort&uacute;n J, et al. Clinical study of 44 cases of Staphylococcus aureus meningitis. Eur J Clin Microbiol Infect Dis 2002; 21:864.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/38/23145/abstract/32\">",
"      Gallagher RM, Pizer B, Ellison JA, Riordan FA. Glycopeptide insensitive Staphylococcus aureus subdural empyema treated with linezolid and rifampicin. J Infect 2008; 57:410.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/38/23145/abstract/33\">",
"      Kessler AT, Kourtis AP. Treatment of meningitis caused by methicillin-resistant Staphylococcus aureus with linezolid. Infection 2007; 35:271.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/38/23145/abstract/34\">",
"      Ntziora F, Falagas ME. Linezolid for the treatment of patients with central nervous system infection. Ann Pharmacother 2007; 41:296.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/38/23145/abstract/35\">",
"      Levitz RE, Quintiliani R. Trimethoprim-sulfamethoxazole for bacterial meningitis. Ann Intern Med 1984; 100:881.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/38/23145/abstract/36\">",
"      Vartzelis G, Theodoridou M, Daikos GL, et al. Brain abscesses complicating Staphylococcus aureus sepsis in a premature infant. Infection 2005; 33:36.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/38/23145/abstract/37\">",
"      Lee DH, Palermo B, Chowdhury M. Successful treatment of methicillin-resistant staphylococcus aureus meningitis with daptomycin. Clin Infect Dis 2008; 47:588.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/38/23145/abstract/38\">",
"      Wallace MR, Sander AW, Licitra C, et al. Methicillin-resistant Staphylococcus aureus meningitis successfully treated with daptomycin. Infect Dis Clin Pract 2009; 17:69.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/38/23145/abstract/39\">",
"      Levine SR, Twyman RE, Gilman S. The role of anticoagulation in cavernous sinus thrombosis. Neurology 1988; 38:517.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/38/23145/abstract/40\">",
"      Bhatia K, Jones NS. Septic cavernous sinus thrombosis secondary to sinusitis: are anticoagulants indicated? A review of the literature. J Laryngol Otol 2002; 116:667.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/38/23145/abstract/41\">",
"      Shah UK, Jubelirer TF, Fish JD, Elden LM. A caution regarding the use of low-molecular weight heparin in pediatric otogenic lateral sinus thrombosis. Int J Pediatr Otorhinolaryngol 2007; 71:347.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/38/23145/abstract/42\">",
"      Poulopoulos M, Finelli PF. Neurological complications with acute sphenoid sinusitis a surgical emergency? Neurocrit Care 2007; 7:169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/38/23145/abstract/43\">",
"      Seven H, Ozbal AE, Turgut S. Management of otogenic lateral sinus thrombosis. Am J Otolaryngol 2004; 25:329.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/38/23145/abstract/44\">",
"      Scardapane A, Del Torto M, Nozzi M, et al. Gradenigo's syndrome with lateral venous sinus thrombosis: successful conservative treatment. Eur J Pediatr 2010; 169:437.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/38/23145/abstract/45\">",
"      Rollins N, Ison C, Reyes T, Chia J. Cerebral MR venography in children: comparison of 2D time-of-flight and gadolinium-enhanced 3D gradient-echo techniques. Radiology 2005; 235:1011.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/38/23145/abstract/46\">",
"      Dubey SP, Larawin V. Complications of chronic suppurative otitis media and their management. Laryngoscope 2007; 117:264.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/38/23145/abstract/47\">",
"      Seid AB, Sellars SL. The management of otogenic lateral sinus disease at Groote Schuur Hospital. Laryngoscope 1973; 83:397.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/38/23145/abstract/48\">",
"      Singh B. The management of lateral sinus thrombosis. J Laryngol Otol 1993; 107:803.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/38/23145/abstract/49\">",
"      Agarwal A, Lowry P, Isaacson G. Natural history of sigmoid sinus thrombosis. Ann Otol Rhinol Laryngol 2003; 112:191.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/38/23145/abstract/50\">",
"      Wong I, Kozak FK, Poskitt K, et al. Pediatric lateral sinus thrombosis: retrospective case series and literature review. J Otolaryngol 2005; 34:79.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/38/23145/abstract/51\">",
"      Sifri CD, Solenski N. Fatal septic thrombosis of the superior sagittal sinus after face-lift surgery caused by community-associated methicillin-resistant Staphylococcus aureus. Arch Facial Plast Surg 2009; 11:142.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/38/23145/abstract/52\">",
"      Canh&atilde;o P, Ferro JM, Lindgren AG, et al. Causes and predictors of death in cerebral venous thrombosis. Stroke 2005; 36:1720.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/38/23145/abstract/53\">",
"      Haroun A. Utility of contrast-enhanced 3D turbo-flash MR angiography in evaluating the intracranial venous system. Neuroradiology 2005; 47:322.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3410 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-200.131.240.2-EA0AF42627-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_38_23145=[""].join("\n");
var outline_f22_38_23145=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H1319409772\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      SEPTIC CAVERNOUS SINUS THROMBOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Pathogenesis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Clinical manifestations",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Symptoms",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Physical examination",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Differential diagnosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Diagnosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - General laboratories and lumbar puncture",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Microbiology",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Imaging",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Treatment",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Antibiotics",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H24487009\">",
"      MRSA",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Anticoagulation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Glucocorticoids",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Surgery",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H93003671\">",
"      Prevention",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Outcome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      SEPTIC LATERAL SINUS THROMBOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Pathogenesis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Clinical manifestations",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - Symptoms",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      - Physical findings",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Diagnosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Microbiology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Treatment",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      - Antibiotics",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      - Surgery",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      - Anticoagulation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      - Other",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      Outcome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      SEPTIC SUPERIOR SAGITTAL SINUS THROMBOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1319409772\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1319410488\">",
"      Septic cavernous sinus thrombosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1319410496\">",
"      Septic lateral sinus thrombosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1319410581\">",
"      Septic superior sagittal sinus thrombosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ID/3410\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/3410|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?33/40/34434\" title=\"diagnostic image 1\">",
"      Septic cavernous sinus MRI",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/3410|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?9/15/9461\" title=\"figure 1\">",
"      Cavernous sinus anatomy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/60/29642?source=related_link\">",
"      Acute otitis media in children: Epidemiology, microbiology, clinical manifestations, and complications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/48/39688?source=related_link\">",
"      Acute sinusitis and rhinosinusitis in adults: Clinical manifestations and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/38/31335?source=related_link\">",
"      Epidemiology of bacterial meningitis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/30/16873?source=related_link\">",
"      Epidemiology, pathogenesis, and clinical manifestations of odontogenic infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/40/17033?source=related_link\">",
"      Epidural abscess",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/17/22810?source=related_link\">",
"      Initial therapy and prognosis of bacterial meningitis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/16/9482?source=related_link\">",
"      Treatment and prognosis of cerebral venous thrombosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/60/15306?source=related_link\">",
"      Treatment of bacterial meningitis caused by specific pathogens in adults",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f22_38_23146="Three-dimensional echocardiography";
var content_f22_38_23146=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"6\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Three-dimensional echocardiography",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?22/38/23146/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/38/23146/contributors\">",
"     Victor Mor-Avi, PhD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/38/23146/contributors\">",
"     Roberto M Lang, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/38/23146/contributors\">",
"     Lissa Sugeng, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?22/38/23146/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/38/23146/contributors\">",
"     Warren J Manning, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?22/38/23146/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/38/23146/contributors\">",
"     Brian C Downey, MD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?22/38/23146/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Dec 13, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Echocardiography is the major non-invasive diagnostic tool for real-time imaging of cardiac structure and function. One of the significant advances in this field has been the development and refinement of three-dimensional (3D) imaging. Since the potential of 3D echocardiographic imaging to overcome many of the limitations of two-dimensional (2D) echocardiography has been fully recognized, ultrasound imaging has gone through multiple phases of development, each bringing this imaging technology a step closer to real-time imaging. Real-time 3D echocardiography allows for rapid acquisition of pyramidal datasets during a single breath-hold without the need for off-line reconstruction, thus eliminating motion artifacts known to have adversely affected the earlier multiplane acquisition and reconstruction methodology. One major advantage of 3D echocardiography is improvement in the accuracy of evaluation of cardiac chamber volumes by eliminating the need for geometric modeling and the errors caused by foreshortened views. Another benefit of 3D imaging is the global perspective visualization of cardiac valves and congenital abnormalities.",
"   </p>",
"   <p>",
"    3D echocardiography is termed \"four-dimensional\" or \"4D\" echocardiography by some",
"    <span class=\"nowrap\">",
"     vendors/users",
"    </span>",
"    to acknowledge the dimension of time in addition to the three dimensions of space.",
"   </p>",
"   <p>",
"    This topic will review the scientific basis for and the clinical use of 3D ultrasound imaging of the heart.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     CLINICAL APPLICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The usefulness of 3D echocardiography has been demonstrated in a number of areas:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Direct evaluation of cardiac chamber volumes without the need for geometric modeling and without the detrimental effects of foreshortened views [",
"      <a class=\"abstract\" href=\"UTD.htm?22/38/23146/abstract/1-16\">",
"       1-16",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Global perspective views of cardiac valves and valvular and intracardiac masses [",
"      <a class=\"abstract\" href=\"UTD.htm?22/38/23146/abstract/17-34\">",
"       17-34",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Assessment of regional left ventricular wall motion aimed at objective detection of ischemic heart disease at rest and during stress testing, as well as quantification of systolic dyssynchrony to guide ventricular resynchronization therapy in patients with heart failure [",
"      <a class=\"abstract\" href=\"UTD.htm?22/38/23146/abstract/12,35-39\">",
"       12,35-39",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Volumetric quantification of regurgitant valve lesions, shunts, and cardiac output [",
"      <a class=\"abstract\" href=\"UTD.htm?22/38/23146/abstract/40-46\">",
"       40-46",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Volumetric imaging and quantification of myocardial perfusion [",
"      <a class=\"abstract\" href=\"UTD.htm?22/38/23146/abstract/47-51\">",
"       47-51",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Global perspective of interatrial septal defects.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Assessment of left ventricular volume and function",
"    </span>",
"    &nbsp;&mdash;&nbsp;Principal reasons for requesting an echocardiogram in clinical practice include the assessment of left ventricular (LV) chamber size and systolic function. This assessment is predominantly performed using qualitative visual interpretation, or \"eye-balling,\" of dynamic ultrasound images of the beating heart, which requires adequate training and experience to accurately estimate LV ejection fraction (LVEF). Quantification of LVEF from 2D echocardiographic data requires geometric modeling of the ventricle. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/21/11610?source=see_link&amp;anchor=H22#H22\">",
"     \"Noninvasive methods for measurement of left ventricular systolic function\", section on 'Three dimensional echocardiography'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Limitations of this subjective interpretation have been long recognized, and the use of quantitative techniques has been recommended. Additional limitations of 2D imaging include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The \"missing third dimensions\" have been considered the main source of the relatively wide inter-measurement variability of the 2D echocardiographic estimates of ventricular size and function.",
"     </li>",
"     <li>",
"      The frequently encountered limitations in endocardial visualization, particularly in the apical-lateral segments of the LV, are commonly compensated for by tilting the transducer. This maneuver generally improves endocardial visualization, but also generates oblique or \"foreshortened\" views of the ventricle, resulting in less accurate and reproducible measurements.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The advantage of 3D echocardiography is that it does not require image plane positioning or geometric modeling and thus can provide more accurate chamber quantification.",
"   </p>",
"   <p>",
"    3D technology permits frame-by-frame detection of the 3D endocardial surface from real-time 3D datasets [",
"    <a class=\"abstract\" href=\"UTD.htm?22/38/23146/abstract/15\">",
"     15",
"    </a>",
"    ]. Nearly all studies that have directly compared the accuracy of 3D measurements of LV volumes (",
"    <a class=\"graphic graphic_figure graphicRef51316 \" href=\"UTD.htm?5/61/6100\">",
"     figure 1",
"    </a>",
"    ) and LVEF have demonstrated the superiority of the 3D approach over the 2D methodology, which consistently underestimated LV volumes. This superiority was demonstrated in both accuracy and reproducibility when compared against independent reference techniques, such as radionuclide ventriculography or cardiovascular magnetic resonance (CMR) (",
"    <a class=\"graphic graphic_figure graphicRef64082 \" href=\"UTD.htm?14/56/15247\">",
"     figure 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/38/23146/abstract/5,9,10,15,52-55\">",
"     5,9,10,15,52-55",
"    </a>",
"    ]. In a study in patients post myocardial infarction, serial real-time 3D echocardiography measurements had low test-retest variability and were thus able to detect with confidence subtle changes in LV volumes that were not detectable by 2D echocardiography [",
"    <a class=\"abstract\" href=\"UTD.htm?22/38/23146/abstract/56\">",
"     56",
"    </a>",
"    ]. Similar findings were described by other investigators who used real-time 3D echocardiography-derived measurements for risk stratification in patients postmyocardial infarction and in patients with heart failure [",
"    <a class=\"abstract\" href=\"UTD.htm?22/38/23146/abstract/57\">",
"     57",
"    </a>",
"    ]. Additionally, reference values for 3D echocardiographically-derived LV volumes and LVEF have been published from a cohort of 978 persons free of cardiovascular disease, hypertension, and diabetes mellitus.",
"   </p>",
"   <p>",
"    However, despite high correlation with CMR reference values and high reproducibility, several studies have reported that real-time 3D echocardiography significantly underestimated LV volumes, albeit less than has been seen with 2D echocardiography [",
"    <a class=\"abstract\" href=\"UTD.htm?22/38/23146/abstract/5,11,56,58-62\">",
"     5,11,56,58-62",
"    </a>",
"    ]. In a multicenter study designed to identify the potential sources of error, the major source of volume underestimation was the limited spatial resolution of real-time 3D echocardiographic imaging, which in many patients hinders the differentiation between the myocardium and the endocardial trabeculae [",
"    <a class=\"abstract\" href=\"UTD.htm?22/38/23146/abstract/63\">",
"     63",
"    </a>",
"    ]. The results of this study underscored the need for unified guidelines for tracing LV endocardial boundary in order to measure LV volumes that are comparable to the current standard reference technique of CMR.",
"   </p>",
"   <p>",
"    Subsequently, in a cohort of 91 patients, accurate real-time 3D echocardiography LV volumes and LVEF were reproducibly obtained using a fully automated endocardial contouring algorithm [",
"    <a class=\"abstract\" href=\"UTD.htm?22/38/23146/abstract/64\">",
"     64",
"    </a>",
"    ]. This fully automated technique, which decreased the time required to obtain measurements, yielded results which correlated well with CMR measurements of LV end-diastolic volume, LV end-systolic volume, and LVEF (r values greater than 0.9). Importantly, the technique was also shown to be highly accurate in a variety of patient groups, including those with LVEF at least 50 percent, LVEF less than 50 percent, and in patients with atrial fibrillation [",
"    <a class=\"abstract\" href=\"UTD.htm?22/38/23146/abstract/64\">",
"     64",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Assessment of right ventricular volumes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Due to the complex crescent shape of the right ventricle (RV), estimation of its volume based on geometric modeling from 2D images has been challenging. The intrinsic ability of 3D imaging to directly measure RV volumes without the need for geometrical modeling has resulted in significant improvements in accuracy and reproducibility in RV volume quantification [",
"    <a class=\"abstract\" href=\"UTD.htm?22/38/23146/abstract/1,6,65,66\">",
"     1,6,65,66",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Surprisingly however, the first studies to compare these two techniques side-by-side against cardiovascular magnetic resonance (CMR) found that real-time 3D echocardiographic measurements offered little advantage over traditional 2D measurements [",
"    <a class=\"abstract\" href=\"UTD.htm?22/38/23146/abstract/67,68\">",
"     67,68",
"    </a>",
"    ]. Although the major sources of errors have not yet been identified in the estimation of RV volumes, it is clear that RV volume measurements can be affected by multiple factors, including gain settings as well as thickness and orientation of disks used by the disk summation technique [",
"    <a class=\"abstract\" href=\"UTD.htm?22/38/23146/abstract/69,70\">",
"     69,70",
"    </a>",
"    ]. Importantly, subsequent studies using new software designed specifically for volumetric analysis of the RV reported high levels of agreement with CMR values or small underestimation in RV volumes [",
"    <a class=\"abstract\" href=\"UTD.htm?22/38/23146/abstract/71-73\">",
"     71-73",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Assessment of atrial volumes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Improved accuracy and reproducibility of the 3D approach [",
"    <a class=\"abstract\" href=\"UTD.htm?22/38/23146/abstract/74\">",
"     74",
"    </a>",
"    ] have been demonstrated in studies that compared 2D and 3D echocardiographic measurements of left and right atrial volumes against an independent gold standard such as cardiovascular magnetic resonance imaging [",
"    <a class=\"abstract\" href=\"UTD.htm?22/38/23146/abstract/14,45,75-78\">",
"     14,45,75-78",
"    </a>",
"    ]. These findings may have important clinical implications for the diagnosis and management of patients with atrial fibrillation, diastolic dysfunction, and acute myocardial infarction [",
"    <a class=\"abstract\" href=\"UTD.htm?22/38/23146/abstract/79-84\">",
"     79-84",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Assessment of left ventricular mass",
"    </span>",
"    &nbsp;&mdash;&nbsp;Another clinically important variable that is frequently assessed by 2D echocardiography is LV mass. Measurement of LV mass relies on both endocardial and epicardial visualization, with the latter being more difficult because of problems in identifying the epicardial border. As with measurements of LV volumes, there are also other limitations such as inaccurate modeling and foreshortening.",
"   </p>",
"   <p>",
"    The use of 3D imaging appears to overcome these limitations, as several studies have reported significant improvements in the accuracy and reproducibility of 3D estimates of LV mass compared to their traditional M-mode and 2D counterparts [",
"    <a class=\"abstract\" href=\"UTD.htm?22/38/23146/abstract/61,85-93\">",
"     61,85-93",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Assessment of left ventricular wall motion",
"    </span>",
"    &nbsp;&mdash;&nbsp;Assessment of regional wall motion abnormalities using 2D echocardiography is routinely performed by visually integrating regional endocardial motion and wall thickness. The reproducibility of this interpretation is limited due to its subjective nature, which is also dependent upon the experience of the interpreting clinician. The accuracy of this approach is of particular concern in patients with suboptimal image quality that impedes endocardial visualization. Endocardial segments that are poorly visualized may be incorrectly interpreted as having abnormal wall motion, and discrete areas of hypokinesis may be missed because they are not visualized in the standard imaging planes.",
"   </p>",
"   <p>",
"    Volumetric 3D echocardiographic imaging is different from 2D imaging because the 3D dataset contains complete dynamic information on LV chamber contraction and filling, from which the ventricle can be viewed in any arbitrary plane. Several studies have explored the potential of quantitative evaluation of regional LV function based upon segmental analysis of the dynamic 3D endocardial surface [",
"    <a class=\"abstract\" href=\"UTD.htm?22/38/23146/abstract/12,94-97\">",
"     12,94-97",
"    </a>",
"    ]. Because the motion of any ventricular wall can be quantified by measuring a variety of wall motion parameters, 3D datasets permit evaluation of regional LV function and objective detection of wall motion abnormalities (",
"    <a class=\"graphic graphic_figure graphicRef76859 \" href=\"UTD.htm?25/15/25846\">",
"     figure 3",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Real-time 3D imaging can also detect stress-induced wall motion abnormalities during",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/57/25494?source=see_link\">",
"     dobutamine",
"    </a>",
"    stress echocardiography [",
"    <a class=\"abstract\" href=\"UTD.htm?22/38/23146/abstract/52,98\">",
"     52,98",
"    </a>",
"    ]. A study comparing 3D with 2D stress image acquisition demonstrated high levels of agreement between 3D and 2D based wall motion scores, with 3D imaging also permitting a shorter acquisition time [",
"    <a class=\"abstract\" href=\"UTD.htm?22/38/23146/abstract/99\">",
"     99",
"    </a>",
"    ]. The use of this methodology in routine clinical practice requires further study.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Assessment of left ventricular dyssynchrony",
"    </span>",
"    &nbsp;&mdash;&nbsp;3D echocardiography has been studied as a potential tool in the evaluation of candidates for cardiac resynchronization therapy (CRT). A byproduct of 3D quantification of regional LV wall motion is the ability to quantify the timing of regional endocardial systolic contraction. Data from 3D echocardiography can provide objective evidence of LV systolic dyssynchrony, which may serve as an additional criterion for referral for cardiac resynchronization therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?22/38/23146/abstract/37,38\">",
"     37,38",
"    </a>",
"    ]. The standard deviation of the regional ejection times (interval between the R wave and peak systolic endocardial motion) has been used as an index of ventricular dyssynchrony. This dyssynchrony index was compared against phase analysis of gated single-photon emission computed tomography (SPECT) images and showed good inter-technique correlation [",
"    <a class=\"abstract\" href=\"UTD.htm?22/38/23146/abstract/100\">",
"     100",
"    </a>",
"    ]. This approach has also been used to assess the short- and long-term benefits of CRT (",
"    <a class=\"graphic graphic_figure graphicRef71176 \" href=\"UTD.htm?27/28/28103\">",
"     figure 4",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    One population of patients that may benefit from mechanical dyssynchrony evaluation is those with depressed left ventricular systolic function and narrow QRS for whom the role of CRT is unclear. Although a few series suggested that these patients may experience clinical improvement and reverse remodeling with CRT, a randomized trial found no benefit from CRT in patients with systolic dysfunction with narrow QRS and M-mode and 2D echocardiographic evidence of dyssynchrony [",
"    <a class=\"abstract\" href=\"UTD.htm?22/38/23146/abstract/101\">",
"     101",
"    </a>",
"    ]. The predictive value of 3D echocardiography is such a population is not known. In one study, 3D echocardiographic measures of dyssynchrony identified patients with severe heart failure and asynchronous LV contraction including a subgroup that would not have been considered candidates based upon their QRS duration [",
"    <a class=\"abstract\" href=\"UTD.htm?22/38/23146/abstract/39\">",
"     39",
"    </a>",
"    ]. A more recent study reported significant difficulties with the evaluation of LV dyssynchrony in patients with severely reduced LV function and underscored the need for new analysis techniques to overcome these difficulties [",
"    <a class=\"abstract\" href=\"UTD.htm?22/38/23146/abstract/102\">",
"     102",
"    </a>",
"    ]. Further work is needed to determine the prognostic value of 3D echocardiography in potential CRT candidates. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/56/18314?source=see_link\">",
"     \"Cardiac resynchronization therapy in heart failure: Indications\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    One possible explanation for the failure of CRT to improve outcomes in approximately one-third of the patients selected using the current criteria, could be that pacing electrode placement was not optimized because of the lack of sufficiently accurate tools for placement at the site of latest activation. In this regard, real time 3D echocardiography imaging may also prove useful since mapping of regional contraction times demonstrates which LV myocardial segments are the latest to contract [",
"    <a class=\"abstract\" href=\"UTD.htm?22/38/23146/abstract/103,104\">",
"     103,104",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Contrast-enhanced 3D echocardiography",
"    </span>",
"    &nbsp;&mdash;&nbsp;The feasibility of applying volumetric analysis to contrast-enhanced real-time 3D echocardiography datasets obtained in patients with suboptimal image quality has been tested. This approach allows quantification of global as well as regional LV function, when used with selective dual triggering at end-systole and end-diastole to reduce the destructive effects of ultrasound on contrast microbubbles [",
"    <a class=\"abstract\" href=\"UTD.htm?22/38/23146/abstract/105,106\">",
"     105,106",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Prior to the development of real-time 3D echocardiography, assessment of myocardial perfusion was limited to visualization of perfusion defects since quantification of tissue blood flow would require repeated contrast administration to assess flow dynamics for each imaging plane, rendering this methodology clinically inapplicable [",
"    <a class=\"abstract\" href=\"UTD.htm?22/38/23146/abstract/47\">",
"     47",
"    </a>",
"    ]. Real-time 3D echocardiography offers an opportunity for online volumetric imaging of the entire heart during a single contrast enhancement maneuver [",
"    <a class=\"abstract\" href=\"UTD.htm?22/38/23146/abstract/48,49\">",
"     48,49",
"    </a>",
"    ]. The feasibility of volumetric perfusion imaging has been tested in animal models in conjunction with volumetric quantitative analysis of myocardial perfusion from contrast-enhanced real-time 3D echocardiographic datasets [",
"    <a class=\"abstract\" href=\"UTD.htm?22/38/23146/abstract/50,51\">",
"     50,51",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Valvular heart disease",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Mitral valve",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most reports of the evaluation of valvular heart disease using 3D echocardiography have focused on the mitral valve. Volume-rendered 3D displays of transthoracic or transesophageal echocardiography (TEE) images enable improved evaluation of the anatomy of the mitral valve and its supporting structures [",
"    <a class=\"abstract\" href=\"UTD.htm?22/38/23146/abstract/107\">",
"     107",
"    </a>",
"    ]. 3D echocardiographic studies have played a crucial role in describing and quantifying the geometry of the mitral annulus, leaflet surface, tethering distances, and tenting volumes. As an example, 3D visualization of the mitral valve was instrumental in describing the saddle shape of the mitral annulus and redefining the diagnostic criteria for mitral valve prolapse [",
"    <a class=\"abstract\" href=\"UTD.htm?22/38/23146/abstract/17\">",
"     17",
"    </a>",
"    ]. They have also defined and quantified the relationship between the mitral apparatus and the position of the papillary muscles, thus providing insight into the pathophysiology of mitral regurgitation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/41/32409?source=see_link\">",
"     \"Echocardiographic evaluation of the mitral valve\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The development of a fully-sampled matrix array transducer has enabled real-time volumetric imaging of the mitral valve from the transthoracic approach (",
"    <a class=\"graphic graphic_figure graphicRef53815 \" href=\"UTD.htm?5/18/5414\">",
"     figure 5",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/38/23146/abstract/108\">",
"     108",
"    </a>",
"    ]. The anterior mitral valve leaflet is more readily visualized than the posterior leaflet, probably due to its larger size. The mitral leaflets, commissures, and mitral valve orifice are also easily viewed. The posterior leaflet is best visualized from the parasternal window, whereas the anterior mitral leaflet was equally well seen from either the parasternal or apical windows. Real time 3D echocardiography has also reported to be a useful tool in the evaluation of prosthetic valve endocarditis [",
"    <a class=\"abstract\" href=\"UTD.htm?22/38/23146/abstract/109,110\">",
"     109,110",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The utility of real-time 3D echocardiography in the evaluation of patients with mitral stenosis, and in particular the assessment of mitral valve area, has been established by multiple studies [",
"    <a class=\"abstract\" href=\"UTD.htm?22/38/23146/abstract/22,27,33,111-114\">",
"     22,27,33,111-114",
"    </a>",
"    ]. The main advantage of 3DE is the ability to achieve a perpendicular en-face cut-plane of the mitral valve orifice enabling accurate mitral valve area measurements. When compared to traditional 2D and Doppler measurements, such as 2D planimetry, pressure half-time and flow convergence, 3DE best agreed with mitral orifice area calculations derived using the Gorlin formula during cardiac catheterization [",
"    <a class=\"abstract\" href=\"UTD.htm?22/38/23146/abstract/27,33,113\">",
"     27,33,113",
"    </a>",
"    ]. The 3D measurements had the additional advantage of having lower intra- and inter-observer variability [",
"    <a class=\"abstract\" href=\"UTD.htm?22/38/23146/abstract/27,33,113\">",
"     27,33,113",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/18/13610?source=see_link&amp;anchor=H30#H30\">",
"     \"Pathophysiology, clinical features, and evaluation of mitral stenosis\", section on 'Echocardiography'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The ease of acquisition and on-line review of real-time 3D echocardiography facilitates immediate assessment of the mitral valve commissural splitting, stretching or tearing after percutaneous balloon mitral valvuloplasty in the cardiac catheterization laboratory. Immediately following balloon valvuloplasty, changes in left atrial and ventricular compliance together with irregularities of the mitral valve orifice limit the utility of the pressure half-time method and 2D planimetry. The high accuracy and reproducibility of 3D echocardiography before and after balloon valvuloplasty compared to the pressure half-time method and 2DE planimetry were demonstrated in a study using invasively determined (Gorlin formula) mitral valve area as the standard [",
"    <a class=\"abstract\" href=\"UTD.htm?22/38/23146/abstract/114\">",
"     114",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Characterization of the mitral valve apparatus using 3DE (",
"    <a class=\"graphic graphic_figure graphicRef53815 \" href=\"UTD.htm?5/18/5414\">",
"     figure 5",
"    </a>",
"    ) has shed new light on the pathophysiology of mitral regurgitation in patients with non-ischemic and ischemic cardiomyopathy. Functional mitral regurgitation is associated with annular dilatation and reduced cyclic variations in annular shape and area [",
"    <a class=\"abstract\" href=\"UTD.htm?22/38/23146/abstract/28\">",
"     28",
"    </a>",
"    ]. Further investigations revealed differences in patients with ischemic mitral regurgitation compared to normal subjects in mitral annular shape with increased inter-commissural and antero-posterior diameters along with increased leaflet tenting indicating chordal tethering [",
"    <a class=\"abstract\" href=\"UTD.htm?22/38/23146/abstract/3,23,34,115\">",
"     3,23,34,115",
"    </a>",
"    ]. Also, patients with anterior wall myocardial infarction have flattened mitral annulus, which is more pronounced than with posterior myocardial infarction [",
"    <a class=\"abstract\" href=\"UTD.htm?22/38/23146/abstract/116\">",
"     116",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/55/18297?source=see_link&amp;anchor=H9#H9\">",
"     \"Ischemic mitral regurgitation\", section on 'Diagnosis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Several studies have reported that mitral regurgitation due to ischemia occurs in conjunction with remodeling of the ischemic region leading to LV dilatation with subsequent papillary muscle displacement (previously known as papillary muscle dysfunction) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/38/23146/abstract/117,118\">",
"     117,118",
"    </a>",
"    ]. This results in increased chordal tethering and leaflet tenting, which in turn leads to mitral regurgitation due to decreased leaflet apposition. The insights provided by 3D echocardiography have demonstrated that the presence of mitral regurgitation in patients with dilated or ischemic cardiomyopathy is a disease of the remodeled myocardium rather than being due to a true valvular abnormality.",
"   </p>",
"   <p>",
"    Several studies demonstrated that analysis of 3D echocardiography of the mitral valve can provide information on dynamic changes in mitral valve annular surface area and annular longitudinal displacement throughout the cardiac cycle, as well as define the position of the papillary muscles in 3D space [",
"    <a class=\"abstract\" href=\"UTD.htm?22/38/23146/abstract/119-121\">",
"     119-121",
"    </a>",
"    ]. Specifically, in patients with dilated cardiomyopathy and mitral regurgitation, symmetric papillary muscle displacement with simultaneous enlargement of the mitral annulus leads to progressive chordal tethering and leaflet tenting, resulting in predominantly central mitral regurgitation, as a result of decreased leaflet coaptation [",
"    <a class=\"abstract\" href=\"UTD.htm?22/38/23146/abstract/119-121\">",
"     119-121",
"    </a>",
"    ]. These changes were associated with a relatively non-pulsatile mitral annulus, which displaces minimally towards the apex during systole. In contrast, in patients with ischemic mitral regurgitation, LV remodeling caused by abnormal inferior wall motion results in uneven papillary muscle displacement and asymmetric localized tethering associated with eccentric mitral regurgitation [",
"    <a class=\"abstract\" href=\"UTD.htm?22/38/23146/abstract/119,122\">",
"     119,122",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In addition, the characteristics of the mitral annular function were compared between patients with hypertrophic cardiomyopathy and LV hypertrophy secondary to hypertension or aortic stenosis [",
"    <a class=\"abstract\" href=\"UTD.htm?22/38/23146/abstract/123\">",
"     123",
"    </a>",
"    ]. Annular function in the LV hypertrophy group was similar to that of normal subjects, whereas annular apical-basal motion and annular area changes were reduced in hypertrophic cardiomyopathy [",
"    <a class=\"abstract\" href=\"UTD.htm?22/38/23146/abstract/123\">",
"     123",
"    </a>",
"    ]. All of these observations carry important implications in the planning of mitral valve repair.",
"   </p>",
"   <p>",
"    One study demonstrated the usefulness of real-time 3D echocardiography in the evaluation of degenerative mitral valve disease: quantitative analysis of real-time 3D echocardiography images allowed accurate classification of the etiology of mitral valve prolapse and determination of the anticipated complexity of mitral valve repair [",
"    <a class=\"abstract\" href=\"UTD.htm?22/38/23146/abstract/124\">",
"     124",
"    </a>",
"    ]. The role of 3D echocardiography in assessing mitral valve anatomy prior to surgical repair of mitral valve prolapse is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/41/32409?source=see_link&amp;anchor=H28#H28\">",
"     \"Echocardiographic evaluation of the mitral valve\", section on 'Mitral valve lesions causing mitral regurgitation'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    3D echocardiography has also been used to evaluate the differences in the shape and dynamics of two types of prosthetic mitral annular rings: while the Duran ring appeared nonplanar and exhibited changes in annular area throughout the cardiac cycle, the Carpentier ring was planar and without change in area during the cardiac cycle [",
"    <a class=\"abstract\" href=\"UTD.htm?22/38/23146/abstract/125\">",
"     125",
"    </a>",
"    ]. The additional information provided by 3D imaging may aid in surgical planning and design of future mitral prostheses and rings.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Aortic valve",
"    </span>",
"    &nbsp;&mdash;&nbsp;Real-time 3D echocardiography of the aortic valve from either the transthoracic or TEE approaches is challenging probably due to the oblique angle of incidence of the ultrasound beam and relatively small leaflet size. Real-time 3D echocardiography has been used to improve the accuracy of the quantification of aortic stenosis. Planimetry of the aortic valve using real-time 3D echocardiography showed good agreement with the standard 2D TEE technique, flow derived methods and cardiac catheterization data, with the advantage of improved reproducibility [",
"    <a class=\"abstract\" href=\"UTD.htm?22/38/23146/abstract/126\">",
"     126",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Analysis of real-time 3D echocardiography in a small group of normal subjects revealed that the shape of LV outflow tract cross-section was not round but rather elliptical in half of the subjects. Incorrectly assuming a round LV outflow tract geometry during assessment of aortic stenosis may lead to significant underestimation of aortic valve area [",
"    <a class=\"abstract\" href=\"UTD.htm?22/38/23146/abstract/127\">",
"     127",
"    </a>",
"    ]. This hypothesis was confirmed in an animal model of upper septal hypertrophy, the severity of which correlated with the discrepancy between the traditional 2DE and real-time 3D echocardiography measurements of aortic valve area [",
"    <a class=\"abstract\" href=\"UTD.htm?22/38/23146/abstract/128\">",
"     128",
"    </a>",
"    ]. Calculations based on real-time 3D echocardiography color Doppler derived estimates of stroke volume correlated with invasive outflow tract flow measurements better than 2D echocardiographic measurements.",
"   </p>",
"   <p>",
"    An alternative approach based on direct volumetric measurements of stroke volume using semi-automated LV endocardial border detection was compared to Doppler continuity equation and 2D Simpson's technique against invasive Gorlin formula results in patients with aortic stenosis [",
"    <a class=\"abstract\" href=\"UTD.htm?22/38/23146/abstract/129\">",
"     129",
"    </a>",
"    ]. This study showed that volumetric evaluation from real-time 3Dechocardiography was more accurate than traditional noninvasive techniques.",
"   </p>",
"   <p>",
"    The diagnostic value of epicardial real-time 3D echocardiography during cardiac surgery has been described [",
"    <a class=\"abstract\" href=\"UTD.htm?22/38/23146/abstract/130\">",
"     130",
"    </a>",
"    ]. Epicardial real-time 3D was superior to 2D TEE in depicting aortic cusp morphology lesions, LV outflow tract spatial relationships with the mitral apparatus and aortic root, and both anterior and posterior mitral leaflet scallops [",
"    <a class=\"abstract\" href=\"UTD.htm?22/38/23146/abstract/130\">",
"     130",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Tricuspid valve",
"    </span>",
"    &nbsp;&mdash;&nbsp;Limited data are available on the utility of 3D echocardiography in the evaluation of tricuspid valve disease. There have been case reports describing tricuspid abnormalities such as tricuspid stenosis, cleft tricuspid valve, and a flail tricuspid leaflet [",
"    <a class=\"abstract\" href=\"UTD.htm?22/38/23146/abstract/131-135\">",
"     131-135",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Characterization of the tricuspid annulus and leaflets in patients with rheumatic heart disease with mitral stenosis and severe tricuspid regurgitation was performed using gated 3D TEE, which demonstrated thickened leaflets with restricted motion, along with annular dilatation [",
"    <a class=\"abstract\" href=\"UTD.htm?22/38/23146/abstract/136\">",
"     136",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A small study found that real time 3D echocardiography measurements of the tricuspid annulus were comparable to those obtained from magnetic resonance images and thus may be helpful for tricuspid valve surgical planning [",
"    <a class=\"abstract\" href=\"UTD.htm?22/38/23146/abstract/137\">",
"     137",
"    </a>",
"    ]. Several studies have explored the 3D geometry of the normal tricuspid annulus and compared it with the mitral annulus using 3DE imaging combined with quantitative analysis software [",
"    <a class=\"abstract\" href=\"UTD.htm?22/38/23146/abstract/138\">",
"     138",
"    </a>",
"    ]. The tricuspid annulus was found to have round or oval shape that is more planar than the saddle shape of the mitral annulus [",
"    <a class=\"abstract\" href=\"UTD.htm?22/38/23146/abstract/138\">",
"     138",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In patients with functional tricuspid regurgitation, the annulus is even larger, more planar and more circular [",
"    <a class=\"abstract\" href=\"UTD.htm?22/38/23146/abstract/139\">",
"     139",
"    </a>",
"    ]. In patients with tricuspid regurgitation secondary to pulmonary hypertension, in addition to annular dilatation, an enlargement in tenting volume was reported [",
"    <a class=\"abstract\" href=\"UTD.htm?22/38/23146/abstract/140\">",
"     140",
"    </a>",
"    ]. The severity of tricuspid regurgitation was found to be mainly determined by septal leaflet tethering, septal-lateral annular dilatation, and the severity of pulmonary hypertension [",
"    <a class=\"abstract\" href=\"UTD.htm?22/38/23146/abstract/141\">",
"     141",
"    </a>",
"    ]. Characterization of the tricuspid annulus and leaflets in patients with rheumatic heart disease with mitral stenosis and severe tricuspid regurgitation was performed using real-time 3DE imaging, which enabled tricuspid valve planimetry, separate evaluation of each tricuspid valve leaflet with regard to thickness, mobility and calcification, as well as assessment of the commissural width at the time of maximal tricuspid valve opening [",
"    <a class=\"abstract\" href=\"UTD.htm?22/38/23146/abstract/142\">",
"     142",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Real-time 3D transesophageal echocardiography",
"    </span>",
"    &nbsp;&mdash;&nbsp;Advances in ultrasound transducer technology have allowed the miniaturization of matrix-array transducers, which was achieved by fitting thousands of piezoelectric elements into the tip of a TEE transducer and using integrated circuits for most of the beam forming. These technological advances have simplified the connection between the transducer and the imaging system, resulting in a reduction of the size of the connecting cable and significantly lowering power consumption, thus allowing real-time 3D TEE imaging.",
"   </p>",
"   <p>",
"    The initial experience with this technology, its feasibility, and its clinical utility for real-time 3D imaging of different cardiac structures, including mitral, aortic and tricuspid valves, inter-atrial septum, left atrial appendage and pulmonic veins, has been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?22/38/23146/abstract/143\">",
"     143",
"    </a>",
"    ]. One of the major findings of this study was that real-time 3D TEE consistently provided excellent quality volume-rendered images of the mitral valve apparatus including the anterior and posterior leaflets, as well as annulus and subvalvular structures. A large number of subsequent publications strongly suggest that matrix TEE imaging is likely to become the modality of choice for perioperative planning of mitral valve surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?22/38/23146/abstract/144-151\">",
"     144-151",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Similar to previous 3D TEE acquisition methods, the views of the mitral valve from both left atrial and LV perspectives are unique to 3D imaging; but what distinguishes matrix TEE from rotational 3D acquisition is the consistency of superb quality of visualization of the mitral valve, the absence of rotational artifacts, and immediate on-line display of volume-rendered views. With the unparalleled level of anatomic detail, these volume renderings allow detailed volumetric analysis of the geometry and dynamics of the mitral valve.",
"   </p>",
"   <p>",
"    Real-time 3D TEE can be employed in any of the usual clinical settings in which TEE is performed. Additionally, real-time 3D TEE can be utilized in the evaluation of the interatrial septum as well as during interventional cardiology procedures (eg, percutaneous valvuloplasty, percutaneous septal defect closure, etc).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Volumetric color Doppler imaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many noninvasive methods for measuring cardiac output and stroke volume are limited by dependence on geometric assumptions, which can be overcome by the use of quantitative volumetric color flow imaging. This approach was initially validated in an in-vitro setup and in open-chest animals then evaluated in human subjects [",
"    <a class=\"abstract\" href=\"UTD.htm?22/38/23146/abstract/152-155\">",
"     152-155",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The feasibility of visualizing valvular regurgitant jets using real-time 3D echocardiography color flow imaging has also been demonstrated, and the quantification of mitral and tricuspid regurgitation jet volumes was shown to correlate well with 2D flow convergence methods [",
"    <a class=\"abstract\" href=\"UTD.htm?22/38/23146/abstract/156\">",
"     156",
"    </a>",
"    ]. 3D echocardiography-derived ratio of mitral regurgitant jet volume over left atrial volume has been proposed as a new method to assess the severity of regurgitant lesions, although these ratios were smaller than those measured using 2D echocardiography [",
"    <a class=\"abstract\" href=\"UTD.htm?22/38/23146/abstract/156\">",
"     156",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Having the advantage of volumetric imaging of the geometry of the flow convergence surface, without the assumption of rotational symmetry, real-time 3D echocardiography color flow imaging can quantify mitral regurgitation more reliably than 2D echocardiography [",
"    <a class=\"abstract\" href=\"UTD.htm?22/38/23146/abstract/157\">",
"     157",
"    </a>",
"    ]. Indeed, it was shown that the true proximal flow convergence region is more hemielliptic than hemispheric, as previously believed [",
"    <a class=\"abstract\" href=\"UTD.htm?22/38/23146/abstract/158\">",
"     158",
"    </a>",
"    ]. Based on these observations, a hemielliptic approach was proposed for improved 2DE quantification of mitral regurgitation [",
"    <a class=\"abstract\" href=\"UTD.htm?22/38/23146/abstract/158\">",
"     158",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Direct assessment of the vena contracta area using real-time 3D echocardiography revealed significant asymmetry of the vena contracta with functional versus organic mitral regurgitation [",
"    <a class=\"abstract\" href=\"UTD.htm?22/38/23146/abstract/159\">",
"     159",
"    </a>",
"    ]. Effective regurgitant orifice area correlated more strongly with 3D vena contracta area than 2D measures of vena contracta width.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     LIMITATIONS AND FUTURE DIRECTIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;As an evolving technology, 3D echocardiography is rapidly advancing in terms of its technical capabilities, but is still limited in some regards. As discussed above, fully automated endocardial border detection performed as part of real-time 3D echocardiography offers the promise of improved accuracy and reproducibility of LV volume and ejection fraction measurements as well as improved workflow due to shorter examination times. (See",
"    <a class=\"local\" href=\"#H3\">",
"     'Assessment of left ventricular volume and function'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    The assessment of valvular function and pathology with real-time 3D echocardiography offers some notable improvements over 2D echocardiography. However, the temporal resolution of 3D echocardiography is limited to the sampling rates of commercially available software (10 to 20 volumes per second). Investigators have proposed a technique of acquiring sample volumes over several heart beats and then using the simultaneously obtained electrocardiographic signal to \"reorder\" the samples [",
"    <a class=\"abstract\" href=\"UTD.htm?22/38/23146/abstract/160\">",
"     160",
"    </a>",
"    ]. This technique achieves higher frame rates using the currently available technology but relies on assumptions of periodicity of heart motion from beat to beat, which limits the applicability of the technique in patients with variable R-R intervals (eg, those with atrial fibrillation, frequent ventricular or atrial premature beats, etc). While this appears to be a promising way to improve the dynamic real-time 3D echocardiographic assessment of valvular function, the techniques needs to be validated in additional studies.",
"   </p>",
"   <p>",
"    Future advances in 3D echocardiography hardware (transducer, computer processing speed) and software should allow wider angle acquisition and color flow imaging to be completed in a single cardiac cycle, which will shorten data acquisition and eliminate stitching artifacts. The transducers will have smaller footprints and weight with higher spatial and temporal resolution. In addition, transducers capable of 2D imaging only will be gradually phased out and replaced by new probes that will be versatile in their capability of imaging in different modes, including 2D, 3D, color, and tissue Doppler. With these multi-tasking transducers, it may be possible to significantly reduce the number of steps required to complete an echocardiographic examination, and thus reduce the time of the test. For example, the standard 2D views could theoretically be obtained from a single volumetric dataset and used for diagnostic purposes assuming that both spatial and temporal resolutions are sufficiently high.",
"   </p>",
"   <p>",
"    Significant improvements are needed in temporal and spatial resolution in the far field. We also anticipate that the quantification of all cardiac chambers, including flow dynamics, will be performed on the imaging system in an increasingly automated fashion, thus gradually eliminating the need for off-line analysis. This is of crucial importance, in particular, in the interventional settings of the catheterization laboratory and the operating room, where immediate visual and quantitative feedback is important.",
"   </p>",
"   <p>",
"    It is anticipated that with the ability of real-time acquisition, on-line adjustments of rendering, and cropping capabilities, real-time 3D TEE will be used routinely in perioperative planning of mitral valve surgery as well as guidance of percutaneous interventions. The ease and speed of data acquisition coupled with the ability to display cardiac structures using unique 3D views is likely to result in rapid integration of this imaging modality into clinical practice and an impact on echocardiographic diagnosis of valve disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Real-time three-dimensional (3D) echocardiography allows for rapid acquisition of images and datasets during a single breath-hold without the need for off-line reconstruction. Major advantages of 3D echocardiography compared to traditional two-dimensional (2D) echocardiography are the improved accuracy of evaluation of cardiac chamber volumes (by eliminating the need for geometric modeling as well as a reduction in errors caused by foreshortened views) and more realistic visualization of cardiac valves and congenital abnormalities. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Principal reasons for requesting an echocardiogram in clinical practice include the assessment of left ventricular (LV) chamber size and systolic function. 3D technology permits frame-by-frame detection of the 3D endocardial surface from real-time 3D datasets. Nearly all studies that have directly compared the accuracy of 3D measurements of LV volumes and LV ejection fraction have demonstrated the superiority of the 3D approach over the traditional 2D methodology. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Assessment of left ventricular volume and function'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Due to the complex crescent shape of the right ventricle (RV), estimation of its volume based on geometric modeling from 2D images has been challenging. The intrinsic ability of 3D imaging to directly measure RV volumes without the need for geometrical modeling has resulted in significant improvements in accuracy and reproducibility in RV volume quantification. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Assessment of right ventricular volumes'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Assessment of regional wall motion abnormalities using 2D echocardiography is routinely performed by visually integrating regional endocardial motion and wall thickness. The reproducibility of this interpretation is limited due to its subjective nature, which is also dependent upon the experience of the interpreting clinician. Because the motion of any ventricular wall can be quantified by measuring a variety of wall motion parameters, 3D echocardiography permits evaluation of regional LV function and objective detection of wall motion abnormalities. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Assessment of left ventricular wall motion'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A byproduct of 3D quantification of regional LV wall motion is the ability to quantify the timing of regional endocardial systolic contraction. Data from 3D echocardiography can provide objective evidence of LV systolic dyssynchrony which may serve as an additional criterion for referral for cardiac resynchronization therapy. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Assessment of left ventricular dyssynchrony'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Volume-rendered 3D displays of transthoracic or transesophageal images enable improved evaluation of the anatomy of the mitral valve and its supporting structures. 3D imaging of the mitral valve is particularly helpful to the cardiac surgeon or interventional cardiologist to provide the most detailed anatomic and functional information when planning an intervention on the mitral valve. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Mitral valve'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Real-time 3D transesophageal echocardiography offers detailed anatomic views of many cardiac structures and is likely to become the preoperative and perioperative imaging modality of choice for patients undergoing mitral valve surgery. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Real-time 3D transesophageal echocardiography'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/38/23146/abstract/1\">",
"      Ota T, Fleishman CE, Strub M, et al. Real-time, three-dimensional echocardiography: feasibility of dynamic right ventricular volume measurement with saline contrast. Am Heart J 1999; 137:958.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/38/23146/abstract/2\">",
"      Schmidt MA, Ohazama CJ, Agyeman KO, et al. Real-time three-dimensional echocardiography for measurement of left ventricular volumes. Am J Cardiol 1999; 84:1434.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/38/23146/abstract/3\">",
"      Shiota T, McCarthy PM, White RD, et al. Initial clinical experience of real-time three-dimensional echocardiography in patients with ischemic and idiopathic dilated cardiomyopathy. Am J Cardiol 1999; 84:1068.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/38/23146/abstract/4\">",
"      Qin JJ, Jones M, Shiota T, et al. New digital measurement methods for left ventricular volume using real-time three-dimensional echocardiography: comparison with electromagnetic flow method and magnetic resonance imaging. Eur J Echocardiogr 2000; 1:96.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/38/23146/abstract/5\">",
"      Qin JX, Jones M, Shiota T, et al. Validation of real-time three-dimensional echocardiography for quantifying left ventricular volumes in the presence of a left ventricular aneurysm: in vitro and in vivo studies. J Am Coll Cardiol 2000; 36:900.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/38/23146/abstract/6\">",
"      Schindera ST, Mehwald PS, Sahn DJ, Kececioglu D. Accuracy of real-time three-dimensional echocardiography for quantifying right ventricular volume: static and pulsatile flow studies in an anatomic in vitro model. J Ultrasound Med 2002; 21:1069.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/38/23146/abstract/7\">",
"      Sugeng L, Weinert L, Thiele K, Lang RM. Real-time three-dimensional echocardiography using a novel matrix array transducer. Echocardiography 2003; 20:623.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/38/23146/abstract/8\">",
"      Zeidan Z, Erbel R, Barkhausen J, et al. Analysis of global systolic and diastolic left ventricular performance using volume-time curves by real-time three-dimensional echocardiography. J Am Soc Echocardiogr 2003; 16:29.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/38/23146/abstract/9\">",
"      Arai K, Hozumi T, Matsumura Y, et al. Accuracy of measurement of left ventricular volume and ejection fraction by new real-time three-dimensional echocardiography in patients with wall motion abnormalities secondary to myocardial infarction. Am J Cardiol 2004; 94:552.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/38/23146/abstract/10\">",
"      Jenkins C, Bricknell K, Hanekom L, Marwick TH. Reproducibility and accuracy of echocardiographic measurements of left ventricular parameters using real-time three-dimensional echocardiography. J Am Coll Cardiol 2004; 44:878.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/38/23146/abstract/11\">",
"      K&uuml;hl HP, Schreckenberg M, Rulands D, et al. High-resolution transthoracic real-time three-dimensional echocardiography: quantitation of cardiac volumes and function using semi-automatic border detection and comparison with cardiac magnetic resonance imaging. J Am Coll Cardiol 2004; 43:2083.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/38/23146/abstract/12\">",
"      Corsi C, Lang RM, Veronesi F, et al. Volumetric quantification of global and regional left ventricular function from real-time three-dimensional echocardiographic images. Circulation 2005; 112:1161.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/38/23146/abstract/13\">",
"      Fleming SM, Cumberledge B, Kiesewetter C, et al. Usefulness of real-time three-dimensional echocardiography for reliable measurement of cardiac output in patients with ischemic or idiopathic dilated cardiomyopathy. Am J Cardiol 2005; 95:308.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/38/23146/abstract/14\">",
"      Jenkins C, Bricknell K, Marwick TH. Use of real-time three-dimensional echocardiography to measure left atrial volume: comparison with other echocardiographic techniques. J Am Soc Echocardiogr 2005; 18:991.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/38/23146/abstract/15\">",
"      Jacobs LD, Salgo IS, Goonewardena S, et al. Rapid online quantification of left ventricular volume from real-time three-dimensional echocardiographic data. Eur Heart J 2006; 27:460.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/38/23146/abstract/16\">",
"      van den Bosch AE, Robbers-Visser D, Krenning BJ, et al. Real-time transthoracic three-dimensional echocardiographic assessment of left ventricular volume and ejection fraction in congenital heart disease. J Am Soc Echocardiogr 2006; 19:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/38/23146/abstract/17\">",
"      Levine RA, Handschumacher MD, Sanfilippo AJ, et al. Three-dimensional echocardiographic reconstruction of the mitral valve, with implications for the diagnosis of mitral valve prolapse. Circulation 1989; 80:589.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/38/23146/abstract/18\">",
"      Cheng TO, Wang XF, Zheng LH, et al. Three-dimensional transesophageal echocardiography in the diagnosis of mitral valve prolapse. Am Heart J 1994; 128:1218.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/38/23146/abstract/19\">",
"      Nanda NC, Roychoudhury D, Chung SM, et al. Quantitative assessment of normal and stenotic aortic valve using transesophageal three-dimensional echocardiography. Echocardiography 1994; 11:617.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/38/23146/abstract/20\">",
"      Pai RG, Tanimoto M, Jintapakorn W, et al. Volume-rendered three-dimensional dynamic anatomy of the mitral annulus using a transesophageal echocardiographic technique. J Heart Valve Dis 1995; 4:623.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/38/23146/abstract/21\">",
"      Salustri A, Becker AE, van Herwerden L, et al. Three-dimensional echocardiography of normal and pathologic mitral valve: a comparison with two-dimensional transesophageal echocardiography. J Am Coll Cardiol 1996; 27:1502.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/38/23146/abstract/22\">",
"      Chen Q, Nosir YF, Vletter WB, et al. Accurate assessment of mitral valve area in patients with mitral stenosis by three-dimensional echocardiography. J Am Soc Echocardiogr 1997; 10:133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/38/23146/abstract/23\">",
"      Otsuji Y, Handschumacher MD, Schwammenthal E, et al. Insights from three-dimensional echocardiography into the mechanism of functional mitral regurgitation: direct in vivo demonstration of altered leaflet tethering geometry. Circulation 1997; 96:1999.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/38/23146/abstract/24\">",
"      Ge S, Warner JG Jr, Abraham TP, et al. Three-dimensional surface area of the aortic valve orifice by three-dimensional echocardiography: clinical validation of a novel index for assessment of aortic stenosis. Am Heart J 1998; 136:1042.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/38/23146/abstract/25\">",
"      Legget ME, Bashein G, McDonald JA, et al. Three-dimensional measurement of the mitral annulus by multiplane transesophageal echocardiography: in vitro validation and in vivo demonstration. J Am Soc Echocardiogr 1998; 11:188.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/38/23146/abstract/26\">",
"      Yao J, Masani ND, Cao QL, et al. Clinical application of transthoracic volume-rendered three-dimensional echocardiography in the assessment of mitral regurgitation. Am J Cardiol 1998; 82:189.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/38/23146/abstract/27\">",
"      Binder TM, Rosenhek R, Porenta G, et al. Improved assessment of mitral valve stenosis by volumetric real-time three-dimensional echocardiography. J Am Coll Cardiol 2000; 36:1355.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/38/23146/abstract/28\">",
"      Kaplan SR, Bashein G, Sheehan FH, et al. Three-dimensional echocardiographic assessment of annular shape changes in the normal and regurgitant mitral valve. Am Heart J 2000; 139:378.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/38/23146/abstract/29\">",
"      Otsuji Y, Handschumacher MD, Liel-Cohen N, et al. Mechanism of ischemic mitral regurgitation with segmental left ventricular dysfunction: three-dimensional echocardiographic studies in models of acute and chronic progressive regurgitation. J Am Coll Cardiol 2001; 37:641.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/38/23146/abstract/30\">",
"      Wong S, French R, Bolson E, et al. Morphologic features of the rheumatic mitral regurgitant valve by three-dimensional echocardiography. Am Heart J 2001; 142:897.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/38/23146/abstract/31\">",
"      Gilon D, Cape EG, Handschumacher MD, et al. Effect of three-dimensional valve shape on the hemodynamics of aortic stenosis: three-dimensional echocardiographic stereolithography and patient studies. J Am Coll Cardiol 2002; 40:1479.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/38/23146/abstract/32\">",
"      Kwan J, Shiota T, Agler DA, et al. Geometric differences of the mitral apparatus between ischemic and dilated cardiomyopathy with significant mitral regurgitation: real-time three-dimensional echocardiography study. Circulation 2003; 107:1135.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/38/23146/abstract/33\">",
"      Zamorano J, Cordeiro P, Sugeng L, et al. Real-time three-dimensional echocardiography for rheumatic mitral valve stenosis evaluation: an accurate and novel approach. J Am Coll Cardiol 2004; 43:2091.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/38/23146/abstract/34\">",
"      Watanabe N, Ogasawara Y, Yamaura Y, et al. Quantitation of mitral valve tenting in ischemic mitral regurgitation by transthoracic real-time three-dimensional echocardiography. J Am Coll Cardiol 2005; 45:763.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/38/23146/abstract/35\">",
"      S&oslash;gaard P, Kim WY, Jensen HK, et al. Impact of acute biventricular pacing on left ventricular performance and volumes in patients with severe heart failure. A tissue doppler and three-dimensional echocardiographic study. Cardiology 2001; 95:173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/38/23146/abstract/36\">",
"      Smith SW, Light ED, Idriss SF, Wolf PD. Feasibility study of real-time three-dimensional intracardiac echocardiography for guidance of interventional electrophysiology. Pacing Clin Electrophysiol 2002; 25:351.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/38/23146/abstract/37\">",
"      Krenning BJ, Szili-Torok T, Voormolen MM, et al. Guiding and optimization of resynchronization therapy with dynamic three-dimensional echocardiography and segmental volume--time curves: a feasibility study. Eur J Heart Fail 2004; 6:619.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/38/23146/abstract/38\">",
"      van der Heide JA, Mannaerts HF, Spruijt HJ, et al. Noninvasive mapping of left ventricular electromechanical asynchrony by three-dimensional echocardiography and semi-automatic contour detection. Am J Cardiol 2004; 94:1449.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/38/23146/abstract/39\">",
"      Kapetanakis S, Kearney MT, Siva A, et al. Real-time three-dimensional echocardiography: a novel technique to quantify global left ventricular mechanical dyssynchrony. Circulation 2005; 112:992.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/38/23146/abstract/40\">",
"      Lange A, Walayat M, Turnbull CM, et al. Assessment of atrial septal defect morphology by transthoracic three dimensional echocardiography using standard grey scale and Doppler myocardial imaging techniques: comparison with magnetic resonance imaging and intraoperative findings. Heart 1997; 78:382.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/38/23146/abstract/41\">",
"      Irvine T, Derrick G, Morris D, et al. Three-dimensional echocardiographic reconstruction of mitral valve color Doppler flow events. Am J Cardiol 1999; 84:1103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/38/23146/abstract/42\">",
"      Mukhtari O, Horton CJ Jr, Nanda NC, et al. Transesophageal color Doppler three-dimensional echocardiographic detection of prosthetic aortic valve dehiscence: correlation with surgical findings. Echocardiography 2001; 18:393.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/38/23146/abstract/43\">",
"      Sugeng L, Spencer KT, Mor-Avi V, et al. Dynamic three-dimensional color flow Doppler: an improved technique for the assessment of mitral regurgitation. Echocardiography 2003; 20:265.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/38/23146/abstract/44\">",
"      Hofmann T, Franzen O, Koschyk DH, et al. Three-dimensional color Doppler echocardiography for assessing shunt volume in atrial septal defects. J Am Soc Echocardiogr 2004; 17:1173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/38/23146/abstract/45\">",
"      King DL, Harrison MR, King DL Jr, et al. Improved reproducibility of left atrial and left ventricular measurements by guided three-dimensional echocardiography. J Am Coll Cardiol 1992; 20:1238.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/38/23146/abstract/46\">",
"      Gopal AS, Keller AM, Rigling R, et al. Left ventricular volume and endocardial surface area by three-dimensional echocardiography: comparison with two-dimensional echocardiography and nuclear magnetic resonance imaging in normal subjects. J Am Coll Cardiol 1993; 22:258.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/38/23146/abstract/47\">",
"      Yao J, De Castro S, Delabays A, et al. Bulls-eye display and quantitation of myocardial perfusion defects using three-dimensional contrast echocardiography. Echocardiography 2001; 18:581.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/38/23146/abstract/48\">",
"      Camarano G, Jones M, Freidlin RZ, Panza JA. Quantitative assessment of left ventricular perfusion defects using real-time three-dimensional myocardial contrast echocardiography. J Am Soc Echocardiogr 2002; 15:206.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/38/23146/abstract/49\">",
"      Chen LX, Wang XF, Nanda NC, et al. Real-time three-dimensional myocardial contrast echocardiography in assessment of myocardial perfusion defects. Chin Med J (Engl) 2004; 117:337.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/38/23146/abstract/50\">",
"      Pemberton J, Li X, Hickey E, et al. Live real-time three-dimensional echocardiography for the visualization of myocardial perfusion--a pilot study in open-chest pigs. J Am Soc Echocardiogr 2005; 18:956.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/38/23146/abstract/51\">",
"      Toledo E, Lang RM, Collins KA, et al. Imaging and quantification of myocardial perfusion using real-time three-dimensional echocardiography. J Am Coll Cardiol 2006; 47:146.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/38/23146/abstract/52\">",
"      Ahmad M, Xie T, McCulloch M, et al. Real-time three-dimensional dobutamine stress echocardiography in assessment stress echocardiography in assessment of ischemia: comparison with two-dimensional dobutamine stress echocardiography. J Am Coll Cardiol 2001; 37:1303.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/38/23146/abstract/53\">",
"      Altmann K, Shen Z, Boxt LM, et al. Comparison of three-dimensional echocardiographic assessment of volume, mass, and function in children with functionally single left ventricles with two-dimensional echocardiography and magnetic resonance imaging. Am J Cardiol 1997; 80:1060.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/38/23146/abstract/54\">",
"      Buck T, Hunold P, Wentz KU, et al. Tomographic three-dimensional echocardiographic determination of chamber size and systolic function in patients with left ventricular aneurysm: comparison to magnetic resonance imaging, cineventriculography, and two-dimensional echocardiography. Circulation 1997; 96:4286.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/38/23146/abstract/55\">",
"      Guti&eacute;rrez-Chico JL, Zamorano JL, P&eacute;rez de Isla L, et al. Comparison of left ventricular volumes and ejection fractions measured by three-dimensional echocardiography versus by two-dimensional echocardiography and cardiac magnetic resonance in patients with various cardiomyopathies. Am J Cardiol 2005; 95:809.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/38/23146/abstract/56\">",
"      Jenkins C, Bricknell K, Chan J, et al. Comparison of two- and three-dimensional echocardiography with sequential magnetic resonance imaging for evaluating left ventricular volume and ejection fraction over time in patients with healed myocardial infarction. Am J Cardiol 2007; 99:300.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/38/23146/abstract/57\">",
"      Gopal AS, Chukwu EO, Mihalatos DG, et al. Left ventricular structure and function for postmyocardial infarction and heart failure risk stratification by three-dimensional echocardiography. J Am Soc Echocardiogr 2007; 20:949.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/38/23146/abstract/58\">",
"      Sugeng L, Mor-Avi V, Weinert L, et al. Quantitative assessment of left ventricular size and function: side-by-side comparison of real-time three-dimensional echocardiography and computed tomography with magnetic resonance reference. Circulation 2006; 114:654.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/38/23146/abstract/59\">",
"      Jenkins C, Chan J, Hanekom L, Marwick TH. Accuracy and feasibility of online 3-dimensional echocardiography for measurement of left ventricular parameters. J Am Soc Echocardiogr 2006; 19:1119.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/38/23146/abstract/60\">",
"      Krenning BJ, Kirschbaum SW, Soliman OI, et al. Comparison of contrast agent-enhanced versus non-contrast agent-enhanced real-time three-dimensional echocardiography for analysis of left ventricular systolic function. Am J Cardiol 2007; 100:1485.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/38/23146/abstract/61\">",
"      Pouleur AC, le Polain de Waroux JB, Pasquet A, et al. Assessment of left ventricular mass and volumes by three-dimensional echocardiography in patients with or without wall motion abnormalities: comparison against cine magnetic resonance imaging. Heart 2008; 94:1050.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/38/23146/abstract/62\">",
"      Soliman OI, Krenning BJ, Geleijnse ML, et al. Quantification of left ventricular volumes and function in patients with cardiomyopathies by real-time three-dimensional echocardiography: a head-to-head comparison between two different semiautomated endocardial border detection algorithms. J Am Soc Echocardiogr 2007; 20:1042.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/38/23146/abstract/63\">",
"      Mor-Avi V, Jenkins C, K&uuml;hl HP, et al. Real-time 3-dimensional echocardiographic quantification of left ventricular volumes: multicenter study for validation with magnetic resonance imaging and investigation of sources of error. JACC Cardiovasc Imaging 2008; 1:413.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/38/23146/abstract/64\">",
"      Thavendiranathan P, Liu S, Verhaert D, et al. Feasibility, accuracy, and reproducibility of real-time full-volume 3D transthoracic echocardiography to measure LV volumes and systolic function: a fully automated endocardial contouring algorithm in sinus rhythm and atrial fibrillation. JACC Cardiovasc Imaging 2012; 5:239.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/38/23146/abstract/65\">",
"      Jiang L, Handschumacher MD, Hibberd MG, et al. Three-dimensional echocardiographic reconstruction of right ventricular volume: in vitro comparison with two-dimensional methods. J Am Soc Echocardiogr 1994; 7:150.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/38/23146/abstract/66\">",
"      Dorosz JL, Bolson EL, Waiss MS, Sheehan FH. Three-dimensional visual guidance improves the accuracy of calculating right ventricular volume with two-dimensional echocardiography. J Am Soc Echocardiogr 2003; 16:675.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/38/23146/abstract/67\">",
"      Kjaergaard J, Petersen CL, Kjaer A, et al. Evaluation of right ventricular volume and function by 2D and 3D echocardiography compared to MRI. Eur J Echocardiogr 2006; 7:430.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/38/23146/abstract/68\">",
"      Prakasa KR, Dalal D, Wang J, et al. Feasibility and variability of three dimensional echocardiography in arrhythmogenic right ventricular dysplasia/cardiomyopathy. Am J Cardiol 2006; 97:703.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/38/23146/abstract/69\">",
"      Hoch M, Vasilyev NV, Soriano B, et al. Variables influencing the accuracy of right ventricular volume assessment by real-time 3-dimensional echocardiography: an in vitro validation study. J Am Soc Echocardiogr 2007; 20:456.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/38/23146/abstract/70\">",
"      Gopal AS, Chukwu EO, Iwuchukwu CJ, et al. Normal values of right ventricular size and function by real-time 3-dimensional echocardiography: comparison with cardiac magnetic resonance imaging. J Am Soc Echocardiogr 2007; 20:445.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/38/23146/abstract/71\">",
"      Jenkins C, Chan J, Bricknell K, et al. Reproducibility of right ventricular volumes and ejection fraction using real-time three-dimensional echocardiography: comparison with cardiac MRI. Chest 2007; 131:1844.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/38/23146/abstract/72\">",
"      Niemann PS, Pinho L, Balbach T, et al. Anatomically oriented right ventricular volume measurements with dynamic three-dimensional echocardiography validated by 3-Tesla magnetic resonance imaging. J Am Coll Cardiol 2007; 50:1668.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/38/23146/abstract/73\">",
"      Sugeng L, Mor-Avi V, Weinert L, et al. Multimodality comparison of quantitative volumetric analysis of the right ventricle. JACC Cardiovasc Imaging 2010; 3:10.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/38/23146/abstract/74\">",
"      Aune E, Baekkevar M, Roislien J, et al. Normal reference ranges for left and right atrial volume indexes and ejection fractions obtained with real-time three-dimensional echocardiography. Eur J Echocardiogr 2009; 10:738.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/38/23146/abstract/75\">",
"      Keller AM, Gopal AS, King DL. Left and right atrial volume by freehand three-dimensional echocardiography: in vivo validation using magnetic resonance imaging. Eur J Echocardiogr 2000; 1:55.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/38/23146/abstract/76\">",
"      Kawai J, Tanabe K, Wang CL, et al. Comparison of left atrial size by freehand scanning three-dimensional echocardiography and two-dimensional echocardiography. Eur J Echocardiogr 2004; 5:18.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/38/23146/abstract/77\">",
"      Poutanen T, Ikonen A, Vainio P, et al. Left atrial volume assessed by transthoracic three dimensional echocardiography and magnetic resonance imaging: dynamic changes during the heart cycle in children. Heart 2000; 83:537.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/38/23146/abstract/78\">",
"      Artang R, Migrino RQ, Harmann L, et al. Left atrial volume measurement with automated border detection by 3-dimensional echocardiography: comparison with Magnetic Resonance Imaging. Cardiovasc Ultrasound 2009; 7:16.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/38/23146/abstract/79\">",
"      Badano LP, Pezzutto N, Marinigh R, et al. How many patients would be misclassified using M-mode and two-dimensional estimates of left atrial size instead of left atrial volume? A three-dimensional echocardiographic study. J Cardiovasc Med (Hagerstown) 2008; 9:476.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/38/23146/abstract/80\">",
"      Delgado V, Vidal B, Sitges M, et al. Fate of left atrial function as determined by real-time three-dimensional echocardiography study after radiofrequency catheter ablation for the treatment of atrial fibrillation. Am J Cardiol 2008; 101:1285.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/38/23146/abstract/81\">",
"      Marsan NA, Tops LF, Holman ER, et al. Comparison of left atrial volumes and function by real-time three-dimensional echocardiography in patients having catheter ablation for atrial fibrillation with persistence of sinus rhythm versus recurrent atrial fibrillation three months later. Am J Cardiol 2008; 102:847.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/38/23146/abstract/82\">",
"      Oliveira W, Campos O, Bezerra Lira-Filho E, et al. Left atrial volume and function in patients with obstructive sleep apnea assessed by real-time three-dimensional echocardiography. J Am Soc Echocardiogr 2008; 21:1355.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/38/23146/abstract/83\">",
"      Shin MS, Fukuda S, Song JM, et al. Relationship between left atrial and left ventricular function in hypertrophic cardiomyopathy: a real-time 3-dimensional echocardiographic study. J Am Soc Echocardiogr 2006; 19:796.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/38/23146/abstract/84\">",
"      Suh IW, Song JM, Lee EY, et al. Left atrial volume measured by real-time 3-dimensional echocardiography predicts clinical outcomes in patients with severe left ventricular dysfunction and in sinus rhythm. J Am Soc Echocardiogr 2008; 21:439.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/38/23146/abstract/85\">",
"      Gopal AS, Keller AM, Shen Z, et al. Three-dimensional echocardiography: in vitro and in vivo validation of left ventricular mass and comparison with conventional echocardiographic methods. J Am Coll Cardiol 1994; 24:504.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/38/23146/abstract/86\">",
"      Sapin PM, Gopal AS, Clarke GB, et al. Three-dimensional echocardiography compared to two-dimensional echocardiography for measurement of left ventricular mass anatomic validation in an open chest canine model. Am J Hypertens 1996; 9:467.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/38/23146/abstract/87\">",
"      Rodevand O, Bjornerheim R, Kolbjornsen O, et al. Left ventricular mass assessed by three-dimensional echocardiography using rotational acquisition. Clin Cardiol 1997; 20:957.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/38/23146/abstract/88\">",
"      K&uuml;hl HP, Hanrath P, Franke A. M-mode echocardiography overestimates left ventricular mass in patients with normal left ventricular shape: a comparative study using three-dimensional echocardiography. Eur J Echocardiogr 2003; 4:312.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/38/23146/abstract/89\">",
"      Mor-Avi V, Sugeng L, Weinert L, et al. Fast measurement of left ventricular mass with real-time three-dimensional echocardiography: comparison with magnetic resonance imaging. Circulation 2004; 110:1814.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/38/23146/abstract/90\">",
"      Caiani EG, Corsi C, Sugeng L, et al. Improved quantification of left ventricular mass based on endocardial and epicardial surface detection with real time three dimensional echocardiography. Heart 2006; 92:213.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/38/23146/abstract/91\">",
"      van den Bosch AE, Robbers-Visser D, Krenning BJ, et al. Comparison of real-time three-dimensional echocardiography to magnetic resonance imaging for assessment of left ventricular mass. Am J Cardiol 2006; 97:113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/38/23146/abstract/92\">",
"      Takeuchi M, Nishikage T, Mor-Avi V, et al. Measurement of left ventricular mass by real-time three-dimensional echocardiography: validation against magnetic resonance and comparison with two-dimensional and m-mode measurements. J Am Soc Echocardiogr 2008; 21:1001.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/38/23146/abstract/93\">",
"      Chuang ML, Salton CJ, Hibberd MG, et al. Relation between number of component views and accuracy of left ventricular mass determined by three-dimensional echocardiography. Am J Cardiol 2007; 99:1321.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/38/23146/abstract/94\">",
"      Maffessanti F, Nesser HJ, Weinert L, et al. Quantitative evaluation of regional left ventricular function using three-dimensional speckle tracking echocardiography in patients with and without heart disease. Am J Cardiol 2009; 104:1755.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/38/23146/abstract/95\">",
"      Jaochim Nesser H, Sugeng L, Corsi C, et al. Volumetric analysis of regional left ventricular function with real-time three-dimensional echocardiography: validation by magnetic resonance and clinical utility testing. Heart 2007; 93:572.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/38/23146/abstract/96\">",
"      Jenkins C, Haluska B, Marwick TH. Assessment of temporal heterogeneity and regional motion to identify wall motion abnormalities using treadmill exercise stress three-dimensional echocardiography. J Am Soc Echocardiogr 2009; 22:268.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/38/23146/abstract/97\">",
"      Kleijn SA, Aly MF, Terwee CB, et al. Three-dimensional speckle tracking echocardiography for automatic assessment of global and regional left ventricular function based on area strain. J Am Soc Echocardiogr 2011; 24:314.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/38/23146/abstract/98\">",
"      Takeuchi M, Otani S, Weinert L, et al. Comparison of contrast-enhanced real-time live 3-dimensional dobutamine stress echocardiography with contrast 2-dimensional echocardiography for detecting stress-induced wall-motion abnormalities. J Am Soc Echocardiogr 2006; 19:294.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/38/23146/abstract/99\">",
"      Yang HS, Pellikka PA, McCully RB, et al. Role of biplane and biplane echocardiographically guided 3-dimensional echocardiography during dobutamine stress echocardiography. J Am Soc Echocardiogr 2006; 19:1136.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/38/23146/abstract/100\">",
"      Marsan NA, Henneman MM, Chen J, et al. Real-time three-dimensional echocardiography as a novel approach to quantify left ventricular dyssynchrony: a comparison study with phase analysis of gated myocardial perfusion single photon emission computed tomography. J Am Soc Echocardiogr 2008; 21:801.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/38/23146/abstract/101\">",
"      Beshai JF, Grimm RA, Nagueh SF, et al. Cardiac-resynchronization therapy in heart failure with narrow QRS complexes. N Engl J Med 2007; 357:2461.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/38/23146/abstract/102\">",
"      Sonne C, Sugeng L, Takeuchi M, et al. Real-time 3-dimensional echocardiographic assessment of left ventricular dyssynchrony: pitfalls in patients with dilated cardiomyopathy. JACC Cardiovasc Imaging 2009; 2:802.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/38/23146/abstract/103\">",
"      Burgess MI, Jenkins C, Chan J, Marwick TH. Measurement of left ventricular dyssynchrony in patients with ischaemic cardiomyopathy: a comparison of real-time three-dimensional and tissue Doppler echocardiography. Heart 2007; 93:1191.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/38/23146/abstract/104\">",
"      Becker M, Hoffmann R, Schmitz F, et al. Relation of optimal lead positioning as defined by three-dimensional echocardiography to long-term benefit of cardiac resynchronization. Am J Cardiol 2007; 100:1671.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/38/23146/abstract/105\">",
"      Caiani EG, Coon P, Corsi C, et al. Dual triggering improves the accuracy of left ventricular volume measurements by contrast-enhanced real-time 3-dimensional echocardiography. J Am Soc Echocardiogr 2005; 18:1292.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/38/23146/abstract/106\">",
"      Corsi C, Coon P, Goonewardena S, et al. Quantification of regional left ventricular wall motion from real-time 3-dimensional echocardiography in patients with poor acoustic windows: effects of contrast enhancement tested against cardiac magnetic resonance. J Am Soc Echocardiogr 2006; 19:886.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/38/23146/abstract/107\">",
"      Godoy IE, Bednarz J, Sugeng L, et al. Three-dimensional echocardiography in adult patients: comparison between transthoracic and transesophageal reconstructions. J Am Soc Echocardiogr 1999; 12:1045.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/38/23146/abstract/108\">",
"      Sugeng L, Coon P, Weinert L, et al. Use of real-time 3-dimensional transthoracic echocardiography in the evaluation of mitral valve disease. J Am Soc Echocardiogr 2006; 19:413.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/38/23146/abstract/109\">",
"      Kort S. Real-time 3-dimensional echocardiography for prosthetic valve endocarditis: initial experience. J Am Soc Echocardiogr 2006; 19:130.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/38/23146/abstract/110\">",
"      Sugeng L, Shernan SK, Weinert L, et al. Real-time three-dimensional transesophageal echocardiography in valve disease: comparison with surgical findings and evaluation of prosthetic valves. J Am Soc Echocardiogr 2008; 21:1347.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/38/23146/abstract/111\">",
"      Applebaum RM, Kasliwal RR, Kanojia A, et al. Utility of three-dimensional echocardiography during balloon mitral valvuloplasty. J Am Coll Cardiol 1998; 32:1405.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/38/23146/abstract/112\">",
"      Limbu YR, Shen X, Pan C, et al. Assessment of mitral valve volume by quantitative three-dimensional echocardiography in patients with rheumatic mitral valve stenosis. Clin Cardiol 1998; 21:415.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/38/23146/abstract/113\">",
"      Sugeng L, Weinert L, Lammertin G, et al. Accuracy of mitral valve area measurements using transthoracic rapid freehand 3-dimensional scanning: comparison with noninvasive and invasive methods. J Am Soc Echocardiogr 2003; 16:1292.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/38/23146/abstract/114\">",
"      Zamorano J, Perez de Isla L, Sugeng L, et al. Non-invasive assessment of mitral valve area during percutaneous balloon mitral valvuloplasty: role of real-time 3D echocardiography. Eur Heart J 2004; 25:2086.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/38/23146/abstract/115\">",
"      Watanabe N, Ogasawara Y, Yamaura Y, et al. Geometric deformity of the mitral annulus in patients with ischemic mitral regurgitation: a real-time three-dimensional echocardiographic study. J Heart Valve Dis 2005; 14:447.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/38/23146/abstract/116\">",
"      Watanabe N, Ogasawara Y, Yamaura Y, et al. Geometric differences of the mitral valve tenting between anterior and inferior myocardial infarction with significant ischemic mitral regurgitation: quantitation by novel software system with transthoracic real-time three-dimensional echocardiography. J Am Soc Echocardiogr 2006; 19:71.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/38/23146/abstract/117\">",
"      Aikawa K, Sheehan FH, Otto CM, et al. The severity of functional mitral regurgitation depends on the shape of the mitral apparatus: a three-dimensional echo analysis. J Heart Valve Dis 2002; 11:627.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/38/23146/abstract/118\">",
"      Liel-Cohen N, Guerrero JL, Otsuji Y, et al. Design of a new surgical approach for ventricular remodeling to relieve ischemic mitral regurgitation: insights from 3-dimensional echocardiography. Circulation 2000; 101:2756.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/38/23146/abstract/119\">",
"      Veronesi F, Corsi C, Sugeng L, et al. Quantification of mitral apparatus dynamics in functional and ischemic mitral regurgitation using real-time 3-dimensional echocardiography. J Am Soc Echocardiogr 2008; 21:347.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/38/23146/abstract/120\">",
"      Tsukiji M, Watanabe N, Yamaura Y, et al. Three-dimensional quantitation of mitral valve coaptation by a novel software system with transthoracic real-time three-dimensional echocardiography. J Am Soc Echocardiogr 2008; 21:43.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/38/23146/abstract/121\">",
"      Song JM, Fukuda S, Kihara T, et al. Value of mitral valve tenting volume determined by real-time three-dimensional echocardiography in patients with functional mitral regurgitation. Am J Cardiol 2006; 98:1088.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/38/23146/abstract/122\">",
"      Daimon M, Saracino G, Gillinov AM, et al. Local dysfunction and asymmetrical deformation of mitral annular geometry in ischemic mitral regurgitation: a novel computerized 3D echocardiographic analysis. Echocardiography 2008; 25:414.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/38/23146/abstract/123\">",
"      Yal&ccedil;in F, Shiota M, Greenberg N, et al. Real time three-dimensional echocardiography evaluation of mitral annular characteristics in patients with myocardial hypertrophy. Echocardiography 2008; 25:424.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/38/23146/abstract/124\">",
"      Chandra S, Salgo IS, Sugeng L, et al. Characterization of degenerative mitral valve disease using morphologic analysis of real-time three-dimensional echocardiographic images: objective insight into complexity and planning of mitral valve repair. Circ Cardiovasc Imaging 2011; 4:24.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/38/23146/abstract/125\">",
"      Yamaura Y, Yoshida K, Hozumi T, et al. Three-dimensional echocardiographic evaluation of configuration and dynamics of the mitral annulus in patients fitted with an annuloplasty ring. J Heart Valve Dis 1997; 6:43.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/38/23146/abstract/126\">",
"      Goland S, Trento A, Iida K, et al. Assessment of aortic stenosis by three-dimensional echocardiography: an accurate and novel approach. Heart 2007; 93:801.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/38/23146/abstract/127\">",
"      Doddamani S, Bello R, Friedman MA, et al. Demonstration of left ventricular outflow tract eccentricity by real time 3D echocardiography: implications for the determination of aortic valve area. Echocardiography 2007; 24:860.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/38/23146/abstract/128\">",
"      Poh KK, Levine RA, Solis J, et al. Assessing aortic valve area in aortic stenosis by continuity equation: a novel approach using real-time three-dimensional echocardiography. Eur Heart J 2008; 29:2526.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/38/23146/abstract/129\">",
"      Guti&eacute;rrez-Chico JL, Zamorano JL, Prieto-Moriche E, et al. Real-time three-dimensional echocardiography in aortic stenosis: a novel, simple, and reliable method to improve accuracy in area calculation. Eur Heart J 2008; 29:1296.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/38/23146/abstract/130\">",
"      De Castro S, Salandin V, Cavarretta E, et al. Epicardial real-time three-dimensional echocardiography in cardiac surgery: a preliminary experience. Ann Thorac Surg 2006; 82:2254.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/38/23146/abstract/131\">",
"      Trocino G, Salustri A, Roelandt JR, et al. Three-dimensional echocardiography of a flail tricuspid valve. J Am Soc Echocardiogr 1996; 9:91.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/38/23146/abstract/132\">",
"      Vogel M, Ho SY, Lincoln C, Anderson RH. Transthoracic three-dimensional echocardiography for the assessment of straddling tricuspid or mitral valves. Cardiol Young 2000; 10:603.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/38/23146/abstract/133\">",
"      Nekkanti R, Nanda NC, Ahmed S, et al. Transesophageal three-dimensional echocardiographic demonstration of clefts in the anterior tricuspid valve leaflet. Am J Geriatr Cardiol 2002; 11:329.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/38/23146/abstract/134\">",
"      Faletra F, La Marchesina U, Bragato R, De Chiara F. Three dimensional transthoracic echocardiography images of tricuspid stenosis. Heart 2005; 91:499.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/38/23146/abstract/135\">",
"      Schnabel R, Khaw AV, von Bardeleben RS, et al. Assessment of the tricuspid valve morphology by transthoracic real-time-3D-echocardiography. Echocardiography 2005; 22:15.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/38/23146/abstract/136\">",
"      Henein MY, O'Sullivan CA, Li W, et al. Evidence for rheumatic valve disease in patients with severe tricuspid regurgitation long after mitral valve surgery: the role of 3D echo reconstruction. J Heart Valve Dis 2003; 12:566.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/38/23146/abstract/137\">",
"      Anwar AM, Soliman OI, Nemes A, et al. Value of assessment of tricuspid annulus: real-time three-dimensional echocardiography and magnetic resonance imaging. Int J Cardiovasc Imaging 2007; 23:701.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/38/23146/abstract/138\">",
"      Kwan J, Kim GC, Jeon MJ, et al. 3D geometry of a normal tricuspid annulus during systole: a comparison study with the mitral annulus using real-time 3D echocardiography. Eur J Echocardiogr 2007; 8:375.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/38/23146/abstract/139\">",
"      Ton-Nu TT, Levine RA, Handschumacher MD, et al. Geometric determinants of functional tricuspid regurgitation: insights from 3-dimensional echocardiography. Circulation 2006; 114:143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/38/23146/abstract/140\">",
"      Sukmawan R, Watanabe N, Ogasawara Y, et al. Geometric changes of tricuspid valve tenting in tricuspid regurgitation secondary to pulmonary hypertension quantified by novel system with transthoracic real-time 3-dimensional echocardiography. J Am Soc Echocardiogr 2007; 20:470.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/38/23146/abstract/141\">",
"      Park YH, Song JM, Lee EY, et al. Geometric and hemodynamic determinants of functional tricuspid regurgitation: a real-time three-dimensional echocardiography study. Int J Cardiol 2008; 124:160.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/38/23146/abstract/142\">",
"      Anwar AM, Geleijnse ML, Soliman OI, et al. Evaluation of rheumatic tricuspid valve stenosis by real-time three-dimensional echocardiography. Heart 2007; 93:363.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/38/23146/abstract/143\">",
"      Sugeng L, Shernan SK, Salgo IS, et al. Live 3-dimensional transesophageal echocardiography initial experience using the fully-sampled matrix array probe. J Am Coll Cardiol 2008; 52:446.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/38/23146/abstract/144\">",
"      Biner S, Perk G, Kar S, et al. Utility of combined two-dimensional and three-dimensional transesophageal imaging for catheter-based mitral valve clip repair of mitral regurgitation. J Am Soc Echocardiogr 2011; 24:611.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/38/23146/abstract/145\">",
"      La Canna G, Arendar I, Maisano F, et al. Real-time three-dimensional transesophageal echocardiography for assessment of mitral valve functional anatomy in patients with prolapse-related regurgitation. Am J Cardiol 2011; 107:1365.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/38/23146/abstract/146\">",
"      Maffessanti F, Marsan NA, Tamborini G, et al. Quantitative analysis of mitral valve apparatus in mitral valve prolapse before and after annuloplasty: a three-dimensional intraoperative transesophageal study. J Am Soc Echocardiogr 2011; 24:405.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/38/23146/abstract/147\">",
"      Altiok E, Hamada S, van Hall S, et al. Comparison of direct planimetry of mitral valve regurgitation orifice area by three-dimensional transesophageal echocardiography to effective regurgitant orifice area obtained by proximal flow convergence method and vena contracta area determined by color Doppler echocardiography. Am J Cardiol 2011; 107:452.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/38/23146/abstract/148\">",
"      Thompson KA, Shiota T, Tolstrup K, et al. Utility of three-dimensional transesophageal echocardiography in the diagnosis of valvular perforations. Am J Cardiol 2011; 107:100.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/38/23146/abstract/149\">",
"      Wei J, Hsiung MC, Tsai SK, et al. The routine use of live three-dimensional transesophageal echocardiography in mitral valve surgery: clinical experience. Eur J Echocardiogr 2010; 11:14.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/38/23146/abstract/150\">",
"      Salcedo EE, Quaife RA, Seres T, Carroll JD. A framework for systematic characterization of the mitral valve by real-time three-dimensional transesophageal echocardiography. J Am Soc Echocardiogr 2009; 22:1087.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/38/23146/abstract/151\">",
"      Grewal J, Mankad S, Freeman WK, et al. Real-time three-dimensional transesophageal echocardiography in the intraoperative assessment of mitral valve disease. J Am Soc Echocardiogr 2009; 22:34.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/38/23146/abstract/152\">",
"      Pemberton J, Li X, Karamlou T, et al. The use of live three-dimensional Doppler echocardiography in the measurement of cardiac output: an in vivo animal study. J Am Coll Cardiol 2005; 45:433.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/38/23146/abstract/153\">",
"      Pemberton J, Li X, Kenny A, et al. Real-time 3-dimensional Doppler echocardiography for the assessment of stroke volume: an in vivo human study compared with standard 2-dimensional echocardiography. J Am Soc Echocardiogr 2005; 18:1030.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/38/23146/abstract/154\">",
"      Lodato JA, Baumann R, Weinert L, et al. Noninvasive measurement of cardiac output using real-time 3D color Doppler imaging of mitral inflow volumes. J Am Soc Echocardiogr 2005; 18:515.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/38/23146/abstract/155\">",
"      Ge S, Bu L, Zhang H, et al. A real-time 3-dimensional digital Doppler method for measurement of flow rate and volume through mitral valve in children: a validation study compared with magnetic resonance imaging. J Am Soc Echocardiogr 2005; 18:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/38/23146/abstract/156\">",
"      Sugeng L, Weinert L, Lang RM. Real-time 3-dimensional color Doppler flow of mitral and tricuspid regurgitation: feasibility and initial quantitative comparison with 2-dimensional methods. J Am Soc Echocardiogr 2007; 20:1050.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/38/23146/abstract/157\">",
"      Sitges M, Jones M, Shiota T, et al. Real-time three-dimensional color doppler evaluation of the flow convergence zone for quantification of mitral regurgitation: Validation experimental animal study and initial clinical experience. J Am Soc Echocardiogr 2003; 16:38.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/38/23146/abstract/158\">",
"      Yosefy C, Levine RA, Solis J, et al. Proximal flow convergence region as assessed by real-time 3-dimensional echocardiography: challenging the hemispheric assumption. J Am Soc Echocardiogr 2007; 20:389.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/38/23146/abstract/159\">",
"      Kahlert P, Plicht B, Schenk IM, et al. Direct assessment of size and shape of noncircular vena contracta area in functional versus organic mitral regurgitation using real-time three-dimensional echocardiography. J Am Soc Echocardiogr 2008; 21:912.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/38/23146/abstract/160\">",
"      Perrin DP, Vasilyev NV, Marx GR, del Nido PJ. Temporal enhancement of 3D echocardiography by frame reordering. JACC Cardiovasc Imaging 2012; 5:300.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5322 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0602-201.77.166.39-DF771C1915-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_38_23146=[""].join("\n");
var outline_f22_38_23146=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H17\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      CLINICAL APPLICATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Assessment of left ventricular volume and function",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Assessment of right ventricular volumes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Assessment of atrial volumes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Assessment of left ventricular mass",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Assessment of left ventricular wall motion",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Assessment of left ventricular dyssynchrony",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Contrast-enhanced 3D echocardiography",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Valvular heart disease",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Mitral valve",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Aortic valve",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Tricuspid valve",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Real-time 3D transesophageal echocardiography",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Volumetric color Doppler imaging",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      LIMITATIONS AND FUTURE DIRECTIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"CARD/5322\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/5322|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?5/61/6100\" title=\"figure 1\">",
"      Assess LV volume and function 3",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?14/56/15247\" title=\"figure 2\">",
"      Assess LV volume and function 4",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?25/15/25846\" title=\"figure 3\">",
"      Assess LV wall motion 3",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?27/28/28103\" title=\"figure 4\">",
"      Assess LV asynchrony",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?5/18/5414\" title=\"figure 5\">",
"      3D echo mitral valve",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/56/18314?source=related_link\">",
"      Cardiac resynchronization therapy in heart failure: Indications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/41/32409?source=related_link\">",
"      Echocardiographic evaluation of the mitral valve",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/55/18297?source=related_link\">",
"      Ischemic mitral regurgitation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/21/11610?source=related_link\">",
"      Noninvasive methods for measurement of left ventricular systolic function",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/18/13610?source=related_link\">",
"      Pathophysiology, clinical features, and evaluation of mitral stenosis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f22_38_23147="Treatment of shigellosis in adults";
var content_f22_38_23147=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F68382&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F68382&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Treatment of shigellosis in adults",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Antibiotic",
"       </td>",
"       <td class=\"subtitle1\">",
"        Dose",
"       </td>",
"       <td class=\"subtitle1\">",
"        Duration",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Levofloxacin",
"       </td>",
"       <td>",
"        500 mg orally once daily",
"       </td>",
"       <td>",
"        3 days",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ciprofloxacin",
"       </td>",
"       <td>",
"        500 mg orally twice daily or 750 mg orally once daily",
"       </td>",
"       <td>",
"        3 days",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Azithromycin",
"       </td>",
"       <td>",
"        500 mg orally once daily",
"       </td>",
"       <td>",
"        3 days",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Trimethoprim-sulfamethoxazole (co-trimoxazole)",
"       </td>",
"       <td>",
"        160/800 mg (one double strength tablet) orally twice daily",
"       </td>",
"       <td>",
"        5 days",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ceftriaxone",
"       </td>",
"       <td>",
"        1 to 2 g intravenously once daily",
"       </td>",
"       <td>",
"        5 days",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    See text for approach to choice of therapy and comments regarding antimicrobial therapy. The duration of therapy is as outlined above; in addition, five to seven days of therapy should be administered to patients with infection due to S. dysenteriae type 1 or patients with HIV coinfection.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_38_23147=[""].join("\n");
var outline_f22_38_23147=null;
var title_f22_38_23148="Antibody tests celiac";
var content_f22_38_23148=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F75505&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F75505&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Sensitivity and specificity of antibody tests for celiac disease in children",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        &nbsp;",
"       </td>",
"       <td class=\"subtitle1\">",
"        Sensitivity, (percent)",
"       </td>",
"       <td class=\"subtitle1\">",
"        Specificity, (percent)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Tissue transglutaminase; tTG&nbsp;(IgA, human)",
"        <sup>",
"         [1-3]",
"        </sup>",
"       </td>",
"       <td>",
"        90 to 100",
"       </td>",
"       <td>",
"        95 to 100",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Anti-endomysial antibody (IgA)",
"        <sup>",
"         [1]",
"        </sup>",
"       </td>",
"       <td>",
"        93 to 100",
"       </td>",
"       <td>",
"        98 to 100",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Antigliadin antibody IgA",
"        <sup>",
"         [1]",
"        </sup>",
"       </td>",
"       <td>",
"        52 to 100",
"       </td>",
"       <td>",
"        72 to 100",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Antigliadin antibody IgG",
"        <sup>",
"         [1]",
"        </sup>",
"       </td>",
"       <td>",
"        83 to 100",
"       </td>",
"       <td>",
"        47 to 94",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Deamidated gliadin peptide; DGP (IgA)*&nbsp;",
"        <sup>",
"         [4]",
"        </sup>",
"       </td>",
"       <td>",
"        80&nbsp;to 91",
"       </td>",
"       <td>",
"        91&nbsp;to 95",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Deamidated gliadin peptide; DGP (IgG)*",
"        <sup>",
"         [4]",
"        </sup>",
"       </td>",
"       <td>",
"        88&nbsp;to 95",
"       </td>",
"       <td>",
"        86&nbsp;to 98",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     *&nbsp;Sensitivity and specificity&nbsp;of DGP may be better in children younger than two years of age as compared with tTG or anti-endomysial antibodies.",
"     <sup>",
"      [5]",
"     </sup>",
"    </div>",
"    <div class=\"reference\">",
"     References",
"     <ol>",
"      <li>",
"       Hill, ID. What are the sensitivity and specificity of serologic tests for celiac disease? Do sensitivity and specificity vary in different populations? Gastroenterology 2005; 128 (4 Suppl 1):S25",
"      </li>",
"      <li>",
"       Basso, D, Guariso, G, Fasolo, M, et al. A new indirect chemiluminescent immunoassay to measure anti-tissue transglutaminase antibodies. J Pediatr Gastroenterol Nutr 2006; 43:613.",
"      </li>",
"      <li>",
"       Lewis NR, Scott BB. Meta-analysis: deamidated gliadin peptide antibody and tissue transglutaminase antibody compared as screening tests for coeliac disease. Aliment Pharmacol Ther 2010; 31:73.",
"      </li>",
"      <li>",
"       Agardh D. Antibodies against synthetic deamidated gliadin peptides and tissue transglutaminase for the identification of childhood celiac disease. Clin Gastroenterol Hepatol 2007; 5:1276.",
"      </li>",
"      <li>",
"       Mubarak A, Gmelig-Meyling FHJ, Wolters VM et al. Immunoglobulin G antibodies against deamidated-gliadin-peptides outperform anti-endomysium and tissue transglutaminase antibodies in children &lt;2 years age. APMIS 2011; 119:894.",
"      </li>",
"     </ol>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_38_23148=[""].join("\n");
var outline_f22_38_23148=null;
var title_f22_38_23149="Therapeutic options in psoriatic juvenile idiopathic arthritis";
var content_f22_38_23149=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ALLRG%2F64063&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ALLRG%2F64063&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Therapeutic options in psoriatic juvenile idiopathic arthritis",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Drug",
"       </td>",
"       <td class=\"subtitle1\">",
"        Dose",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\">",
"        Intra-articular glucocorticoids",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Triamcinolone hexacetonide",
"       </td>",
"       <td>",
"        0.5 to 1 mg/kg intra-articular, up to 40 mg depending on size of joint. Most effective glucocorticoid for joint injections; not for soft tissue injections.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Methylprednisolone acetate",
"       </td>",
"       <td>",
"        1 mg/kg intra-articular or soft-tissue including dactylitis, up to 80 mg depending upon size of joint or lesion",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\">",
"        Nonsteroidal antiinflammatory drugs (NSAIDs)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Naproxen",
"       </td>",
"       <td>",
"        5 to 10 mg/kg/dose orally twice daily (maximum 1000 mg/day)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Ibuprofen",
"       </td>",
"       <td>",
"        10 mg/kg/dose orally three to four times daily (maximum 2.4 g/day)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Celecoxib",
"       </td>",
"       <td>",
"        Body weight:",
"        <br/>",
"        10 to 25 kg: 50 mg orally twice daily",
"        <br/>",
"        &gt;25 kg:&nbsp;100 mg orally twice daily",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\">",
"        Disease modifying antirheumatic drugs",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Methotrexate*",
"       </td>",
"       <td>",
"        10 to 15 mg/m",
"        <sup>",
"         2",
"        </sup>",
"        per week or 0.5 to 1 mg/kg/week (maximum 25 mg per week) administered orally* or subcutaneously with folic acid 1 mg daily or leucovorin calcium",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Sulfasalazine",
"       </td>",
"       <td>",
"        15 to 30 mg/kg/dose orally&nbsp;twice daily, maximum 2 g/day",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Leflunomide",
"       </td>",
"       <td>",
"        Body weight:",
"        <br/>",
"        &lt;20 kg:&nbsp;10 mg orally every other day",
"        <br/>",
"        20 to 40 kg:&nbsp;10 mg orally&nbsp;daily",
"        <br/>",
"        &gt;40 kg:&nbsp;20 mg orally daily",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2_start\" colspan=\"2\">",
"        Third-line agents in uveitis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Mycophenolate mofetil",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"       <td class=\"sublist_other\">",
"        12 to 18 mg/kg or 600 mg/m",
"        <sup>",
"         2",
"        </sup>",
"        orally twice per day, maximum 3 g/day",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Cyclosporine (microemulsion)",
"       </td>",
"       <td class=\"sublist_other\">",
"        1.5 to 2.5 mg/kg orally twice per day",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Azathioprine",
"       </td>",
"       <td class=\"sublist_other\">",
"        1 to 2 mg/kg orally once per day or in two equal divided doses",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\">",
"        Tumor necrosis factor (TNF) inhibitors",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Adalimumab",
"       </td>",
"       <td>",
"        Body weight:",
"        <br/>",
"        15 to 30 kg: 20 mg subcutaneously every 2 weeks",
"        <br/>",
"        &ge;30 kg: 40 mg subcutaneously every 2 weeks (may escalate to weekly for partial response)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Etanercept",
"       </td>",
"       <td>",
"        0.8 mg/kg (maximum 50 mg) subcutaneously weekly",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Infliximab",
"       </td>",
"       <td>",
"        5 to 10 mg/kg intravenously every 4-8 weeks (after loading doses)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2_start\" colspan=\"2\">",
"        Anti-TNF agents without pediatric indication",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Certolizumab",
"       </td>",
"       <td class=\"sublist_other\">",
"        200 mg subcutaneously every 2 weeks (after loading doses)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Golimumab",
"       </td>",
"       <td class=\"sublist_other\">",
"        50 mg subcutaneously monthly",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\">",
"        CTLA4-Ig (T cell costimulatory blocker)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Abatacept",
"       </td>",
"       <td>",
"        10 mg/kg (maximum 1000 mg) intravenously every 4 weeks",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <strong>",
"     NOTE: Treatment should be performed by clinicians who are experienced in the use, monitoring, adjustment and drug interactions of these agents because of the potential toxicity of these drugs/combinations and the unpredictability of the disease.",
"    </strong>",
"    <div class=\"footnotes\">",
"     * Subcutaneous administration is suggested for methotrexate doses &gt;10 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     since oral absorption decreases with higher doses.",
"     <br>",
"      <span class=\"bullet\">",
"       &bull;",
"      </span>",
"      Mycophenolate mofetil dosing shown is for immediate release oral preparation. Dose adjustment is required for conversion to the delayed-release oral&nbsp;preparation.",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_38_23149=[""].join("\n");
var outline_f22_38_23149=null;
var title_f22_38_23150="Staccato pattern of myoglobin";
var content_f22_38_23150=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F74748&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F74748&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Myoglobin and CK release patterns after MI",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 321px; height: 353px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The serum myoglobin (Mb, blue lines) and creatine kinase (CK, red lines) concentrations in three patients after acute myocardial infarction (MI). Myoglobin is released in a staccato pattern from damaged myocardium; in contrast, CK is steadily released.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from Kagen, L, Scheidt, S, Butt, A, Am J Med 1977; 62:86.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_38_23150=[""].join("\n");
var outline_f22_38_23150=null;
var title_f22_38_23151="Older adult multimorbidity eval and mgmt algo";
var content_f22_38_23151=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F86695&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F86695&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Approach to the evaluation and management of the older adult with multimorbidity",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 401px; height: 550px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     From: Guiding Principles for the Care of Older Adults with Multimorbidity: An Approach for Clinicians: American Geriatrics Society Expert Panel on the Care of Older Adults with Multimorbidity. J Am Geriatr Soc 2012. Reproduced with permission from the American Geriatrics Society. Available at:",
"     <a href=\"file://www.americangeriatrics.org/files/documents/MCC.principles.pdf\" target=\"_blank\">",
"      file://www.americangeriatrics.org/files/documents/MCC.principles.pdf",
"     </a>",
"     . For more information, please visit",
"     <a href=\"file://www.americangeriatrics.org\" target=\"_blank\">",
"      www.americangeriatrics.org",
"     </a>",
"     .",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_38_23151=[""].join("\n");
var outline_f22_38_23151=null;
